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Summary — Inflammatory bowel disease (IBD) causes a prolonged life-quality reduction of patients and high costs for health services. 
The  aim  of  this  study  was  to  explore  the  possible  involvement  of  peptidergic  capsaicin-sensitive  afferent  nerves  (CSN)  in  the  
pathogenesis  of  IBD. For the defunctionalization of colonic CSN, the lower part of the colon (1-4 cm from the anus) was exposed 
through a midline laparotomy and smalt pieces of gclfoam  moistened with a solution of capsaicin (1%.  100 p.L)  was applied onto the 
serosal surface for 30 min  in  male Wistar rats. Colonic vascular permeability  was assesseid  by measuring the extravasation  of [l25I] 
human serum albumin  (2 pCi/kg.  iv. 2 h prior to killing). Two months after capsaicin  treatment a significant  increase  in albumin 
extravasation  was found in the lower (P < 0.005), but not in the upper (5-8 cm from the anus) part of the colon as compared to the 
sham-operated  control.  Intrarectal  (8 cm from anus)  administration  of  trinitrobenzene-sulphonic  acid  (TNBS: 30 mg/ral) induced 
similar plasma leakage  in the lower and upper colon of control  (CSN-intact) rats (P < 0.001)  I  week later. TNBS + ethanol (50%) 
produced further extravasation  throughout the colon (P < 0.001)  of CSN-intact animals.  In the lower colon  of  capsaicin-pretreated 
rats TNBS-alone provoked an increase in plasma extravasation (P < 0.001) similar to that caused by TNBS  -t- ethanol in CSN-intact 
rats. In the upper colon there  was no difference in the effect of TNBS-alone on plasma  leakage between control  (CSN-intact) and 
CSN-depleted rats. The results suggest that capsaicin-sensitive nerves may play a significant protective/anti-inflanimatory role in  the 
colon under normal  and pathological  conditions.  
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Introduction 
Inflammatory  bowel  disease  (IBD)  is  the  collective  
term  used  to describe  two gastrointestinal  disorders:  
ulcerative  colitis  and  Chron's  disease.  Although  
these  diseases  have  distinctive  pathophysiological  
characteristics,  they  are  frequently  considered  
together  because  of  several  clinical  and  therapeutic  
similarities  (Riis,  1990). Implication  of  a causal fac-
tor  remains  elusive,  and  there  is  no  known  cure  
(Riis,  1990;  Hay  and  Hay,  1992).  
Capsaicin-sensitive  sensory  nerves  play  an  im-
portant  role  in  the maintaining  of  the  structural  and  
functional  integrity  of  the  gastrointestinal  mucosa  
(Holzer,  1988).  There  is  ample  evidence  that  this  
effect  is  mediated  by  neuropeptides  released  from  
afferent nerve  endings.  Capsaicin  selectively  stimu-
lates  these  nerves  and  causes  the  release  of  vasoac-
tive  peptides.  Hence,  mucosal  application  of  
capsaicin  at  low  concentrations  may  effect  mucosal  
protection  by releasing  peptides  which  increase  mu-
cosal  blood  flow (Holzer  and  Sametz,  1986;  Holzer.  
1988,  1991).  In  contrast,  systemic  administration  or  
local  application  of  capsaicin  at  higher  concentra-
*Correspondence  and reprints 
tions  results  in  a  selective  destruction  of  capsaicin-
sensitivc  afferent neurons  (for  a  review  see  Jancsó,  
1992).  Thus,  pretreatment  with  capsaicin  may  lead  
to  aggravation  of  tissue  damage.  Available  ex-
perimental  evidence  indicates  that  sensory  nerves  
may  affect the  development  of  colonic  IBD  (Evan-
gélista  and  Meli,  1989;  Reinshagen  et  al,  1994).  
The  present  experiments  were  initiated  in  an  at-
tempt  to  reveal  possible  participation  of  capsaicin-
sensitive  sensory  nerves  in  changes  of  colonic  
vascular  permeability  under  physiological  and  pa-
thological  conditions.  
Part  of  this  work  has  been  presented  to  the  6th  
Annual  Meeting of  the European  Neuropeptide  Club  
in  Pécs.  Hungary.  16-19  June  1996  (Szepes  el  al,  
1996). 
Materials and  methods  
Albumin  leakage  
Male Wistar rats  weighing 220-250 g  were used. The ani-
mals  were  fasted for 24  h,  but  received  water  ad  libitum  
before any experiment. For the determination of the vascular 
albumin leakage as an index of endothelial injury, rats were 
anaesthetized  with  ether  and  l25I-labeled  human  serum al-
bumin (['J5]I-HSA)  was administered  (2 pCi/kg)  via a tail 
vein.  In  all  experiments,  the radiolabeled  albumin  was ad-
ministered 2 h before killing. Under ether anesthesia, blood 
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(1  m L )  w a s  co l l ec t ed  f r o m the a b d o m i n a l  ao r t a  in t ubes  c o n -
ta in ing  t r i s o d i u m  c i t r a t e  ( f ina l  c o n c e n t r a t i o n  0 . 3 1 8 % )  and  
c e n l r i f u g e d  ( 1 0 0 0 0  g,  10 min ,  4 ° C ) .  F o l l o w i n g  ce rv ica l  d is -
loca t ion ,  s e g m e n t s  ( 1 . 5 - 2  c m )  of  the  u p p e r  ( 5 - 8  c m  f r o m  
the  a n u s )  and  l o w e r  par t  ( 1 - 4  c m  f r o m the  a n u s )  of  the  large  
in tes t ine  w e r e  r e m o v e d .  T h e  [ l 3 5 ] I - H S A  c o n t e n t  of  t i s sue  
s a m p l e s  and  a l iquo t s  of  b l o o d  p l a s m a  ( 1 0 0  p L )  was  de te r -
m i n e d  with  a g a m m a - s p e c t r o m e t e r  ( N u c l e a r  E n t e r p r i s e s  N E  
1600).  T h e  o r g a n s  w e r e  t hen  o p e n e d ,  c l e a n e d ,  d r i ed  ou t  at  
I 0 0 ° C  f o r 4 8  h and  w e i g h e d .  T h e  total  r a d i o l a b e l e d  a l b u m i n  
c o n t e n t  in  the  i n t e s t i n a l  t i s s u e  w a s  c a l c u l a t e d .  C o n t r o l  
va lues  w e r e  sub t r ac t ed  f r o m  the  t rea ted  va lues  and  the  da ta  
w e r e  e x p r e s s e d  as the c o n t e n t  of  p l a s m a  in a l b u m i n  equ iva l -
en t s  ( p L / g  dry  t i s sue) .  
Defunaionaiization  of colonic  capsaicin-sensitive  
neurons  {CSN-depletion)  
R a t s  w e r e  a n a e s t h e t i z e d  w i t h  u r e t h a n e  (1  g / k g ,  ip) .  A  smal l  
p i ece  of  g e l f o a m  w a s  m o i s t e n e d  wi th  c a p s a i c i n  ( 1 % ,  100  
p L ;  S i g m a )  and  p l aced  o n t o  the  s e rosa l  s u r f a c e  of  the  l o w e r  
par t  of  the c o l o n  ( 1 - 4  c m  f r o m  the  a n u s )  f o r  3 0  min .  S h a m -
o p e r a t e d  rats  w e r e  t rea ted  with  the  s o l v e n t  of  c apsa i c in .  F o r  
the  d e t e r m i n a t i o n  of  v a s c u l a r  p e r m e a b i l i t y  c h a n g e s ,  t i s sue  
s a m p l e s  of  the  l o w e r  a n d  u p p e r  c o l o n  w e r e  r e m o v e d  2  
m o n t h s  later.  T h i s  e x a m i n a t i o n  p e r i o d  w a s  c h o s e n ,  s ince  
a m o n g  c a p s a i c i n - t r e a t e d  ( C S N - d e p l e t e d )  ra t s  a  m o d e r a t e  
d i a r r h e a  o c c u r r e d  at  this  p o s t o p e r a t i v e  su rv iva l  t ime .  T h e  
s h a m - o p e r a t e d  g r o u p  did  not  s h o w  th is s y m p t o m  of  i n f l a m -
mat ion . 
Induction  of colitis  in CSN-depleted  and  CSN-intact  rats  
C o l o n i c  i n f l a m m a t i o n  w a s  i n d u c e d  wi th  t r i n i t r obenzenesu l -
f o n i c  ac id  ( T N B S )  a c c o r d i n g  to  t h e  m e t h o d  of  M o r r i s  el  al  
( 1 9 8 9 ) .  T N B S  ( 3 0  m g / r a t )  o r / a n d  e t h a n o l  ( 5 0 % )  w e r e  ad-
m i n i s t e r e d  t h r o u g h  the  a n u s  via  a  p l a s t i c  t u b e  a d v a n c e d  
8  c m  into  the  c o l o n  of  C S N - d e p l e t e d  o r  con t ro l  ( C S N - i n -
tact)  rats .  P l a s m a  l e a k a g e  in  the  u p p e r  and  l o w e r  co lon  were  
d e t e r m i n e d  in  T N B S - a l o n e  and  T N B S  +  e t h a n o l  g r o u p s  1  
w e e k  later.  
Statistical  analysis  
T h e  d a t a  a rc  e x p r e s s e d  as  m e a n  ±  S E M .  F o r  s tat is t ical  c o m -
pa r i sons  the  M a n n - W h i t n e y  non-pa ra l l e l  U- tes t  w a s  used ;  
P  <  0 .05  w a s  t aken  as  s ta t i s t ica l ly  s i g n i f i c a n t  d i f f e r e n c e .  
Results 
Effect  of  CSN-depletion  on  colonic  albumin  leakage  
CSN-depletion  in  the  lower  colon  led  to  a  signifi-
cant  plasma  leakage  (P  <  0.005,  n  =  8)  after  2  
months.  There  was  no  difference  in  albumin  ex-
travasation  in  the  lower  colon  of  sham-operated  ani-
mals  as  compared  to  the  intact  control  group  (n  =  5  
and  8,  respectively).  In  CSN-depleted  and  sham-
operated  animals,  albumin  extravasation  in  the  
upper  colon  was  unaffected  (fig  1).  
Effect  of  CSN-depletion  on  albumin  leakage  during  
colitis 
In  CSN-intact  control  rats  administration  of  TNBS  
alone  induced  significant  albumin  extravasation  in  
the  upper  and  lower  colon  after  1 week  (P  <  0.001,  
n  =  5).  In  contrast,  in  CSN-depleted  rats  TNBS  
alone  produced  a  more  marked  increase  in  vascular  
permeability  in  the  lower  colon  (P  <  0.001,  n  =  5),  
while  in  the  upper  colon  there  was  no  difference  in  
F i g  I .  P l a s m a  l e a k a g e  in  the  l o w e r  par t  ( 1 -
4  c m  f r o m  the  a n u s ;  g r a y  c o l u m n )  o f  the  rat  
c o l o n  i n d u c e d  by  local  c a p s a i c i n - s c n s i t i v e  
n e r v e - d e p l e t i o n  ( C S N - d e p l e t e d ) .  T h e  
p l a s m a  l e a k a g e  va lues  in  the  u p p e r  par t  o f  
the  c o l o n  are  d e m o n s t r a t e d  on  h a t c h e d  co l -
u m n s .  P l a s m a  l e a k a g e  w a s  e x p r e s s e d  as  A  
p L  p l a s m a / g  dry  t i s sue .  D a t a  a re  s h o w n  as  
m e a n s  ±  S E M  of  at  leas t  five  e x p e r i m e n t s  
f o r  e a c h  g r o u p ,  w h e r e  s ta t i s t ica l  s i g n i f i c a n t  
inc rease  is  s h o w n  as  *P  <  0 . 0 5 .  
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125 
albumin  extravasation  between  CSN-depleted  and  
CSN-intact  rats  following  the  administration  of  
TNBS-alone  (n  =  5  and  8,  respectively).  
In  CSN-intact  rats  administration  of  TNBS  and  
ethanol  caused  marked  plasma  leakage  in  the  upper  
and  lower  colon  (P  <  0.001,  n  =  5).  In  CSN-intact  
animals  there  was  no  significant  difference  in  the  
enhancement  of  vascular  permeability  between  the  
upper  and  lower  parts  of  the  colon.  In  the  lower  
colon  of  CSN-intact  rats  TNBS  +  ethanol  brought  
about  similar  increase  in  plasma  leakage  as  TNBS  
alone  in  CSN-depleted  animals  (fig  2).  
Discussion 
The  present  findings  showed  that  local  CSN-de-
pletion  led  to  a  sustained  increase  in  vascular  per-
meability  of  the  colon  in  control  rats.  Moreover,  
in  CSN-depleted  rats  administration  of TNBS  pro-
duced  a  further  increase  in  albumin  leakage  which  
was  similar  in  magnitude  to  that  found  after  the  
application  of  TNBS  +  ethanol  in  the  lower  colon  
of  CSN-intact  animals.  On  the  basis  of  these  ob-
servations  it  appears  that  CSN  are  involved  in  the  
modu la t ion  of  co lon i c  v a s c u l a r  pe rmeab i l i ty  
under  phys io logica l  and  pa tho log ica l  c i rcum-
stances. 
Our  results  are  in  agreement  with  previous  find-
ings  showing  that  defunctionalization  of  extrinsic  
CSN  by  systemic  administration  of  capsaicin  aug-
mented  immune-complex-induced  colitis  in  rabbits  
(Reinshagen  et  al,  1994),  rat  colonic  inflammation  
provoked  by  acetic  acid  (Eliakim  et  al,  1995)  and  
TNBS  +  ethanol-induced  mucosal  injury  in  the  rat  
colon  (Evangelista  and  Meli,  1989).  It  has  been  also  
demonstrated  that  local  activation  of  CSN  by  topical  
application  of  capsaicin  protects  against  an  acute  
colonic  injury  provoked  by  TNBS  +  ethanol  in  rats,  
an  effect  which  is  reversed  by  a  competitive  anta-
gonist  of  capsaicin  (Goso  et  al,  1993).  Taken  
together,  these  results  suggest  a  protective  role  for  
CSN  in  experimental  models  of  IBD.  
It  is  known  that  CSN  contain  numerous  neuro-
peptides  (Holzer,  1991).  The  release  of  these  neuro-
peptides  may  be  responsible  for  the  protective  
function  of  this  neuronal  system  in  IBD.  During  in-
duction  of  colitis  by  acute  immune  complex  expo-
sure  in  rabbits,  an  early  reduction  of  the  two  most  
important  CSN  neuropeptides,  ie  substance  P  (SP)  
and  calcitonin  gene-related  peptide  (CGRP)  has  
been  found  (Eysselein  et  al,  1991).  These  findings  
indicate  that  these  peptides  are  released  during  in-
flammation.  Because  of  its  pharmacological  actions  
(Holzer,  1991;  Whittle,  1993)  and  of  its  predomi-
nant  existence  in  the  CSN  of  gastrointestinal  tissues  
(Mulderry  et  al.  1988;  Reinshagen  et  al,  1994),  
CGRP  seems  to  be  the  most  important  peptide  in-
volved  in  the  protective  function  of  CSN  in  ex-
p e r i m e n t a l  m o d e l s  of  IBD.  I n t r a v e n o u s  or  
intra-arteriolar  infusion  of  CGRP  increases  resting  
gastric  mucosal  blood  flow  (Dipctte  et  al.  1987;  
Holzer  and  Guth.  1991;  Whittle  et  al,  1992).  In  con-
trast,  local  infusion  of  the  CSN  neuropeptides,  SP  
and  neurokinin  A  did  not  elevate  resting  mucosal  
blood  flow  (Holzer  and  Guth,  1991).  Therefore,  
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F i g  2.  C o l o n i c  p l a s m a  l e a k a g e  1 w e e k  a f t e r  
in t ra rec ta l  (8 c m  f r o m the  a n u s )  admin i s t r a -
t i o n  o f  t r i n i t r o b e n z e n e s u l p h o n i c  a c i d  
( T N B S ,  3 0  m g / r a t )  o r / a n d  e thano l  ( 5 0 % )  in  
l o w e r  (1—f  c m  f r o m  the  anus ;  g ray  c o l u m n )  
a n d  u p p e r  ( 5 - 8  c m  f r o m  the  a n u s )  of  t he  
c o l o n  f o l l o w i n g  c a p s a i c i n - s e n s i t i v e  ne rve-
d e p l e t i o n  ( C S N - d e p l e t e d )  o r  in  c o n t r o l  
( C S N - i n t a c t )  rats .  P l a s m a  l e a k a g e  w a s  ex-
p re s sed  as  A  p.L  p l a s m a / g  dry  t i ssue.  Data  
are  s h o w n  as  m e a n s  ±  S E M  of  at  leas t  f ive  
e x p e r i m e n t s  f o r  e a c h  g r o u p ,  w h e r e  stat ist i-
c a l  s i g n i f i c a n t  i n c r e a s e  i s  s h o w n  a s  
*P  <  0 . 0 5 .  #P  <  0 . 0 5  r ep re sen t s  s tat is t ical  
d i f f e r e n c e  vr  the  a p p r o p r i a t e  pa r t s  of  t he  
c o l o n  of  T N B S  in  C S N - i n t a c t  rats .  
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CGRP  might  promote  mucosal  integrity  by  increas-
ing  intestinal  blood  flow.  
In  conclusion,  our  results  suggest  that  CSN  may  
play  a  significant  protective/anti-inflammatory  role  
in  the  colon  under  physiological  and  pathological  
conditions.  Finally,  involvement  of  an  impairment  
of  the  capsaicin-sensitive  innervation  of  the  intes-
tine  in  the  development  of  human  IBD  (especially  
Crohn's  disease)  can  not  be excluded.  Indeed,  it  has  
been  demonstrated  that  in patients  with  Crohn's  dis-
ease  the  concentration  of  SP  in  rectal  dialysates  
tends  to  be  lower  (Bernstein  el  al,  1993)  and  in  
these  patients  the  expression  of  SP  receptors  was  
shown  to  be  increased  (Mantyh  el  al,  1995).  
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Abs t rac t  —  The  actions o f  the  female  sex  steroid,  oestradiol  on  cysteamine-induced  mucosal  ulceration  has  been  evaluated  in  female  
Wistar  rats.  Administration  of  cysteamine  (400 nig-kg - 1 ,  s.c.)  provoked  macroscopic  gastroduodenal  mucosal  injury  (assessed  
planimetrically)  and  an  increase  in  microvascular  permeability  (assessed  by  the  extravasation  of  radiolabeled  albumin)  in  the  stomach  
and  duodenum,  determined  24  h  later.  Ovariectomy  (2  weeks  before  cysteamine)  reduced  gastroduodenal  macroscopic  injury,  and  
albumin  extravasation  following  cysteamine  challenge.  Administration  of  oestradiol  ( l - S  mg-kg~',  as  an  i.rn.  depot  1  week  before  
cysteamine)  dose-dependently  augmented  gastric  and  duodenal  macroscopic  mucosal  lesions  and  microvascular  permeability  provoked  
by  cysteamine.  These  findings  indicate  that  oestradiol  can  exacerbate  gastroduodenal  ulceration  and  microvascular  injury.  ©  1999  
Elsevier  Science  Ltd.  Published  by  Editions  scientifiques  et  médicales  Elsevier  SAS  
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1.  Introduction  
On  the  basis  of  experimental  and  clinical  observa-
tions,  it is known that ulceration  of the  gastroduodenal  
mucosa  shows  sexual  dimorphism.  Thus,  in  the  fertile  
age,  peptic  ulcer  disease  occurs  more  frequently  
among  men  than  women  [2].  In  experimental  models  
of  mucosal  damage,  this  sexual  difference of  mucosal  
injury  has  also  been  found.  Oral  administration  of  
ethanol  caused  more  severe  gastric  mucosal  erosions  
in  male  rats  than  in  females  [8,  9].  In  this  model  of  
mucosal  damage,  gonadcctomy  protected  the  stomach  
against  ethanol-induced  injury  in male  rats [8].  More-
over,  administration  of  the  testosterone-synthasc  in-
hibitor,  cyproterone  acetate  attenuated  gastric  hemor-
rhagic  erosions  in  intact  male  rats  following  ethanol  
challenge  [8],  and  reduced  gastric  lesions  and  duode-
nal  ulceration  provoked  by  cysteamine  [11].  Such  
findings suggest  that endogenous  sex  hormones  might  
possibly  play  a  role  in  the  development  of  gas-
troduodenal  mucosal  ulceration.  
The  aim  of  the  present  study  was  to  evaluate  the  
actions  of  the  female  sex  steroid,  oestradiol  on  the  
generation  cysteamine-induced  gastroduodenal  ulcer-
ation  in  the rat. Thus,  in female rats, we  examined  the  
effects of ovariectomy and oestradiol on the severity of  
macroscopically  detectable  lesions  as  well  as  the  
changes  in  microvascular  permeability  in  the  stomach  
and  duodenum  provoked  by  cysteamine.  
* Correspondence  and  reprints  
2.  Materials  and  methods  
2.1.  Experimental  protocol  
Female  Wistar  rats  (200-220 g)  were  injected  with  
cysteamine  (400mgkg - 1 ,  s.c.).  Twenty-four  hours  
after  cysteamine  administration,  the  animals  were  
killed by ether overdose, and their stomach and duode-
num were removed. During this 24-h period, rats were 
deprived  of  food,  but  received  water  ad  libitum.  For  
the  determination  of  plasma  leakage,  l25I-labeled  hu-
man serum albumin  ([125I]-HSA,  2  p.Cikg~',  i.v.)  was  
administered  2 h  before  autopsy.  In  some  groups  of  
rats, ovariectomy was perfonncd under ether  anaesthe-
sia  2  weeks  before  any  experimental  procedure.  For  
additional  groups  of  rats,  a  depot  injection  of  oestra-
diol  (1-5 mg-kg-1.  i.m.)  were  administered  1  week  
before cysteamine  challenge.  
2.2  Macroscopic  evaluation  of  lesions  
The area of damage and the total mucosal  surface of 
the stomach and duodenum were measured by a digital 
planimeter  (Sokkia  Planimcter  KP-82-N,  Japan),  and  
the  injured  area  was  expressed  as  percentage  of  the  
total  mucosal  surface.  
2.3. Albumin  leakage  
Leakage of | l 2 sI]-HSA was detennined  in the  stom-
ach  and  duodenum  as  an  index  of  microvascular  
damage.  Blood  was  collected  from  the  abdominal  
aorta  into  syringes  containing  trisodium  citrate  (final  
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concentration  0.318%)  and  centrifuged  (10  000  g,  
10  rnin,  4  °C).  The  [ 1 2 5 I ] -HSA  content  of  the  plasma  
and  segments  of  gastric  and  duodenal  tissue  was  
determined  in  a  gamma-spectrometer  (Nuclear  Enter-
prises  NE  1600)  and  the  albumin  content  in  the  
stomach  and  duodenum  calculated,  taking  into  account  
any  changes  in  gastroduodenal  blood  volume  as  de-
scribed  previously  [4],  Values  f rom  control  tissues  
were  subtracted  from  the  values  of  treated  tissue  and  
the  data  were  expressed  as  plasma  leakage,  pL  
p lasmag" 1  wet  tissue.  
2.4.  17-fi-oestradiol  plasma  level  
Plasma  17-(3-oetradiol  levels  were  determined  after  
ovariectomy  by  a  radioimmuno-assay  method  de-
scribed  previously  [8].  
2.5.  Materials  
[125I]-labeled  human  serum  albumin  was  obtained  
from  Izinta  (Budapest,  Hungary).  Oestradiol  benzoate  
was  purchased  from  Intervet  International  (Boxmeer,  
the  Netherlands).  All  other  compounds  were  from  
Sigma  Chemical  Company.  
2.6.  Statistical  evaluation  
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The  data  are  expressed  as  mean  ±  SE  from  (n)  rats  
per  experimental  group.  For  statistical  comparisons,  
Student 's  /-test  test  for  unpaired  data  or  analysis  of  
variance  with  the  Bonferroni  test  were  used,  where  
P  <  0.05  was  taken  as  significant  difference.  
3.  Results  
3.1.  Gastroduodenal  ulceration  provoked  by  
cysteamine 
Administration  of  cysteamine  (400  mg-kg"1,  s.c.)  
provoked  macroscopic  injury  in the  gastric  and  duode-
nal  mucosa  (4.5  + 0.6%  and  1 2 . 9 + 1 . 0 %  of  total  
mucosal  area, respectively;  n = 7 ,  P<  0.001)  as  shown  
in  figure  1.  Cysteamine  challenge  also  increased  mi-
crovascular  permeability  in  the  stomach  
(A57  ±  9 pL-g"'  tissue,  n  =  l,P<  0.001)  and  duode-
num  (A155  ±  6 pL-g - 1  tissue;  n  =  7, P <  0.001)  after  
24  h,  as  shown  in  figure  2.  
3.2.  Effects  of  ovariectomy  
Ovariectomy  (2  weeks  before  cysteamine  chal-
lenge)  decreased  plasma  17-P-oestradiol  level  (from  
1 8 2 + 1 0  to  87  +  5  pmol-L  ',  n=  6).  Ovariectomy  
significantly  lowered  the  gastric  and  duodenal  macro-
scopic  mucosal  injury  provoked  by  cysteamine  (by  
F i g u r e  1.  I n d u c t i o n  o f  ra t  g a s t r i c  a n d  d u o d e n a l  m u c o s a l  
m a c r o s c o p i c  i n j u r y  b y  c y s t e a m i n e  ( C y s t .  4 0 0  m g - k g " 1 ,  s .c . )  
a f t e r  2 4  h .  T h e  i nh ib i t i on  o f  c y s t e a m i n e - i n d u c e d  d a m a g e  b y  
o v a r i e c t o m y  (Ova r . ,  2  w e e k s  b e f o r e  c y s t e a m i n e  c h a l l e n g e )  
a n d  t h e  p o t e n t i a t i o n  o f  c y s t e a m i n c - p r o v o k e d  m u c o s a l  le-
s i o n s  b y  o e s t r a d i o l  ( 1 - 5  m g - k g " ' - w e e k " ' ,  i .m. )  p r e t r e a t m e n t  
is  s h o w n .  T h e  c o l u m n s  s h o w  the  e x t e n t  o f  gas t r i c  a n d  
d u o d e n a l  m a c r o s c o p i c  l e s i o n s  ( e x p r e s s e d  as  l es ion  a r ea ,  
p e r c e n t a g e  total  m u c o s a l  a r ea ) .  D a t a  a re  g i v e n  as  t h e  m e a n  ±  
S E  o f 4 - 7  ra t s  p e r  g r o u p ;  s ta t i s t i ca l  s i g n i f i c a n c e  is  s h o w n  as  
*P  < 0 . 0 5 ,  i n h i b i t i o n  o f  c y s t e a m i n e - i n d u c e d  l e s ion ;  
"P  < 0 . 0 5 ,  p o t e n t i a t i o n  o f  c y s t e a m i n e - i n d u c e d  l e s ion .  
62 ± 1 3 %  and  65  ±  15%,  respectively;  P  <  0.001,  
n  =  5)  as  shown  in  figure  1.  Ovariectomy  likewise  
attenuated  albumin  extravasation  in  the  gastric  mucosa  
and  duodenum  provoked  by  cysteamine  (by  63  ±  19%  
and  65  ±  7%,  respectively;  P  < 0.001,  n  =  5)  as  shown  
in  figure  2.  
3.3.  Effects  of  oestradiol  
Administration  of  oestradiol  (1 -5  mg-kg"'-week" ! ,  
i.m.)  to  unoperated  rats  dose-dependently  augmented  
gastric  and  duodenal  macroscopic  mucosal  lesions  
induced  by  cysteamine  (by  138 + 35%  and  by  
114 + 23%,  respectively;  P  <  0.001,  n  -  4). This  treat-
ment  also  increased  the  microvascular  injury  in  the  
stomach  and  duodenum  (by  182  ±  59%  and  by  
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Figure  2.  I n d u c t i o n  o f  ra t  g a s t r i c  a n d  d u o d e n a l  v a s c u l a r  
l e a k a g e  o f  p l a s m a  ( d e t e r m i n e d  u s i n g  r a d i o l a b e l e d  a l b u m i n )  
by  c y s t e a m i n e  ( C y s t . ,  4 0 0  m g - k g - 1 ,  s . c . )  a f t e r  2 4  h .  T h e  
i nh ib i t i on  o f c y s t e a m i n e - i n d u c e d  p l a s m a  l e a k a g e  b y  o v a r i e c -
t o m y  (Ova r . ,  2  w e e k s  b e f o r e  c y s t e a m i n e  c h a l l e n g e )  a n d  
p o t e n t i a t i o n  o f  c y s t e a m i n e - p r o v o k e d  p l a s m a  l e a k a g e  b y  
o e s t r a d i o l  ( 1 - 5  m g  k g  ' - w e e k 1 ,  i .m . ) p r c t r e a t m e n t  is  s h o w n .  
T h e  c o l u m n s  s h o w  the  l e a k a g e  o f  p l a s m a  ( A  p L g - '  t i s sue )  
in  ga s t r i c  a n d  d u o d e n a l  t i s s u e s .  D a t a  a re  g i v e n  as  t h e  m e a n  ±  
S E  o f 4 - 7  r a t s  p e r  g r o u p ;  s t a t i s t i ca l  s i g n i f i c a n c e  is  s h o w n  as  
*P  <  0 . 0 5 ,  i nh ib i t i on  o f c y s t e a m i n e - i n d u c e d  p l a s m a  l e a k a g e ;  
"P  <  0 . 0 5 ,  p o t e n t i a t i o n  o f  c y s t e a m i n e - i n d u c e d  p l a s m a  l e ak -
a g e . 
38 ± 5 % ,  respectively;  P c O . O l ,  n  = 4)  provoked  by  
cysteamine  (figures  1  and  2,  respectively).  
4.  Discussion  
This  study  in  female  rats  following  ovariectomy  
extends  the  previous  observations  in  males  that  fol-
lowing  gonadectomy  the  gastroduodenal  mucosa  is  
less  sensitive  to  various  ulcerogenic  stimuli  [8,  11].  
The  reduction  by  ovariectomy  of  cysteamine-induced  
ulcers  of  the  stomach  and  duodenum  could  be  related  
to  the  observed  decrease  of  plasma  oestradiol  levels.  
Indeed,  mucosal  damage  in  response  to  challenge  was  
increased  by  exogenous  administration  of  oestradiol  
into  intact  female  rats.  
It  is  known  that  an  increase  of  gastric  parietal  cell  
mass  has  a  beneficial  action  against  the  development  
of  mucosal  lesions  following  ulcerogenic  challenge  
and  accelerates ulcer  healing  [6,  7].  Since  ovariectomy  
enhances  gastric  parietal  ccll  m a s s f l ] ,  this  process  
may  contribute  to  the  mechanism  by  which  ovariec-
tomy  protected  the  mucosa  against  cysteamine-
induced  injury.  Other  factors  are  also  likely  to  be  
involved  in  the  apparent  aggressive  actions  of  oestra-
diol  towards  the  gastroduodenal  mucosa.  Thus  admin-
istration  of  oestrogens  can  lead  to  the  inactivation  of  
prostaglandins  in  the  stomach  [5],  and  prostaglandins  
are  known  to  have  key  importance  in  the  defense  
mechanism  of  the  gastroduodenal  mucosa  [13,  16],  
Here,  cysteamine  challenge  also  provoked  mi-
crovascular  plasma  leakage,  as  a  measure  of  vascular  
endothelial  damage.  This  finding  is  in  agreement  with  
the  previous  suggestion  that  aggressive  vascular  fac-
tors  are  involved  in  the  generation  of  cysteamine-
induced  gastroduodenal  ulcers  [3].  It  is  well-
established  that  microcirculatory  injury  and  the  
consequent  hypoxia  are among  those  important  factors  
which  are  considered  to  lead  to  gastroduodenal  mu-
cosal  ulceration  [14,  15],  As  with  the  macroscopic  
injury,  in  our  present  work,  the  reduction  in  endog-
enous  oestradiol  synthesis  following  ovariectomy  lead  
to  the  attenuation  of  cysteamine-induced  microvascu-
lar leakage.  In contrast,  augmentation  of  microvascular  
leakage  followed  the  administration  of  exogenous  
oestradiol  after  cysteamine  challenge.  Although  fur-
ther  studies  are  needed  to  evaluate  whether  the  ob-
served  microvascular  defects  are  the  consequence  or  
the cause  of cysteamine-provoked  mucosal  injury,  it  is  
relevant  that  oestrogens  have  vasoconstrictor  actions  
by  modulating  the  pressor  effect  of  vasopressin  [12],  
The  significant  aggressive  role  of  endogenous  vaso-
pressin  via  its pressor  receptors  in  the  development  of  
gastroduodenal  mucosal  ulceration  has  been  described  
previously  [10,  12],  
In  conclusion,  oestradiol  appears  to  exert  a  pro-
ulcerogenic  action  in  the  generation  of  macroscopic  
and  microvascular  injury  in  the  stomach  and  duode-
num  following  cysteamine  administration  in  female  
rats.  Thus  inappropriate  levels  of  endogenous  oestra-
diol  might  possibly  be  involved  in the  pathogenesis  of  
gastroduodenal  mucosal  damage.  
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1  The  products  released  by  Helicobacter  pylori  (H.  pylori)  in  the  gastric  antral  and  duodenal  
mucosa  ma;,  be  involved  in  mucosal  ulceration  by  stimulating  the  local  formation  of  cytotoxic  
factors  such  as  nitric  oxide  (NO),  superoxide  or  peroxynitrite.  
2  The  present  study  investigates  the  ability  of  purified  H.  pylori  lipopolysaccharide  (LPS)  to  induce  
nitric  oxide  wnthase  (iNOS)  in  rat  duodenal  epithelial  cells  following  in  vivo  challenge  and  its  
interaction  with  superoxide  in  promoting  cellular  damage  and  apoptosis.  
3  H.  pylor:  LPS  (0 .75-3  mg  kg" '  i.v.  or  3 - 1 2  mg kg" '  p.o.)  induced  a  dose-dependent  
expression  of  iNOS  activity  after  5  h  in  the  duodenal  epithelial  cells,  determined  by  [l4C]  arginine  
conversion  to  citrulline.  
4  The  epithelial  cell  viability,  as  assessed  by  Trypan  Blue  exclusion  and  MTT  conversion,  was  
reduced  5  h  after  challenge  with  H.  pylori  LPS,  while  the  incidence  of  apoptosis  was  increased.  
5  The  iNOS  activity  and  reduction  in  cell  viability  following  H.  pylori  LPS  challenge  i.v.  was  
inhibited  by  ;he  selective  iNOS  inhibitor,  1400  W  (0 .2-5  mg  kg" '  i.v.).  
6  Concurrent  administration  of  superoxide  dismutase  conjugated  with  polyethylene  glycol  (250-
500  i.u.  kg"  .  i.v.),  which  did  not  modify  the  cellular  iNOS  activity,  reduced  the  epithelial  cell  
damage  provoked  by  i.v.  H.  pylori  LPS,  and  abolished  the  increased  incidence  of  apoptosis.  
7  These  results  suggest  that  expression  of  iNOS  following  challenge  with  H.  pylori  LPS  provokes  
duodenal  epithelial  cell  injury  and  apoptosis  by  a  process  involving  superoxide,  implicating  
peroxynitrite  involvement.  These  events  may  contribute  to  the  pathogenic  mechanisms  of  H.  pylori  
in  promoting  peptic  ulcer  disease.  
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Introduction 
Infection  with  Helicobacter  pylori  (H.  pylori)  is  a  dominant  
pathogenic  factor  in  peptic  ulcer  disease  (Blaser.  1990).  This  
bacterium  colonises  the  gasirtc  antrum  and  sites  of  gastric  
metaplasia  in  the  duodenum,  und  induces  local  inflammation  
(Carrick  et  al..  1989).  H.  pylor:  infection  may  provoke  damage  
in  the stomach  and  duodenum  by releasing  soluble  factors  that  
activate  inflammatory  cells  such  as  neutrophils,  to  produce  
cytotoxic  mediators  such  as  superoxide  (Mooney  et  al..  1991)  
and  nitric  oxide  (NO)  (McCall  et  al..  1989).  High  concentra-
tion  of  NO  are  known  to  be  cytotoxic,  and  in  combination  
with  the  superoxide  radical,  leads  to  the subsequent  formation  
of  the  moieties,  peroxynitrite  and  hydroxyl  radicals,  which  are  
highly  injurious to cells (Ischiropoulos  et  al.,  1995; Beckman  et  
al.,  1990).  
' A u t h o r  f o r  c o r r e s p o n d e n c e .  
The  inducible  isoform  of NO  synthase  (iNOS)  is capable  of  
the  sustained  production  of high  levels  of NO  (Knowles  et  al.,  
1990;  Salter  et  al.,  1991).  This  isoform  can  be  expressed  
following  challenge  with  endotoxin  lipopolysaccharide  (LPS),  
not  only  in  inflammatory  cells,  but  also  in  gastro-intestinal  
epithelial  cells and  its expression  is associated  with  cytotoxicity  
(Brown  et  al.,  1994;  Tepperman  et  al.,  1993;  1994).  Since  H.  
pylori  can  synthesize  an  endotoxin  (Moran,  1996),  expression  
of iNOS  in  gastro-duodenal  epithelial  cells could  play  a  role  in  
the  pathogenesis  of  mucosal  lesions  related  to  infection  by  this  
organism.  Studies  on  gastric  mucosal  biopsies  from  patients  
with  gastritis  associated  with  H.  pylori  infection  exhibited  
increased  antral  mRNA  for iNOS.  as  well  as  iNOS  protein  in  
epithelium,  endothelium  and  inflammatory  cells,  compared  
with  tissue  from  H. pylori  -negative  gastritis or controls  (Fu  et  
al.,  1999).  In  another  report,  a correlation  was  found  between  
the  iNOS  immunostaining,  the  degree  of  inflammation,  the  
apoptotic  index  and  the  density  of  H.  pylori  infection,  all  of  
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which  decreased  on  eradication  of the  bacterium  (Hahm  ei  al.,  
1997). 
Previous  studies  have  shown  that  intravenous  challenge  
with  a  water extract  of  H. pylori  can  express iNOS and  lead  to  
epithelial  injury  in  the  rat  duodenum  (Lamarque  ei  al..  199S).  
These  effects were  inhibited  by  polymixin  B, which  binds  LPS  
(Morrison  & Jacobs,  1976).  suggesting  an  important  role  for  
an  LPS  in  this  process.  However,  although  in  vitro  studies  
have  shown  that  H.  pylori  LPS  can  lead  to  the  expression  of  
iNOS  in  murine  and  human  macrophage  cell  lines  in  culture,  
this  LPS  was  only  weakly  active  under  those  conditions  
(Perez-Perez  et  al..  1995).  Such  findings  cast  some  doubt  on  
the  possibility  that  the expression  of iNOS through  the  actions  
of  the  LPS  is  involved  in  the  pathogenic  processes  associated  
with  H.  pylori  infection,  although  in  vitro  studies  of  that  
nature  do  have  limitations,  including  lack  of  cross-talk  
between  different  cell  types  and  mediators.  The  aim  of  the  
present  study  was.  therefore,  to  investigate  the  ability  of  a  
purified  preparation  of  LPS  from / / .  pylori  to  induce  iNOS  in  
duodenal  epithelial  cells and  determine  its association  with  cell  
damage  and  apoptosis  following  its  administration  in  vivo  to  
the  rat.  As  the main  objective was  to  evaluate  the potential  of  
the  LPS  to  induce  iNOS  activity  in  an  experimental  setting  in  
vivo,  rather  than  provide  a  model  of  clinical  infection,  the  
intravenous  route  was  utilized  in  the  majority  of  the  
experiments.  However,  the  ability  of  this LPS  to  induce  iNOS  
activity  and  produce  cellular  injury  after  its  intragastric  
instillation  was  also  studied.  
To  evaluate  the  role  of  iNOS  in  the  cytotoxic  process,  the  
effects of  a  highly  selective  inhibitor  of  iNOS,  1400 W  (N-(3-
(aminomethyl)benzyl)acetamidine;  Garvey  et  al..  1997;  Laszlo  
&  Whittle,  1997)  on  epithelial  cell  injury  were  evaluated.  In  
addition,  to  explore  further  the  mechanisms  underlying  such  
cellular  injury,  the  involvement  of  the  superoxide,  and  hence  
percxynitrite,  on  epithelial  cell  injury  provoked  by  the  H.  
pylori  LPS  was  investigated.  The  effects  of  a  conjugate  of  
superoxide  dismutase  (SOD-PEG),  which  has  previously  
been  shown  to  reduce  the  mucosal  injury  provoked  by  local  
infusion  of NO  donors  in  the  rat  gastric  mucosa  (Lamarque  
&  Whittle,  1995)  was  therefore  evaluated  on  the  cellular  
damage  and  increased  apoptosis  provoked  by  the  LPS  from  
H.  pylori.  
Methods 
Preparation  of  LPS  
Biomass  of  H.  pylori  (NCTC  11637  strain)  was  grown  in  
brain-heart  infusion containing 2% foetal calf serum to  ensure  
expression  of  high  molecular  weight  LPS  (Walsh  &  Moran,  
1997)  Extraction  of  LPS was performed  using  a  phenol-water  
procedure (Westphal  et al.,  1952). Subsequently, extracted  LPS  
was  purified  by  treatment  with  RNase  A,  DNase  II  and  
proteinase K. and  by  ultracentrifugation  at  100,000 x g  at  4 :C  
for  18 h (Moran  et  al.,  1992). For suspension, purified LPS was 
dispersed  in endotoxin-free water  by  sonication.  
Animal  preparation  
Male  Wistar  rats,  weighing  200 -  250  g,  were  fasted  overnight  
but  allowed  free  access  to  water.  In  the  majority  of  the  
experiments,  purified  LPS  from  H.  pylori  (0 .75-3  mg  kg""1)  
was  administered  via  a  tail  vein  under  transient  anaesthesia  
induced  by ether.  In  control  experiments,  rats  were  pretreated  
with  saline  (0.5  ml  kg" ' ,  i.v.).  
In  a  further  series  of  experiments  to  evaluate  the  ability  of  
the  LPS  to  induce  iNOS  after  oral  challenge,  H.  pylori  LPS  
(3 -12  mg kg - 1 )  dissolved  in  saline  (1.0  ml),  was  administered  
intragastrically  through  a  smooth  rubber  feeding  tube.  
Duodenal  epithelial  cell  isolation  
Duodenal  epithelial  cells  were  isolated  as described  previously  
(Lamarque  et  al.,  1998; Lentze  et  al.,  1985). A  5 cm segment  of  
duodenum  was  slowly  flushed  with  50 ml  of  a  solution  
containing  0.15  M NaCl  and  0.1  mM  dithiothreitol  (DTT).  
The segment  was then  filled  with  5 ml  of  a solution  containing  
(in  mM):  KC1  1.5. NaCl  96.  sodium  citrate  27, K H ; P 0 4  8 and 
Na,HP0 4  5.6  (pH  7.3),  and  the  proximal  and  the  distal  ends  
were  ligated.  The  segment  was  then  immersed  in  phosphate-
buffered  saline  (PBS)  kept  at  37°C,  which  was  bubbled  with  
95%  0 , - 5 %  CO,.  After  15 min,  the  instilled  solution  was  
removed  and  another  solution  containing  1.5  mM  EDTA  and  
0.5  mM DTT  was instilled  over  5 min,  as described  previously  
(Tepperman  et  al..  1993).  The  epithelial  cells  were  collected  in  
suspension  in  this  solution.  The  cells  were  washed  twice  with  
PBS  (pH  7.4)  and  centrifuged  for  5  min  at  800 xg .  The  cells  
were  suspended  in  a  buffer containing  (V-2-hydroxyethylpiper-
azipine-Al'-2-ethanesulphonic  acid  (HEPES)  (10  m.M),  sucrose  
(320  mM),  DTT  (1  mM),  soybean  trypsin  inhibitor  
(10  fig ml" ') ,  leupeptin  (10  pg ml - 1 ) ,  aprotonin  (2  pg m l ' ' ) . 
To assess the purity of  epithelial cells in the aliquots  isolated  
from the duodenum,  in  some experiments  the  cells  were  fixed  
with  formaldehyde,  stained  by  hematoxylin-eosin-safran  and  
counted  under  light  microscopy  and  expressed  as  the  
percentage  of  epithelial  cells  by  fields.  
NO  synthase  activity  
NO synthase  activity  in duodenal  epithelial  cells was  measured  
as  the  conversion  of  L-[l4C]-arginine  monohydrochloride  to  
['"C]-citrulline,  based  on  the  method  described  previously  
(Knowles  et  al..  1990;  Lamarque  et  al.,  1998).  Cells  were  
homogenized  (30 s,  Ultra-Turrax;  5 mm  blade)  in  buffer  
(pH  7.4)  containing  HEPES  (10  mM),  sucrose  (32  mM).  DTT  
(1  mM),  leupeptin  ( l O u g m l - ' ) ,  soybean  trypsin  inhibitor  
(10  pg  ml - 1 )  and  aprotonin  (2  pg  ml - 1 ) .  
Following  centrifugation  (10,000 x g  4°C),  an  aliquot  of  
the  supernatant  (40  p\)  was  used  for  the  determination  of  the  
enzymatic  activity  and  the  remaining  kept  for protein  content  
measurement  by  a  modification  of  Bradford's  method  
(Lamarque  et  al.,  1998).  The  aliquot  was  placed  in  100  p\  
of  the  pre-warmed  incubation  buffer  containing  (final  
concentration)  potassium  phosphate  (50  mM;  pH  7.4),  L-
valine  (50  mM),  MgCl_-  (1  mM),  CaCl2  (200  pM),  DL-
dithiothreitol  (1  mM),  L-citrulline  (1  mM), NADPH  (0.3  mM).  
FAD  (3 /Al),  FMN  (3  p\i),  BH4  (3 pM)  L-[,4C]arginine  
monohydrochloride  (15.5  nM)  and  incubated  for  10 min  at  
37°C.  The  incubation  was  terminated  by  binding  arginine  
following  the  addition  of  500 pi  of  1:1  suspension  of  Dowex  
(AG  50W-8)  in  water.  The  resin  was  allowed  to  settle  
(30  min)  and  975 pi  of  supernatant  taken  for  scintillation  
counting  in  3  ml  of  scintillation  liquid.  
Product  formation that  was inhibited  by  in  vitro  incubation  
with  the NO synthase inhibitor  NG-monomethyl-L-arginine  (L-
NMMA;  300  /<M).  but  not  by  ethylene  glycol-bis-(/?-amino-
ethyl  ether)-N.N.N'.N'-tetraacctic  acid  (EGTA;  1 mM),  was  
taken  as  an  index  of  iNOS  activity  (Salter  et  al..  1991).  The  
constitutive  NOS  activity  (designated  cNOS  as  the  nature  of  
the  isoform  was  not  established)  was  taken  as  that  activity  
inhibited  by  both  l - N M M A  and  EGTA.  
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Duodenal  epithelial  cells  viability  
The  viability  of  duodenal  epithelial  cells  was  determined  in  
cells  collected  from  rats  :hat  had  been  challenged.  5  h  
previously,  with  purified  H.  pylori  LPS  or  saline. The  viability  
of  cells  was  determined  by  Trypan  blue  dye  exclusion  (0.5%,  
Trypan  blue in PBS) as described previously (Tepperman  et  al.,  
1991).  The  number  of  viable  cells  was  determined  by  light  
microscopy  ( x  40  magnification)  by  counting  those  cells  that  
excluded  the  dye.  Cells  were counted  in  a  randomized  manner  
using  a  haemocytometer.  
Viability  of duodenal  epithelial  cells  was determined  also  by  
the  conversion  of  the  tetrazolium  salt,  3-[4.5-dimethylthiazol-
2-yl]-2.5-diphenyl  tetrazolium bromide (MTT) to the formazan 
salt  by  mitochondrial  dehydrogenases  (Mosmann,  1983).  
Briefly,  300  pi  of  MTT  was  added  to  50  ul  of  suspension  of  
the  homogenized  cells  prepared  as  described  above  and  
suspended  in  a  buffer  containing  HEPES  (10  m.vt),  sucrose  
(320  m.M),  DTT  (1  m.Ml.  soybean  trypsin  inhibitor  
(10  ug ml - 1) ,  Ieupeptin  (10  :;g ml - 1 ) ,  aprotonin  (2  pg  ml - 1) .  
After  4  h  of  incubation  at  37CC.  the  suspension  was  
centrifuged  (10,000 xg ,  2  min),  the  pellet  was  solubilized  in  
DMSO  (1  ml)  and  centrifuged  again.  The  spectrophotometric  
absorbance  of  the  formazan  salt  was  measured  in  the  
supernatant  at  540 nm.  Protein  content  in  the  initial  
suspension  of  homogenized  cells  was  determined  as  above.  
Results  were  expressed  as  OD mg - 1  of  protein.  
Effects  of  H .  pylori  LPS  on  MO  synthase  activity  and  
viability  in  duodenal  epithelial  cells  
At  5 h after administration  of  H. pylori  LPS (0.75-3  mg  k g - 1  
i.v  or 3 - 1 2  mg k g - 1  p.o.),  the animals  were  killed  by  cervical  
dislocation.  The  duodenum  was  removed,  and  duodenal  
epithelial  cells  isolated  for  the determination  of  iNOS  activity  
and  cell  viability.  At  this  lime  after  LPS  ( 3 m g k g - 1 ,  i.v.)  
challenge,  preliminary  histological  evaluation  of  the  duodenal  
tissue  indicated  some  areas  of epithelial  injury.  
In  further experiments,  ra:s  were  treated  with  the  selective  
iNOS  inhibitor.  1400  W  (0.2-5  mg  kg - 1  i.v.)  or  saline,  
concurrently  administered  with  H.  pylori  LPS  (3  nig  kg - 1 ,  
i.v.).  The  dose  of  1400  W  was  taken  from  previous  in  vivo  
studies  on  rat  gastrointestinal  tissue (Laszlo  & Whittle,  1997).  
In  a separate  series  of  studies,  the  activity  of  H.  pylori  LPS  
(3  mg kg - 1 )  on  iNOS  induction  and  cell  viability  was  
compared  with  that  of  E.  coii  LPS  (3 mgkg - 1 ) ,  5  h  after  
intravenous  administration.  
In  a  further group  of  rats,  a  systemically  acting  conjugate  
of  polyethylene  glycol  and  superoxide  dismutase  ( S O D -
PEG:  250-500  i.u.  kg - 1 )  or  isotonic  saline  was  administered  
by  ar.  intravenous  bolus  injection.  15 min  prior  to  H.  pylori  
LPS  administration  (3 m g k g - 1 ,  i.v.).  The  doses  of  S O D -
PEG  were  taken  from  previous  studies  on  its  inhibitory  
action  on  the  inflammatory  response  in  the  rat  skin  
following  systemic  administration  (Boughton-Smith  et  at..  
1993)  and  its  action  in  preventing  gastric  mucosal  injury  
induced  by  local  intra-arterial  infusion  of  NO  donors  
(Lamarque  &  Whittle.  1995).  The  viability,  and  iNOS  
activity  was  determined  in  duodenal  cells  from  rats  treated  
by  SOD-PEG  or  saline.  5 h  after  H.  pylori  LPS  
administration. 
Determination  of  apoptosis  
The  degree of apoptosis  was determined  in duodenal  epithelial  
cells  collected  from  rats  that  had  been  challenged.  5  h  
previously,  with  purified  H.  pylori  LPS  (3  mg kg - 1 ,  i.v.)  or  
saline  (n = 5  for  each).  The  cells  were  fixed  with  buffered  
formaldehyde  for  10 min  and  then  incubated  with  1 m g m l - 1 
4,6-diamidino-2-phenylindoIe-dihydrochloride  (DAPI)  for  
15 min  at  37"C.  Cells  were  evaluated  by  fluorescent  micro-
scopy,  and  nuclei  with  highly  condensed  and  fragmented  
chromatin  were  considered  apoptotic.  The  percentage  of  
apoptotic  cells  was  determined  in  15  different  fields  per  
preparation  of  duodenal  cells,  with  40  cells  per  field  being  
evaluated. 
In  a  further  group  (n = 5).  the  effect  of  pretreatment  with  
SOD -  PEG  (500 i.u. kg - 1  i.v.)  on  the degree  of apoptosis  was  
also  evaluated.  
Materials 
All chemical  compounds  were  obtained  from  Sigma  Chemical  
Co  (Sigma  France.  St  Quentin  Fallavier)  excepted  L-
[l4C]arginine  monohydrochloride  obtained  from  Amersham  
France  (Les  Ulis),  the  scintillation  liquid  Ready  safe  from  
Beckman  (Division  Biorecherche.  Paris  Nord  II.  Villepinte,  
France)  and  4,6-diamidino-2-phenylindo!e-dihydrochloride  
(DAPI)  from  Boehringer,  Mannheim,  Germany.  The  S O D -
PEG  was  obtained  from  Oxis  international  Inc  (NewYork,  
U.S.A.).  1400  W (N-(3-(aminomethyl)benzyi)acetamidine)  was  
provided  as  a  gift  from GlaxoWellcome  (Stevenage.  U.K).  
Statistical  analysis  
The  data  are  expressed  as  the  mean + s.e.m.  of  (n)  rats  per  
group.  Statistical  comparisons  were  made  by  analysis  of  
variance  with  the  Bonferroni  test  where  P<0 .05  was  taken  
as  significant.  
Results 
Induction  of  iNOS  in  duodenal  epithelial  cells  after  
H.  pylori  LPS  
No  significant  increase  in  the  low  basal  iNOS  activity,  
determined  as  that  NOS  activity  which  was  inhibited  by  L-
NMMA  but  not  by  in  vitro  incubation  with  EGTA  (1  mM),  
could  be  detected  in  the  supernatants  of  the  lysed  duodenal  
epithelial  cells  obtained  from  animals  challenged  with  saline  
alone.  Following  i.v.  administration  of  LPS  (0.75-
3 mg kg - 1 ) ,  a  dose-dependent  increase  in  iNOS  activity  was  
detected,  determined  after  5 h.  as  shown  in  Figure  1.  This  
iNOS activity  remained  at  a  similar  level when  determined  7  h  
after  challenge.  The  basal  cNOS  activity  (705±152pmol  
min - 1  mg protein "1 : n =  10) did  not change  5  h after challenge 
with  3 mg k g - '  of  LPS (728±  172 pmol m i n - 1  mg  protein - 1 ;  
n  = 1 0 ) .  
A significant dose-dependent  increase  in  iNOS  activity  was  
also  detected  5  h  after  intragastric  administration  of  LPS,  
reaching  78±56.  136±82  and  244 + 82  pmol min - 1  mg  
protein - 1  |P<0 .05  for  each:  n = 8)  following  the  dose  of  3,  6  
and  12 mg kg - 1  respectively.  
Effect  of  H.  pylori  LPS  on  duodenal  epithelial  cell  
viability 
The proportion  of epithelial cells in the cell suspension  isolated  
from  the  duodenum  by  dispersion  was  9 S ± 2 %  (n = 4),  as  
determined  by  microscopy,  the  other  cells  identified  by  
morphological  analysis  being  mastocytes.  
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H. pylori  LPS  mg kg"' 
F i g u r e  1  D o s c - d e p e n d e n t  i nc rease  in  i n d u c i b l e  n i t r ic  o x i d e  ( i N O S )  
ac t i v i t y  in  i so la t ed  d u o d e n a l  ep i the l i a l  cel ls ,  h a r v e s t e d  5  h  f o l l o w i n g  
c h a l l e n g e  wi th  H.  pylori  l i p o p o l y s a c c h a r i d e  ( L P S ;  0 . 7 5 - 3  m g  k g - 1 ,  
i .v .)  in  r a t .  D a t a ,  s h o w n  a s  the  i N O S  a c t i v i t y  ( p m o l  m i n  m g  
p r o t e i n - 1 ) ,  a r e  m e a n ± s . e . m e a n  of  5 - 1 0  e x p e r i m e n t s ,  w h e r e  *  
d e n o t e s  a  s ign i f i can t  d i f f e r e n c e  f r o m  t h e  c o n t r o l  g r o u p  ( P < 0 . 0 5 ) .  
The  proportion  of  non-viable  intestinal  ceils  isolated  from  
control  rats,  assessed  by  Trypan  Blue  staining,  was  13±1%;  
n=12.  The  intravenous  administration  of  H.  pylori  LPS  
(0.75-3  mg kg - 1 )  provoked  a  significant  dose-dependent  
increase  of  the  number  of  non-viable  cells  when  assessed  by  
dye exclusion  5 h later  (Figure  2). Likewise,  following H.  pylori  
LPS (0.75-3  mg k g - 1 ,  i.v.)  administration,  the  percentage  of  
non-viable  cells,  estimated  by  MTT  conversion,  was  dose-
dependently  increased,  as  shown  in  Figure  2.  
Following  intragastric  administration  of  H.  pylori  LPS  (3, 6 
and  12 mg kg - 1) ,  the  proportion  of  non-viable  intestinal  cells  
as  assessed  by  Trypan  blue  staining,  was  12 +  1,  15 ± 1  and  
2 0 ± 1 %  (n=12)  respectively,  being  significantly  greater  
(P<0.05)  than  the  control  at  doses  of  6 and  12 mg  kg - 1 .  
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F i g u r e  2  P e r c e n t a g e  o f  v i a b l e  i so la ted  d u o d e n a l  ep i the l i a l  cells,  a s  
a s se s sed  b y  T r y p a n  b l u e  e x c l u s i o n  ( p e r  c e n t  cel ls  e x c l u d i n g  dye :  u p p e r  
g r a p h )  o r  M T T  c o n v e r s i o n  ( p e r  c en t  c o n t r o l ;  l o w e r  g r a p h ) .  5  h  
f o l l o w i n g  c h a l l e n g e  w i t h  H.  pylori  l i p o p o l y s a c c h a r i d e  ( L P S :  0 . 7 5 -
3 m g k g - 1 ,  i .v .) .  D a t a  a r e  m e a n ± s . e . m e a n  o f  5 - 1 2  e x p e r i m e n t s  
w h e r e  * d e n o t e s  a  s ign i f i can t  d i f f e r e n c e  f r o m  t h e  s a l i n e  c o n t r o l  g r o u p  
(P<0.01) . 
Effects  of  1400  W  
The  increase  in iNOS  activity, determined  in  the epithelial  cells  
5  h  after  intravenous  challenge  with  H.  pylori  LPS.  was  
inhibited  dose-dependently  by  concomitant  administration  of  
1400  W (0.2-5  mg kg - 1 ,  i.v.) as shown  in Figure  3. The  cNOS  
activity  measured  5  h after LPS challenge  was not  significantly-
modified  by the treatment  with  1400  W (5 mg kg - 1 ,  i.v.).  being  
643 ±234  and  684 +176  pmol  min - 1  mg  protein - 1  (n = 8) 
respectively. 
The  increase  in  non-viable  cells,  estimated  by  Trypan  blue  
dye exclusion  or  MTT  conversion  5  h  after  the  LPS injection,  
was  dose-dependently  reduced  by  concomitant  treatment  of  
the rats with  1400  W (0.2-5  mg kg - 1 ,  i.v.), as shown in  Figure  
4. 
Comparison  of  the  activity  of  H.  pylori  LPS  and  E.  
LPS  on  cellular  iNOS  and  damage  
coli 
In  a  single-dose  comparative  study,  the  increase  in  iNOS  
activity  in  duodenal  epithelial  cells  was  A  224+34  pmol  
m i n - ' m g  protein - 1  (n = 8)  5  h  following  H.  pylori  LPS  
administration  (3  mg  kg - 1  i.v.),  whereas  that  observed  after  
E.  coli  LPS  administration  (3  mg kg - 1  i.v.)  was  A  463 + 
27  pmol  min - 1  mg  protein - 1  (n = 8). 
The  proportion  of  non-viable  cells,  estimated  by  Trypan  
blue staining,  that  had  been  isolated  from rats  challenged  with  
H.  pylori  LPS  (27 ± 5 % ,  n-  6)  was  not  significantly  different  
than  that  of  E.  coli  LPS-challenged  rats  (25 ± 4 % ,  n = 6). 
Likewise,  a comparable  injurious effect was  also found  in  both  
groups  when the percentage  of non-viable  cells was assessed  by  
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F i g u r e  3  I n d u c i b l e  n i t r i c  o x i d e  s y n t h a s e  ( i N O S )  a c t i v i t y  in  d u o d e n a l  
e p i t h e l i a l  ce l ls  5  h  f o l l o w i n g  c h a l l e n g e  w i t h  H.  pylori  l i p o p o l y s a c c h a r -
ide  ( L P S ;  3  m l  k g - 1 ,  i .v .)  in  ra t  t r e a t e d  c o n c u r r e n t l y  wi th  sa l ine  
( c o n t r o l )  o r  w i t h  N - ( 3 - ( a r n i n o m e t h y l ) b e n z y l ) a c e t a m i d i n e  (1400  W :  
0 . 2 - 5  m g  k g - 1 ,  i .v.).  D a t a ,  s h o w n  a s  i N O S  a c t i v i t y  ( p m o l  m i n -  m g  
p r o t e i n  ),  a r e  m e a n ± s . e . m e a n  o f 5 - 9  e x p e r i m e n t s ,  w h e r e  *  d e n o t e s  
a  s i g n i f i c a n t  d i f f e r e n c e f r o m  t h e  c o n t r o l  ( P < 0 . 0 1 )  a n d  -  a  s igni f icant  
d i f f e r e n c e  f r o m  the  L P S  a l o n e  g r o u p  ( P < 0 . 0 1 ) .  
MTT  conversion  (38 ± 3 % ,  n = 6,  and  38 ± 4 % ,  « = 6, 
respectively). 
Effects  of  SOD-PEG  
Administration  of  S O D - P E G  (500  i.u.  kg - 1 ,  i.v.),  15 min 
prior  to  challenge  with  H.  pylori  LPS,  did  not  significantly  
C o n t r o l  L P S  0.2 0 .5 
1 4 0 0 W m g  k g  
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affect the  increase  in iNOS activity  in duodenal  epithelial  cells , 
determined  5  h  after  challenge  (Figure  5).  The  cNOS  activity  
measured  5  h  after  H.  pylori  LPS  challenge  was  likewise  not  
affected  following  S O D - P E G  administration  (652 ±228  and  
796+175  pmol  min"1  mg  protein"1,  n =  10,  respectively).  
The  proportion  of  non-viable  intestinal  cells,  assessed  by  
Trypan  blue  staining,  that  was  isolated  from  rats  treated  5 h 
previously  with S O D - P E G  (500 i.u. kg" ' ,  i.v.) alone,  was  not  
different from  those  of  cells  taken  from control  rats  (12+1%;  
n = 6 compared  with  12 + 2%,  n = 5).  However,  the  increase  in  
non-viable  cells  5  h  after  H.  pylori  LPS  administration  was  
prevented  by  pretreatment  of  the  rats  with S O D - P E G  (250-
500  i.u.  kg"1 ,  i.v.),  15 min  prior  to  challenge  (Figure  6).  
Likewise,  the  increase  in  non-viable  cells  assessed  by  MTT  
conversion  after  H.  pylori  LPS  challenge  was  prevented  by  
pretreatment  with  these  doses  of S O D - P E G  (Figure  6).  
Effects  of  H .  pylori  LPS  and  SOD-PEG  on  apoptosis  
The  percentage  of  apoptotic  epithelial  cells,  assessed  by  the  
condensed  chromatin  fragments  in  the  nuclei  and  by  the  
segmentation  of  the  nuclei  after  DNA  staining,  5  h  following  
H.  pylori  LPS  injection,  was  significantly  increased  to  
11.0 + 0.6%  (n =  5: P<0.05)  as compared  to  the control  group  
(5.3±0.8%;  n = 5).  This  increase  in  the  incidence  of  apoptosis  
in  the  cells  following  LPS  challenge  was  prevented  by  the  
pretreatment  with  S O D - P E G  (500  i.u.  kg" ' ,  i.v.),  15  min  
prior  to  challenge  (5.6±0.4%;  n = 5: P c 0 . 0 5  compared  with  
LPS  alone).  
Discussion 
In a previous study.  iNOS activity  was detected  in  rat  duodena!  
tissue,  as  well  as  in  isolated  duocenal  epithelial  cells  after  the  
H  nvlnri I  PS  
(i.u.  kg')  
F igure  5  I n d u c i b l e  n i t r i c  o x i d e  i N O s >  ac t iv i ty  in  d u o d e n a l  
ep i the l ia l  ce l ls .  5  h  f o l l o w i n g  c h a l l e n g e  with  H.  pylori  l i p o p o l y s a c -
c h a r i d e  ( L P S ;  3  m g  k g " ' ,  i .v.)  in  ra t  t r e a t e d  c o n c u r r e n t l y  w i t h  sa l ine  
o r  w i t h  s u p e r o x i d e  d i s m u t a s e  c o n j u g a t e d  with  p o l y e t h y l e n e  g lyco l  
( S O D - P E G ;  2 5 0 - 5 0 0  i .u .  k g "  I . V . ) . D a t a ,  e x p r e s s e d  a s  i N O S  
ac t iv i ty  ( p m o l  m i n "  m g  p r o t e i n " ' )  a r e  m e a n  +  s . e . m e a n  o f  5 - 1 0  
e x p e r i m e n t s ,  w h e r e  * d e n o t e s  a  s i g n i f i c a n t  d i f f e rence  f r o m  the  c o n t r o l  
( / > < 0 . 0 1 ) .  In  c o n t r o l  e x p e r i m e n t s ,  a  g r o u p  of  r a t s  rece ived  S O D -
P E G  ( 5 0 0  i .u .  k g " 1 ,  i .v  ).  T h e r e  w a s  no  s ign i f i can t  d i f f e r e n c e  
( P > 0 . 0 5 )  b e t w e e n  v a l u e s  f o r  L P S  a i o n e  and  L P S  wi th  e i t h e r  d o s e  
o f  S O D - P E G .  
1400W mg kg 
Figure  4  P e r c e n t a g e  of  v i a b l e  i sola ted  d u o d e n a l  e p i t h e l i a l  cells,  a s  
assessed  by  T r y p a n  b l u e  e x c l u s i o n  (per  cent  ce l ls  e x c l u d i n g  d y e :  u p p e r  
g r a p h l .  o r  M T T  c o n v e r s i o n  ( p e r  cent  c o n t r o l ;  l o w e r  g r a p h ) .  5  h  
fo l l owing  c h a l l e n g e  wi th  H.  pylori  l i p o p o l y s a c c h a n d c  ( L P S ;  
3  ml  k g " ' .  i .v.)  in  r a t  t r e a t e d  c o n c u r r e n t l y  w i t h  sa l ine  ( c o n t r o l )  o r  with  
N - ( 3 - ( a m i n o m e t h y l ) b c n z y l ) a c e t a m i d i n e  (1400  W :  0 . 2 - 5  m g  k g " 1 .  
• v.).  D a t a  a r e  m e a n ± s . c . m o a n  o f  5 - 4  e x p e r i m e n t s ,  w h e r e  *  d e n o t e s  
a  s ign i f i can t  d i f f e r e n c e  f r o m  t h e  c o n t r o l  ( P c O . O l )  a n d  *  a  s ign i f ican t  
d i f f e r ence  f r o m  t h e  L P S  a l o n e  g r o u p  i P < 0 . 0 5 ) .  
1  S O D - P E G  
i.u.  kg  
F igure  6  P e r c e n t a g e  o f  v i ab le  i s o l a t e d  d u o d e n a l  ep i the l i a l  cei ls ,  a s  
assessed  b y  T r y p a n  b l u e  exc lus ion  ( p e r  c en t  o f  cells  e x c l u d i n g  d y e ;  
u p p e r  g r a p h ) ,  o r  M T T  c o n v e r s i o n  ( p e r  cen t  c o n t r o l ;  l ower  g r a p h ) ,  
5 h  f o l l o w i n g  c h a l l e n g e  w i t h  H.  pyiori  l i p o p o l y s a c c h a r i d e  ( L P S :  
3 m g k g ~ ' .  i .v .)  in  r a t  t r e a t e d  c o n c u r r e n t l y  wi th  sa l ine  o r  w i t h  
s u p e r o x i d e  d i s m u t a s e  c o n j u g a t e d  w i t h  p o l y e t h y l e n e  glycol  ( S O D -
P E G :  2 5 0 - 5 0 0  i .u.  k g " ' ,  i.v  ).  In  c o n t r o l  e x p e r i m e n t s ,  a  g r o u p  o f  
ra t s  r ece ived  S O D - P E G  (500  i .u.  k g " ' ,  i.v.).  D a t a  a r e  m e a n  +  
s . e . m e a n  o f  5 - 1 0  e x p e r i m e n t s ,  w h e r e  *  d e n o t e s  a  s i g n i f i c a n t  
d i f f e r e n c e  f r o m  t h e  c o n t r o l  ( P < 0 . 0 5 >  a n d  *  d e n o t e s  a  s i g n i f i c a n t  
d i f f e r e n c e  f r o m  t h e  H.  pylori  L P S  g r o u p  a l o n e  ( / > < 0 . 0 5 ) .  
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intravenous  administration  of  an  H.  pylori  water  extract  
(Lamarque  et  al..  1998).  In  the  present  investigation,  a  dose-
dependent  elevation  of  iNOS  activity  was  observed  in  rat  
duodenal  epithelial  cells  5  h after intravenous  challenge with  a  
purified  LPS  from  H.  pviori.  In  addition,  dose-dependent  
iNOS  induction  following  a  single  intragastric  administration  
of  H.  pylori  LPS  was  likewise  observed  in  the  current  study.  
The  higher  doses  required  by  this  latter  route  may  reflect  the  
requirement  of  penetration  of  the  LPS  through  the  mucus  
barrier  overlying  the  epithelium.  
Expression  of iNOS in colonic and  small intestinal  epithelial  
cells  following  E.  coli  endotoxin  challenge  is associated  with  a  
reduction  in  epithelial  cell  viability  (Tepperman  et  al.,  1993;  
1994).  Likewise,  in  the  present  study,  a  reduction  in  duodenal  
epithelial  cell  viability,  determined  ex  vivo using  both  Trypan  
blue  dye  exclusion  and  the  MTT  mitochondrial  assay  on  
harvested  cells,  was  observed  5  h  after  intravenous  adminis-
tration  of  the  H.  pylori  LPS.  An  increase  in  the  incidence  of  
apoptosis  was  also  observed  in  these  duodena!  cells  following  
challenge  with  this  LPS.  Duodenal  epithelial  cell  injury  was  
likewise observed after the  single intragastric administration  of  
the  LPS.  Recent  studies  have  also  shown  that  the  repeated  
intragastric  administration  of  an  H.  pylori  LPS  preparation,  
that  induced  iNOS  in  the  rat  gastric  mucosa,  could  also  
provoke  apoptosis  in  the  gastric  epithelial  cells  (Slomiany  et  
al..  1998a.b).  
Other  studies have demonstrated  that duodenal  perfusion of 
an  extrae:  of  H.  pylori  reduced  alkaline  secretion  in  the  rat,  
considered  to  reflect  inhibition  of  NO  formation  by  agents  
formed  from  local  peptidase  activity  on  proteins  contained  in  
the crude extract (Fandriks  et al.,  1997). Comparable effects on 
alkaline  secretion  were  not  seen  with  extracts  of  E.  coli.  
However,  any  such  inhibitors  would  be  unlikely  to  influence  
the  present  results  obtained  following  parenteral  administra-
tion  of  purified  LPS.  
Our  results  suggest  that  the  activity  of  H.  pylori  LPS  on  
iNOS expression, as well as cytotoxicity,  in duodenal  epithelial  
cells were of a similar order  of magnitude to that  observed  with  
E. coli. at  the dose investigated, although dose-response  studies  
were  not  conducted.  Such  a  finding  in  vivo  is  in  contrast  to  
previous  studies  with  LPS  in  vitro  (Perez-Perez  et  al.,  1995;  
Shapiro  &.  Hotchkiss,  1996).  Thus,  although  H.  pylori  LPS  
induced  the production  of NO from macrophages  in culture,  it  
was 2 x  10J  fold  less  potent  than  the  LPS from  E.  coli,  which  
may  reflect  both  the nature  of  the  in  vitro study  and  the  bone-
marrow  derived  cell type  utilized  for iNOS expression  in  those  
studies. 
It  has  been  established  that  administration  in  vivo  of  
preparations  of  H.  pylori  LPS  can  provoke  the  release  of  
pro-inflammatory cytokines,  which may also be involved  in  the 
pathological  processes  (Slomiany  et  al.,  1998b).  These  
cytokines  released  by  H.  pylori  may  also  act  through  NO-
dependen:  pathways  (Crabtree.  199S)  since  :he\  are  potent  
inducers of  the iNOS enzyme.  It  is feasible that  the initiation  of  
a  cascade  of  pro-inflammatory  mediators  in  vivo  that  can  
induce iNOS. may  in part, explain  the activity  seen under  these  
present  conditions  compared  with  the  low  potency  of  the  H.  
pylori  LPS  for  iNOS  expression  in  vitro,  confirming  the  
importance  of  in  vivo  models  in  the  understanding  of  these  
pathological  processes.  
In  the  present  study,  the  reduction  in  cell  viability  and  the  
iNOS  activity  that  followed  challenge  with  the  H.  pylori  LPS  
was inhibited  by concurrent  administration  of  1400 W,  known  
to  be a  highly  selective  inhibitor  of  iNOS (Garvey  et  al,  1997;  
Laszlo  &  Whittle,  1997).  Indeed,  at  the  doses  of  1400  W  that  
abolished  iNOS  activity,  no  greater  cellular  injury  than  under  
control  conditions  was  detected  by  dye-exclusion  or  the  MTT  
assay. These  findings  strongly  implicate  the  involvement  of the 
iNOS  activity  in  the  process  that  lead  to  the  epithelial  cell  
injury following challenge with  the  LPS. The data  also  suggest  
that  the  levels  of  iNOS  activity,  rather  than  the  total  NO  
synthase activity,  is of importance  in  the  process  of cell  injury.  
This may reflect the prevailing conditions  of the  microen\iron-
ment  which  lead  to iNOS expression,  especially the presence  of  
other cytotoxic  moieties and  the subsequent  interactions  of the 
NO  so  generated.  
Intravenous  administration  of  the  systemically  active  
conjugate,  S O D - P E G ,  that  scavenges  superoxide,  die  not  
prevent  the expression  of iNOS activity,  but  did  inhibit  the cell 
damage  induced  by  H.  pylori  LPS.  Such  findings,  therefore,  
support  the  involvement  of  the  superoxide  anion,  along  with  
NO.  in  the  cell  damage  induced  by  H.  pylori  LPS.  These  
findings  also  imply  that  a  close  correlation  between  oniv  one  
potential  cytotoxic  process,  such  as  iNOS  expression  aione,  
would  not  be  anticipated,  especially  if  these  processes  interact  
syncrgistically.  In  recent  studies,  the  damage  induced  by  
intravenous  challenge  with  E.  coli  LPS  in  rat  small  intestinal  
epithelial  cells,  using similar  techniques as described  previously  
(Lamarque  et  al.,  1998), has  also  been shown  to  be  attenuated  
by  administration  of  a  SOD-mimetic  (Salvamini  et  a!..  1999).  
Sonicates  of  H.  pylori  have  been  shown  to  induce  an  
oxidative  burst  in  human  polymorphonuclear  and  monocytes  
(Nielsen  & Andersen,  1992). and  purified  LPS has been  shown  
to  prime  neutrophils  for  increased  activity  on  subsequent  
stimulation  (Nielsen  et  al..  1994).  In  addition,  an  increased  
luminol  chemiluminesence.  which  reflects  the  generation  of  
reactive  oxygen  species,  has  been  found  in  the  gastric  antrum  
of patients infected  by  H. pylori  (Davies  et  al..  1994). The  local  
release  of  these  cytotoxic  oxygen  radicals  has  hence  been  
suggested  to  play  a  role  in  the  mucosal  lesions  observed  in  
peptic  ulcer  disease  associated  with  H.  pylori  (Nielsen  &  
Andersen,  1992;  Davies  et  al.,  1994).  Increased  iNOS  
expression  has  also  be  observed  in  gastric  biopsies  from  
patients  with  H.  p.v/ori-associated  gastritis  (Hahm  et  al..  1997;  
Fu  et  al.,  1999).  By interacting with NO formed by iNOS.  these  
oxygen  species  may  form  further  damaging  products  such  as  
peroxynitrite  that  can  induce  lipid  peroxidation  (Beckman  et  
al.,  1990). Such  reactive species may also provoke epithelial cell  
injury  by  activating  poly  (ADP-ribose)  synthase  that  depletes  
the intracellular  energy  store  (Kennedy  et  al.,  1998).  Although  
superoxide production  has not  determined  in the present  study  
using  freshly  isolated  duodenal  epithelial  cells,  it  has  been  
demonstrated  in previous studies in rat gastric epithelial  cells in 
culture  following  ethanol  challenge  (Hirashi  et  a!..  1999).  
Moreover,  the  damage  induced  by intravenous  challenge  with  
E.  coli  LPS  in  rat  small  intestinal  epithelial  cells  has  been  
shown  to  be  reduced  by  agents  that  act  as  peroxynitrite  
decomposition  catalysts  (Salvemini  et  at.,  1999),  providing  
support  to  the  involvement  of  peroxynitrite  in  such  
cytotoxicity. 
The  increase  in  DNA  fragmentation,  as  an  index  of  
apoptosis,  observed  in  duodenal  epithelial  cells  from  rats  
challenged  with  H.  pylori  LPS  in  the  present  study,  was  
suppressed  in  cells  from  rats  pretreated  with  SOD-PEG.  
These  results  suggest  the  involvement  of  peroxynitrite  in  the  
NO-dependent  apoptopic  process.  The  mechanism  of  the  
apoptosis  induced  by  peroxynitrite  in  neuronal  cells  is  
considered  to  involve  the  Bcl-2  pathway  and  the  impairment  
of  the  mitochondrial  function  (Almeida  et  al..  199S:  Keller  et  
al..  1998).  It  is  therefore  relevant  that  mitochondrial  function  
assessed  by  MTT  conversion  was  diminished  after  H.  pviori  
LPS challenge  which  was prevented S O D - P E G  pretreatment,  
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suggesting  that  this  cytotoxic  process  also  operates  in  the  
duodenal  epithelial  cells.  
The  expression  of  iNOS  in  duodenal  epithelial  cells  could  
reflect  a  host-defence  mechanism  against  colonization  by  H.  
pylori,  since  N O  can  exert  bactericidal  actions  (Evans  et  al„  
1996; Granger  et  ai.,  1988).  Furthermore,  the  present  findings  
indicate  that  induction  of  iNOS  can  provoke  local  epithelial  
cytotoxicity as  well as stimulating apoptosis,  which  would  thus  
lead  to  the  clearance  of  the  epithelial  cells  on  which  H.  pylori  
was adhering  (Kim  et  al.,  1998).  
The  current  findings  thus  give support  to  the  concept  that  
release  of  H.  pylori  LPS  in  vivo  may  lead  to  the  local  
production  of  elevated  concentrations  of  NO  from  duodenal  
epithelium  and  possibly  other  mucosal  cells,  through  the  
expression  of  iNOS.  The  findings  that  the  cytotoxic  actions  
and  apoptosis  in  these cells  following challenge  with  H.  pylori  
LPS  can  be  attenuated  both  by  the  selective  iNOS  inhibitor,  
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Abstract 
W e  s t u d i e d  t h e  a c t i o n s  o f  p u r i f i e d  Helicobacter  pylori  e n d o t o x i n  (3 m g  k g " 1 ,  i .v . ) o n  r a t  i n t e s t i n a l  v a s c u l a r  p e r m e a b i l i t y  ( a s s e s s e d  
b y  t h e  r a d i o l a b e l l e d  h u m a n  s e r u m  a l b u m i n  l e a k a g e  t e c h n i q u e )  a n d  o n  n i t r i c  o x i d e  s y n t h a s e  i n d u c t i o n  ( a s s e s s e d  by  t h e  c i t r u l l i n e  
a s s a y )  4  h  l a t e r .  W e  f o u n d  i n c r e a s e d  a l b u m i n  l e a k a g e  a n d  e x p r e s s i o n  o f  t h e  i n d u c i b l e  n i t r i c  o x i d e  s y n t h a s e  in j e j u n u m  a n d  c o l o n ,  
e f f e c t s  r e v e r s e d  b y  a  se l ec t ive  i n d u c i b l e  n i t r i c  o x i d e  s y n t h a s e  i n h i b i t o r  N - ( 8 - ( a m i n o m e t h y l ) b e n z y l ) - a c e t a m i d i n e  ( 1 4 0 0 W ;  0 . 2 - 1  m g  
k g " ' ,  s .c. ,  c o n c u r r e n t l y  w i t h  e n d o t o x i n ) .  T h u s ,  H. pylori  e n d o t o x i n  s e e m s  t o  b e  c a p a b l e  o f  p r o v o k i n g  a n  i n f l a m m a t o r y  r e s p o n s e  in  
t h e  r a t  i n t e s t i n a l  t i s sue .  S y s t e m i c  l i b e r a t i o n  o f  H.  pylori  e n d o t o x i n  m i g h t  p o s s i b l y  a t t e n u a t e  j e j u n a l  a n d  c o l o n i c  m u c o s a l  b a r r i e r  
f u n c t i o n ,  a  p r o c e s s  m e d i a t e d  b y  t h e  e x p r e s s i o n  o f  t h e  i n d u c i b l e  n i t r i c  o x i d e  s y n t h a s e .  ©  2 0 0 1  E l s e v i e r  S c i e n c e  L t d .  A l l  r i g h t s  
r e s e r v e d . 
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1.  Introduction  
Helicobacter  pylori  is  an  acid-resistant  bacterium,  
which  can  grow  only  at  low  pH,  predominantly  in  the  
antral  part  of  the  stomach.  The  incidence  of  H.  pylori  
infection  is  high,  approaching  50-80%  in  European  
adults.  The  pathological  involvement  of  H.  pylori  is  
known  in  gastroduodenal  inflammation  and  duodenal  
ulceration,  and  it  might  participate  in  the  generation  of  
gastric  malignancies  [6]. Although  the  clinical  impact  of  
a  better  understanding  of  how  H.  pylori  affects  gastro-
intestinal  mucosa  is  high,  only  few  investigations  had  
been  carried  out  by  using  its  purified  endotoxin  for  
exploring  its  local  or/and  systemic  effect.  In  chronic  
inflammatory  diseases  of  the  gut  (e.g.  in  inflammatory  
bowel  diseases),  the  overproduction  of  nitric  oxide  (NO)  
*  Corresponding  au thor .  Tel.:  +  36-1-210  9400  ext.  150;  fax:  +  36-
1-210  9423.  
E-mail  address:  l asz lof@kokl .hu  (F.  László).  
by  the  expression  of  the  inducible  N O  synthase  enzyme  
(iNOS)  is  cytotoxic,  and  has  a  pathological  impact  [7],  
It  increases  vascular  permeability,  and  leads  to  vaso-
congestion  [4],  
In  the  present  study,  we  investigated  the  relation  
between  the  expression  of  iNOS  and  intestinal  inflam-
mation  following  systemic  administration  of  a  purified  
H.  pylori  endotoxin  [5].  
2.  Materials  and  methods  
2.1.  Treatments  
We  used  male  Wistar  rats  (230-250  g).  They  were  
fasted  overnight,  but  received  water  ad  libitum.  Under  
transient  ether  anaesthesia,  purified  H.  pylori  endotoxin  
(from A.P.  Moran ' s  laboratory,  Ireland;  3 mg  kg""1)  was  
administered  intravenously.  In  a  separate  experiment,  
we  administered  a  bisisothiourea  derivative  selective  
iNOS  inhibitor  (from  Wellcome  Research  Laboratories,  
0928-4257/01/$  -  see  f ront  mat te r  ©  2001  Elsevier  Science  Ltd.  All  rights  reserved.  
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N-(8-(aminomethyl)-benzyl)acetamidine  [1400W],  0.2-1  
mg  k g - 1 ,  s.c.;  [2]) concurrently  with  endotoxin.  For  the  
measurement  of  vascular  permeability  or  iNOS  enzyme  
activity,  segments  of  the  je junum  and  colon  were  
removed  from  standard  sites  4  h  following  treatments.  
2.2.  Intestinal  nitric  oxide  synthase  enzyme  activity  
In  this  experiment,  we  used  untreated  (control)  and  
H.  pylori  endotoxin  (3  mg  k g - 1 ,  i.v.)-treated  groups  
alone  or  with  1400W  (1 mg k g - 1 ,  s.c.,  concurrently  with  
endotoxin)  administration.  In  jejunal  and  colonic  tis-
sues,  we  measured  the  calcium-dependent  constitutive  
N O  synthase  (cNOS)  and  the  calcium-independent  
iNOS  activity  by  the  citrulline  assay  as  described  pre-
viously  [1,2].  
2.4.  Chemicals  
We  obtained  [1 2 5I]human  serum  albumin  f rom  
IZINTA  (Budapest,  Hungary)  and  L-[U-14C]arginine  
monohydrochloride  from  Amersham  International  
(UK).  All  other  compounds  were  from  Sigma.  
2.5.  Statistics  
In  these  studies,  the  results  were  expressed  as  mean-
± S . E . M .  of  (n)  rats  in  a  group.  Data  were  analysed  
with  the  Tukey-Kramer  multiple  comparisons  test,  
where  F < 0 . 0 5  was  taken  as  significant.  
3.  Results  
2.3.  Intestinal  vascular  permeability  3.1.  Expression  of  intestinal  inducible  nitric  oxide  synthase  
In  separate  groups  of  rats,  as  a  measure  of  inflamma-
tion,  we  examined  jejunal  and  colonic  vascular  perme-
ability  by using  the  radiolabeled  human  serum  albumin  
leakage  technique  as  has  been  established  in  earlier  
studies  [1],  We  used  H.  pylori  endotoxin  (3  mg  k g - 1 ,  
i.v.)-treated  groups  alone  or  with  1400W  (0.2-1  mg  
k g - 1 ,  s.c.,  concurrently  with  endotoxin)  administration.  
Administration  of  H.  pylori  endotoxin  led  to  the  
expression  of  iNOS  activity  in  the  jejunum  and  colon  
(n = 4,  P < 0.001)  4  h later,  an  effect which  was  abolished  
by  the  administration  of  1400W  (p = 4,  F<0 .001)  in  
both  intestinal  tissues  (Fig.  1).  Basal  cNOS  activities  
remained  unchanged  throughout  the  experiments  (n = 4, 
data  are  not  shown).  
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Fig.  1.  Expression  of  i N O S  (described  in  pmol  m i n - 1  m g - 1  protein  
units)  in  the  rat  jejunal  and  colonic  tissue  4  h  af ter  the  adminis t ra t ion  
of  purified  Helicobacter  pylori  endotoxin  (LPS;  3 mg  kg~ ' ,  i.V.), and  its  
reversal  by  the  selective  i N O S  inhibi tor  1400W  (1  mg  k g - 1 ,  s.c.,  con-
currently  with  LPS).  D a t a  are  expressed  as m e a n i S . E . M . ,  where  n =  4  
rats  in  a  group.  *P<0.05  means  significant  increase  in  iNOS  activity  
compared  with  the  untreated  cont ro l  (Cont . )  group;  # P <  0.05  means  
significant  decrease  in  i N O S  activity  compared  to  the  LPS  alone  
group . 
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Fig.  2.  Provocat ion  of je junal  and  colonic  a lbumin  leakage  (expressed  
as  pi  a lbumin  g _ l  dry  tissue)  by  the  adminis t ra t ion  of  a  purified  Heli-
cobacter  pylori  endotoxin  (LPS;  3 mg k g - 1 ,  i.v.)  4  h  later,  and  its  dose-
dependent  a t tenuat ion  by  the  concurrent  adminis t ra t ion  of  a  selective  
i N O S  inhibitor  ( I400W,  0 .2-1  mg  k g - 1 ,  s.c.).  Da ta  are  expressed  as  
m e a n i S . E . M . ,  where  n = 4 - 6  rats  in  a  group.  * P <  0.05  means  sig-
nificant  increase  in  a lbumin  leakage;  # P <  0.05  means  significant  
decrease  in  a lbumin  leakage  c o m p a r e d  to  the  LPS  alone  group.  
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3.2.  Intestinal  vascular  permeability  
Administration  of  H.  pylori  endotoxin  (3  mg  kg - 1 ,  
i.v.)  alone  provoked  significant  small  and  large  intest-
inal  albumin  leakage  4  h  later  (Fig.  2).  Concurrent  
administration  of  the  selective  inhibitor  of  iNOS,  
1400W  with  H.  pylori  endotoxin  dose-dependently  atte-
nuated  jejunal  and  colonic  albumin  leakage  after  4  h  
(83±5%  and  9 4 ± 3 %  maximal  reduction,  respectively;  
« = 4-6,  F <0.01)  as demonstrated  in  Fig.  2.  
4.  Discussion  
Our  present  results  support  previous  observations,  
when  a  H.  pylori  extract  was  administered  intrave-
nously,  and  the  expression  of  iNOS  in  the  duodenum  
and  in  its  epithelial  cells  had  been  found  [3].  The  
expression  of iNOS correlated  with  epithelial  cell  death,  
and  could  be  reversed  by  the  administration  of  the  cor-
ticosteroid,  dexamethasone,  and  by  the  treatment  with  
NG-nitro-L-arginine  methyl  ester,  a  non-specific  NO  
synthase  blocker  at  the  time  of  the  expression  of  iNOS  
[3]. Thus,  H.  pylori  extract  could  damage  the  intestinal  
mucosa  by its direct  toxic effect on epithelial  cells,  which 
is  mediated  by  iNOS.  The  vascular  injury  correlating  
with  iNOS expression, and  their  reversal  by the  selective  
iNOS  inhibitor,  1400W  following  the  challenge  with  H.  
pylori  purified  endotoxin  in  our  study  suggest  that,  
besides  the  damage  of  epithelial  cells,  microcirculatory  
dysfunction  can  also  participate  in  H.  pylori-related  
inflammation.  Moreover,  the  induction  of NO  synthase  
and  microvascular  leakage  in  the  jejunum  and  colon  
might  also  reflect  H.  pylori  endotoxin-provoked  muco-
sal  injury in  other  parts  of  the  gastrointestinal  tract.  
In  conclusion,  H.  pylori  endotoxin  is capable  of  pro-
voking  an  inflammatory  response  in  the  rat  intestinal  
tissue.  Systemic  release  and  circulation  of  H.  pylori  
endotoxin  could  attenuate  the  mucosal  barrier  function  
455 
of  the jejunum  and  colon.  This  process  is  mediated  by  
iNOS.  Thus,  the  clinical  implication  is  that  selective  
inhibitors  of  iNOS  might  have  potential  therapeutic  
benefit  in  the  prevention  and  treatment  of  H.  pylori-
associated  gastrointestinal  mucosal  inflammation.  
Acknowledgements 
This  work  was supported  by  the  Hungarian  Research  
Foundation  (OTKA  T-03  2143)  and  by  the  Hungarian  
Ministry  of  Health  (ETT  84/2000).  Ferenc  László  and  
Éva Morschl  were sponsored  by the  Széchenyi  Professor  
Fellowship  of  the Hungarian  Ministry  of Education  and  
by  the  Soros  Foundation,  respectively.  
References 
[1]  N.K.  Boughton-Smith,  S.M.  Evans,  F.  Laszlo,  B.J.R.  Whittle,  
S. Moncada, The  induction or nitric oxide synthase and  intestinal  
vascular  permeability  by  endotoxin  in  the  rat,  Br.  J.  Pharmacol.  
110(1993)  1189-1195.  
[2]  E.  Garvey,  J.A.  Oplinger,  E.S.  Furfine,  R.J.  Ki IT,  F.  László,  
B.J.R.  Whittle,  R.G.  Knowles,  I400W  is  a  slow-,  tight-binding  
and  highly selective inhibitor  of inducible nitric oxide synthase  in  
vitro  and  in  vivo, J.  Biol.  Chem.  272 (1997)  4959-4963.  
[3]  D.  Lamarque,  J.  Kiss,  J.  Tankovic,  J.F.  Flejou,  J.C.  Delchier,  
B.J.R.  Whittle,  Induction  of  nitric oxide  synthase  in  vivo and  cell  
injury  in  rat  duodenal  epithelium  by  water  soluble  extract  of  
Helicobacter  pylori,  Br.  J.  Pharmacol.  123 (1998)  1073-1078.  
[4]  S. Moncada,  E.A.  Higgs,  Molecular  mechanisms  and  therapeutic  
strategies  related  to  nitric  oxide,  FASEB J.  9 (1995)  1319-1330.  
[5]  A.P.  Moran,  Helicobacter  pylori  lipopolysaccharide-mediated  
gastric  and  extragastric  pathology,  J.  Physiol.  Pharmacol.  50  
(1998)  787-805.  
[6]  NIH  consensus  development  panel  on  Helicobacter  pylori  in  
peptic  ulcer  disease, JAMA  272 (1994)  65-69.  
[7]  B.J.R.  Whittle,  F.  Laszlo,  S.M.  Evans,  S. Moncada,  Induction  of  
nitric  oxide synthase  and  microvascular  injury  in  the  rat jejunum 
provoked  by  indomethacin,  Br.  J.  Pharmacol.  116  (1995)  2286-
2290. 
1 . 
Varga  Cs.,  Pavo  I., Lamarque  D.,  Szepes  Z.,  Kiss J., Karacsony  G.,  Laszlo  F.A.,  
Laszlo  F.  
Endogenous  vasopressin  increases  acute endotoxin  shock-provoked  
gastrointestinal  mucosal  injury  in the  rat. Eur.  J. Pharmacol.  1998;352:257-261.  
E L S E V I E R  European  Journal  of  Pharmacology  352  ( 1998)  257-261  
ejp 
Endogenous  vasopressin  increases  acute  endotoxin  shock-provoked  
gastrointestinal  mucosal  injury  in the  rat  
Csaba  Varga  a,  Imre  Pávó  b,  Dominique  Lamarque  Zoltán  Szepes  d,  József  Kiss  d,  
Gizella  Karácsony  d,  Ferenc  A.  László  a,  Ferenc  László  d'*  
"  Dept.  of  Comparative  Physiology,  Attila  József  University  of  Sciences,  Szeged,  Hungary  
b  Endocrine  Unit,  Albert  Szent-Györgyi  Medical  University,  Szeged,  Hungary  
c  Hospital  Henri  Mondor,  University  of  Paris  XII,  INSERM  U99,  Creteil,  France  
d  First  Dept.  of  Medicine,  Albert  Szent-Györgyi  Medical  University,  P.B.  469,  H-6701  Szeged,  Hungary  
Received  5 January  1998; revised  27  April  1998;  accepted  30  April  1998  
Abstract 
A d m i n i s t r a t i o n  o f  a  l o w  d o s e  o f  e n d o t o x i n  ( f r o m  Escherichia  coli,  3  m g k g - 1 ,  i .v.) ,  w h i c h  d o e s  not  a f f e c t  v a s c u l a r  pe rmeab i l i t y  o r  
b l o o d  p re s su re  o v e r  1 h,  l eads  to  the  r e l ea se  o f  e n d o g e n o u s  v a s o p r e s s i n  and  d a m a g e  to  the  m u c o s a l  m i c r o v a s c u l a t u r e .  T h u s ,  e n d o g e n o u s  
v a s o p r e s s i n  c o u l d  b e  i n v o l v e d  in  sep t i c  s h o c k .  In  the  p r e s e n t  s tudy ,  w e  inves t iga ted  the  ro le  o f  e n d o g e n o u s  v a s o p r e s s i n  in  gas t ro in tes t ina l  
m u c o s a l  i n ju ry  i n d u c e d  b y  a c u t e  e n d o t o x i n  s h o c k ,  w h i c h  w a s  g e n e r a t e d  in  ra ts  b y  a d m i n i s t e r i n g  a  h igh  d o s e  o f  E.  coli  e n d o t o x i n  ( 5 0  
m g k g - 1 ,  i .v.).  T i s s u e s  w e r e  r e m o v e d  15  m i n  a f t e r  e n d o t o x i n .  T h e  v a s o p r e s s i n  V,  r e c e p t o r  a n t a g o n i s t ,  d [ C H 2 ] 5 T y r [ M e ] a r g i n i n e -
vasop re s s in  ( 0 . 2 - 1  / u g k g - 1 ,  i .v . ) ,  w a s  i n j e c t e d  10  m i n  b e f o r e  e n d o t o x i n .  M o n a s t r a l  b lue  ( 3 0  m g k g - 1 ,  i .v.),  w h i c h  s ta ins  d a m a g e d  
vascu l a tu r e ,  w a s  i n j e c t e d  10  m i n  b e f o r e  a u t o p s y .  E n d o t o x i n  r e d u c e d  sy s t emic  ar ter ia l  b l o o d  p r e s s u r e  ( f r o m  115  +  5  to  4 2  ±  4  m m H g ) ,  
g e n e r a t e d  m a c r o s c o p i c  a n d  m i c r o v a s c u l a r  i n ju ry ,  a n d  e l eva t ed  p l a s m a  v a s o p r e s s i n  leve ls  ( f r o m  3 .4  +  0 .2  to  178  ±  16  p g m l " 1 ) .  T h e  
v a s o p r e s s i n  V,  r e c e p t o r  a n t a g o n i s t  r e d u c e d  th i s  m a c r o s c o p i c  in ju ry ,  and  in  the  v a s o p r e s s i n - d e f i c i e n t  B r a t t l e b o r o  rat  a  s imi la r  r e d u c t i o n  o f  
gas t ro in tes t ina l  m u c o s a l  d a m a g e  w a s  f o u n d .  Subs tan t i a l  d e c r e a s e s  in  e n d o t o x i n - i n d u c e d  m i c r o v a s c u l a r  d a m a g e  w e r e  o b s e r v e d  in  each  
t i s sue ,  e.g. ,  t he  gas t r ic  M o n a s t r a l  b l u e  s t a in ing  w a s  r e d u c e d  b y  4 7  ±  3 %  and  9 6  ±  3 %  (  P  <  0 . 0 1 )  a f t e r  v a s o p r e s s i n  V,  r e c e p t o r  an t agon i s t  
t r e a t m e n t  and  in  B r a t t l e b o r o  rats ,  r e s p e c t i v e l y .  V a s o p r e s s i n ,  a c t i n g  t h r o u g h  its  V,  r e c e p t o r s ,  t h u s  a p p e a r s  to  be  i n v o l v e d  in  acu t e  
e n d o t o x i n  s h o c k - p r o v o k e d  gas t ro in t e s t i na l  i n ju ry .  ©  1998  E l s e v i e r  Sc i ence  B .V.  All  r igh t s  r e s e rved .  
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1.  Introduction  
Endotoxin  shock  is  characterised  by  hypotension,  in-
creased  vascular  permeability  and  gastrointestinal  damage.  
Bleeding  from  this  gastrointestinal  erosions  commonly  oc-
curs.  Once  the  bleeding  becomes  manifested,  it  augments  
the  severe  condition  and  elevates  the  mortality  rate  (Robert  
and  Kauffman,  1989;  Root  and  Jacobs,  1991).  Although  it  
is  important  to  prevent  these  stress  erosions,  it  is  currently  
not  known  how  this  should  be  done  (Ben-Manachem  et  al.,  
1994). 
Stress  erosions  have  a  multifactorial  pathogenesis.  Mi-
crovascular  damage,  which  leads  to  hypoxia,  has  been  
'  Corresponding  author.  Tel.:  +  36-62-455-186;  fax:  +36-62-455-185.  
shown  to  be  an  important  factor  in  the  generation  of  
gastrointestinal  stress  erosions  (Robert  and  Kauffman,  
1989)  as  well  as  in  the  septic  shock  (Bone,  1991).  In  
endotoxin  shock,  the  impaired  microcirculation  may  result  
from  a  direct  injurious  action  of  the  lipopolysaccharide  
component  of  the  bacterial  wall  on  the  vascular  endothe-
lium  (Harlan  et  al.,  1983;  Meyrick  et  al.,  1986),  or  may  
reflect the formation of tissue-damaging  neutrophil-  and/or  
endothelium-dependent  vasoactive  mediators,  such  as  
platelet-activating  factor,  thromboxanes,  leukotrines  
and/or  endothelin  (Parillo,  1990;  Bone,  1991;  Baker  et  al.,  
1990;  Lefer  and  Lefer,  1993).  
The  early  release  of  the  potent  pituitary  nonapeptide,  
vasopressin,  into  the  plasma  has  been  detected  in  endotox-
aemic  states  in  humans  (Dennhardt  et  al.,  1989) and  in  rats  
(Baker  et  al.,  1990).  Endogenous  vasopressin,  acting  
through  its  pressor  (V,)  receptors,  has  been  demonstrated  
0 0 1 4 - 2 9 9 9 / 9 8 / $  19.00  ©  1998  Elsevier  Science  B.V.  All  riehts  reserved.  
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to have an aggressive  action  on the gastrointestinal  mucosa  
during  the  generation  of  mucosal  stress  erosion,  e.g.,  le-
sions  induced by ethanol,  indomethacin,  reserpine,  cold-re-
straint  stress  and haemorrhagic  shock (László  et  al.,  1991a,  
1994,  1996;  László  and  Whittle,  1994).  It  has  also  been  
found that  in the early phase  of  endotoxaemia,  i.e.,  follow-
ing  the  administration  of  a  low  dose  of  endotoxin  (which  
does  not  affect  vascular  permeability  or  blood  pressure),  
endogenous  vasopressin  counteracts  the  actions  of  en-
dothelium-derived  protective  factors,  such  as  constitutive  
nitric oxide (László  and Whittle,  1994). This might  suggest  
that  endogenous  vasopressin  can  be  involved  in  septic  
shock,  i.e.,  in  the  generation  of  microvascular  dysfunction  
and  damage.  The  aim  of  our  present  study  was  to  investi-
gate  the  effect of  vasopressin  on  the  development  of  acute  
gastrointestinal  mucosal injury induced by endotoxin  shock.  
For  the  evaluation  of  the  actions  of  vasopressin  released  
endogenously,  we  used  a  vasopressin-deficient  rat  strain  
(homozygous  Brattleboro  rats;  for  review  see  Sokol  and  
Valtin,  1982) and  a specific vasopressin  V,  receptor  antag-
onist  (for  review  see  László  et  al.,  1991b).  
Part  of  this  work  has  been  presented  to  The  British  
Society  of  Gastroenterology  (László  et  al.,  1993)  and  to  
The  IVth  International  Vasopressin  Conference  (Berlin,  
Germany,  1993  May).  
2.  Materials  and  methods  
2.1.  Experimental  protocol  
Female  Wistar  and  homozygous  Brattleboro  rats  (from  
our  breeding  farm),  weighing  200-220  g,  were  fasted  for  
24  h,  but  received  water  ad  libitum.  The  animals  were  
anaesthetised  with  Nembutal  (40  m g k g - 1 ,  ¡.p.;  Serva,  
Heidelberg,  Germany)  and  Escherichia  coli  endotoxin  
(serotype  0111 :B4;  50 mg kg"1 ;  Sigma)  or  saline  (control)  
was  injected  into  the  tail  vein  and  the  rats  were  killed  15  
min  later.  This  high  dose  of  endotoxin  was  chosen  on  the  
basis  of  previous  studies  to  generate  a  mild-moderate  
grossly  visible  mucosal  injury  (Hutcheson  et  al.,  1990).  
For  staining  of  the  injured  vasculature,  all  rats  were  in-
jected  with  Monastral  blue  (30  m g k g - 1 ,  i.v.;  Sigma)  10  
min  before  autopsy.  It  should  be  mentioned  here  that  this  
colloidal  stain  penetrates  only  through  damaged  microvas-
cular  endothelial  cells,  and  not  through  the  basal  mem-
brane.  The  vasopressin  V,  receptor  antagonist,  
d[CH2]sTyr[Me]arginine-vasopressin  (0.2-1  /Agkg - 1 ;  
Bachem,  Germany),  was  injected  i.v.  10  min  before endo-
toxin  administration.  These  doses  of  the  vasopressin  V,  
receptor  antagonist  were  selected  from previous  studies  on  
the  basis  of  their  potency  to  reduce  the  increase  in  blood  
pressure  provoked  by  exogenous  vasopressin  and  to  pro-
tect  the  gastric  mucosa  against  damage,  i.e.,  against injury 
provoked  by  ethanol,  indomethacin,  reserpine,  cold-re-
straint  stress  and haemorrhagic  shock (László  et al.,  1991a,  
1994,  1996).  Blood  pressure  in  the  right  carotid  artery  was  
monitored  with  an  Elcomatic  blood  pressure  transducer  
connected  to  a  Grass  Polygraph.  
2.2.  Gross  evaluation  of  lesions  
The  stomach,  duodenum  and  jejunum  were  removed,  
stretched  out  oh  cork  and  photographed.  The  lesions  were  
examined  by  an  investigator  unaware  of  the  nature  of  the  
experiment  and  scored  on  the  basis  of  a  semiquantitative  
scale  (from  0  to  III),  where  0 =  no  damage;  1 = 1 - 5  
petechiae  on  the  mucosal  surface;  II =  more  than  5  pe-
techiae  and/or  mild  vasocongested  parts;  III  =  severe  
vasocongestion  (Hutcheson  et  al.,  1990).  
2.3.  Microvascular  damage  
Two  standard-size  ( 3 X 1 0  mm)  pieces  of  tissue  were  
cut  out  from standard  sites  of  the  stomach,  duodenum  and  
jejunum,  fixed  in  formalin  and  embedded  in  paraffin.  For  
histological  staining  of  vascular  elastic  fibres,  orcein  stain  
was  used.  In  these  sections  the  background  was  light  
brown, blood vessels  were dark brown,  and  injured vessels 
were  blue. The  distance  of  damaged  blood  vessels  (stained  
with  Monastral  blue)  from the  serosal  parts  was  measured  
with  an  ocular  micrometer,  and  data  are  expressed  as  the  
maximum  average  distance  of  injured  (i.e.,  Monastral  
blue-stained)  blood  vessels  from  the  serosal  surface  in  
/¿m. 
2.4.  Plasma  vasopressin  level  
For  the  evaluation  of  changes  in  plasma  arginine-
vasopressin  levels,  in  a  separate  study,  rats  were  decapi-
tated  and  blood  was  immediately  collected  from the  wound  
before  (0  min)  and  after  (15  min)  endotoxin  administra-
tion.  In  control  studies  plasma  arginine-vasopressin  levels  
were  measured  in  intact  animals  that  had  been  fasted  for  
24  h,  but  which  had  access  to  water  ad  libitum.  Plasma  
arginine-vasopressin  level  was  determined  with  a  specific  
radioimmunoassay  system  as  described  previously  (László  
et  al.,  1994).  
2.5.  Statistics  
For  statistical  comparisons,  analysis  of  variance  with  
the  Bonferroni  test  was  used.  Differences  were  taken  as  
significant  when  the  probability  was  less  than  5%.  
3.  Results  
3.1.  Gross  evaluation  of  lesions  
Administration  of  endotoxin  (50 m g k g - 1 ,  i.v.)  reduced  
blood  pressure  by  63%  (Table  l).  As  described  previously  
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Table  1  
Blood  pressure  (mmHg)  before  and  during  acute  (15  min)  endotoxin  
(LPS)  shock  in  rats  
Groups—treatments Before  treatment  After  treatment  
Saline  (control)  98 ± 6 95 ± 5 
LPS (50  m g k g - 1 )  1 1 5 ± 5 42 ±4» 
LPS + V,  antagonist(  1  ¿ r g k g " 1 )  1 1 2 ± 5 50 ±5» 
LPS  in  Brattleboro  105 ± 7 43 ± 6 ' 
n  =  4 - 8 ;  mean±S.E .M.  
'P  <  0.05  before  treatment  groups  compared  to  after  treatment  groups.  
(Hutcheson  et  al.,  1990),  this  acute  endotoxin  shock  gener-
ated  gross  gastric,  duodenal  and  jejunal  mucosal  injury  in  
normal  (Wistar)  rats  15  min  later  (Fig.  1).  
Pretreatment  with  the  vasopressin  V,  receptor  antago-
nist  (0.2-1  / x g k g - 1 ,  i.v.)  dose  dependency  attenuated  the  
mucosal  damage  of  the  stomach,  duodenum  and  jejunum  
provoked  by  endotoxin  in  normal  (Wistar)  rats  (Fig.  1).  
Moreover,  endogenous  vasopressin  deficiency  (in  homozy-
gous  Brattleboro  rats)  also  reduced  macroscopic  mucosal  
damage  (Fig.  1).  The  vasopressin  V,  receptor  antagonist  (1  
/u,g k g - 1 ,  i.v.)  and  vasopressin  deficiency  did  not  affect the 
reduced  blood  pressure  caused  by  endotoxin  shock  (Table  
1). 
3.2.  Microvascular  damage  
Acute  endotoxin  shock  injured  intra-  and  submucosal  
and  subserosal  blood  vessels  in  the  stomach,  duodenum  
Table  2  
Histological  appearance  of  acute  (15  min)  vascular  damage  (assessed  by  
the  combination  of  orcein  staining  of  elastic  fibres  in  blood  vessels  with  
the  Monastral  blue  technique  for  staining  damaged  vessels)  induced  by  E.  
coli  lipopolysaccharide  (LPS,  50  m g k g " 1 ) ,  and  the  protection  provided  
by  a  vasopressin  V,  receptor  antagonist  and  vasopressin  deficiency  
(homozygous  Brattleboro  rat)  
Groups Stomach Duodenum Jejunum 
Saline  (control)  0.0 0.0 3.1  +  0.8"  
LPS 182.3 +  7.8  131.5 +  4.1  56.3 +  3.2  
LPS +  V,  antagonist  137.4 +  4.8"  98.0 +  3.3"  37.3 +  3.8"  
(0.2  / j -gkg" 1 )  
LPS + V,  antagonist  9 3 . 9 ± 5 . 9 a 23.9 +  2.7"  13.4 +  2.2"  
(1.0  M g k g " ' )  
LPS  in  Brattleboro  6 .1+3 .7" 1.8 +  0.9"  13.5  +  4.3"  
n  =  min  4;  mean  +  S.E.M.  
"P  <  0.05  compared  to  LPS-treated  groups,  data  are  expressed  as  the  
maximum  average  distance  (in  /urn)  of  damaged  blood  vessels  (stained  
with  Monastral  blue)  from  the  serosal  parts  of  the  organs.  
and  jejunum  within  15  min.  It  was  found  that  endotoxin  
administration  provoked  microcirculatory  damage  that  in-
volved  almost  the  entire  wall  of  the  gastrointestinal  organs  
investigated.  In  endotoxin-treated  control  rats  the  sub-
serosal  vessels  were  affected  the  most.  This  vascular  en-
dothelial  injury  induced  by  endotoxin  shock  was  signifi-
cantly  and  dose  dependently  attenuated  by  pretreatment  
with  the  vasopressin  V,  receptor  antagonist  (0.2-1  
/xgkg" 1 ,  i.v.)  and  by  vasopressin  deficiency  (in  homozy-
gous  Brattleboro  rats)  as  demonstrated  in  Table  2.  
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Fig.  1.  The  protective  effect  of  a  vasopressin  pressor  (V,)  receptor  
antagonist  (Antagonist;  d / C H 2 / 5 T y r / M e / a r g i n i n e - v a s o p r e s s i n ,  0 .2-1  
/ugkg" 1 ,  i.v.)  and  endogenous  vasopressin  deficiency  (in  homozygous  
Brattleboro  rats  (Brattleboro))  against  acute  (15  min)  endotoxin  (LPS,  50  
m g k g " ' ,  i.v.)  shock-induced  gastric,  duodenal  and  jejunal  lesions.  
Macroscopic  severity  scale:  0—III,  determined  by  an  investigator  unaware  
of  the  nature  of  the  experiment;  n  =  min  4;  mean±S.E.M. ;  *  P  <  0.05  
compared  to  the  LPS-treated  (CONTROL)  groups.  
3.3.  Plasma  vasopressin  level  
Anaesthesia  (Nembutal,  40  m g k g " 1 ,  i.p.)  elevated  cir-
culating  vasopressin  levels.  Endotoxin  shock  caused  a  
further  increase  in  plasma  vasopressin.  In  homozygous  
Brattleboro  rats  the  plasma  vasopressin  level  was  unde-
tectable  (Table  3).  
4.  Discussion  
In  the  present  study,  the  role  of  endogenous  vasopressin  
in  the  development  of  endotoxin  shock-provoked  acute  
Table  3  
Changes  in  plasma  arginine  vasopressin  level  during  acute  (15  min)  
endotoxin  (LPS,  50 m g k g " 1 ,  i.v.)  shock  in  rats  
Groups Vasopressin  levels (pgml  '  )  
Control  (conscious)  3.4 +  0.2"  
Saline  (anaesthetised)  4 3 . 6 ± 9 . 0 b 
LPS  (anaesthetised)  178.1  ±16.0"b  
LPS  in  Brattleboro  (anaesthetised)  >  1.0 + 0.0 
n  =  4 - 8 ,  mean±S.E .M.  
"P  <  0.05  compared  to  the  saline  group.  
bP  <  0.05  compared  to  the  control  group.  
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gastrointestinal  mucosal  and  microcirculatory  damage  was  
evaluated  in  the  stomach,  duodenum  and jejunum  of  rats.  
It  was  shown  that  administration  of  a  high  dose  of  endo-
toxin  reduced  arterial  blood  pressure,  elevated  circulating  
vasopressin  level  and  generated  gastric,  duodenal  and jeju-
nal  macroscopic  mucosal  and  microcirculatory  damage  in  
normal  (Wistar)  rats.  Our  observations,  in  relation  to  
changes  of  plasma  vasopressin  levels,  are  in  agreement  
with  previous  findings  in  which  an  increase  in  circulating  
vasopressin  following anaesthesia  or endotoxin  administra-
tion  has  been  described  (Reichlin,  1985;  Robertson,  1987;  
Dennhardt  et  al.,  1989;  Baker  et  al.,  1990).  Moreover,  we  
found  that  homozygous  Brattleboro  rats,  which  have  a  
congenital  deficiency to  synthesize  vasopressin  and  conse-
quently  have  diabetes  insipidus  (Sokol  and  Valtin,  1982),  
were  less  sensitive  to  the  injurious  actions  of  acute  endo-
toxin  shock.  Finally,  in  normal  rats,  administration  of  a  
vasopressin  V,  receptor  antagonist  dose  dependently  pro-
tected the gastrointestinal  microvasculature against  the  vas-
cular  endothelial  damage  induced  by  endotoxin.  These  
findings indicate  the  role  of  endogenous  vasopressin  in  the  
generation  of  acute  endotoxin  shock-induced  gastrointes-
tinal  stress  erosions.  
Microvascular  permeability  and  gastrointestinal  damage  
may  respond  to  initial  local  changes  in  blood  flow,  as  
vasopressin  is  a  potent  vasoconstrictor  in  the  gastrointes-
tinal  microcirculation (Burnstock,  1990; Baker  et al.,  1990;  
Vanner  et  al.,  1990).  Even  in  endotoxaemic  states  when  
the  vascular  bed  is  less  sensitive  to  endogenous  vasocon-
strictor  agents,  this  hormone  has  been  shown  to  be  the  
most  effective  vasoconstrictor  when  compared  to  other  
endogenous  circulating  constrictor  agents  (Vanner  et  al.,  
1990).  In  addition,  vasopressin,  via  its  V,  receptors,  can  
cause platelet  aggregation  which  may  lead the  formation of 
microthrombi  in  the  microcirculation  (Filep  and  
Rosenkrantz,  1987).  Furthermore,  vasopressin  may  induce  
gastrointestinal  vasoconstriction,  vasocongestion  or  vascu-
lar  endothelial  injury  through  a  thromboxane-dependent  
mechanism,  since  it  can  release  thromboxanes  from  
platelets  and  from vascular  tissues (Filep  and  Rosenkrantz,  
1987;  Nadasy  et  al.,  1992).  The  damaging  effects  of  
thromboxanes  on  the  gastrointestinal  microvasculature  fol-
lowing  the  administration  of  high  doses  of  endotoxin  have  
been  previously  reported.  In  these  studies,  endotoxin  in-
creased  the  intestinal  synthesis  of  thromboxanes,  and  the  
mucosal  injury  was  prevented  by  thromboxane  synthase  
inhibitors  (Boughton-Smith  et  al.,  1989).  All  of  the  above  
described  effects  of  an  increased  vasopressin  formation  
can  lead  to  an  impaired  tissue  oxygen  supply.  Indeed,  in  a  
recent  study  vasopressin  blockade  was  shown  to  improve  
the  impaired  oxygen  extraction  ratio  and  ketone  body  
availability  in  the  mesenteric  circulation  following  endo-
toxin  administration  (Matsuoka  and  Wisner,  1997).  
In  conclusion,  our  current  results  suggest  that  endoge-
nous  vasopressin  has  acute  injurious actions  in  the  gastro-
intestinal  microcirculation  during  endotoxin  shock.  These  
findings,  in  conjunction  with  the  beneficial  actions  of  
vasopressin  deficiency and  vasopressin  V,  receptor  antago-
nists  in  the  development  of  various  experimental  gastro-
intestinal  lesions  (László  et  al.,  1991a,  1994,  1996),  indi-
cate  the  aggressive  role  endogenous  vasopressin  has  in  the  
generation  of gastrointestinal  stress erosions  in acute  septic  
shock. 
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constriction  and provoke platelet  aggregation,  leading to an  impaired tissue  blood supply.  In humans  with  
<..•  pituitary  diabetes  insipidus  the  central  release  of  vasopressin  is  diminished,  and  in  the  Brattleboto  
homozygous  rat  there  is  congenitally  no  synthesis  of  this  hormone.  The  gastroduodenal  intramucosal  
vasopressin  level  is elevated  in  normal rats following various acute ulcerogenic  challenges (after ethanol, 
reserpine,  indomethacin,  cold-restraint  stress, endotoxin  shock  and hemorrhagic  shock),  and  vasopressin-
deficient  rats  are  less  sensitive  to  these  stimuli.  In  a  hospital-  and  population-based  case-control,  age-
matched  retrospective  study, the  incidence  of  human  gastroduodenal  ulceration  is significantly higher  in  
the  normal  population  (in  whom  the  release  of  vasopressin  is  presumed  to  be  intact)  than  in  the  
vasopressin-deficient  one  (central  diabetes  insipidus  patients).  In  conclusion,  endogenous  vasopressin  
plays  an aggressive  role in development  of  gastroduodenal  ulceration,  especially  that  related  to  stress.  
Key  words:  Diabetes  insipidus; gastric and duodenal  mucosa;  human vasopressin;  peptic  ulcer; rat;  stress 
erosion;  vasopressin  antagonist  
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VASOPRESSIN AND  GASTROINTESTINAL  
CIRCULATION 
Vasopressin,  a  potent  pituitary  nonapeptide,  acts  on  two  
different  types  of  receptors  (1):  V!  (pressor)  and  V2  (anti-
diuretic) receptors. Vasopressin is released from the posterior 
pituitary  in  response to  numerous  stimuli,  such  as  hypovole-
mia, hyperosmosis  and  cigarette  smoking (2,3).  Vasopressin  
can also be released locally from the vascular endothelium,  in  
various  vascular  beds  (4-6),  including  the  mesenteric  circu-
lation  (6).  Besides  its  well-known  antidiuretic  effect (via  its  
V2 receptors),  vasopressin can cause vasoconstriction  (via  its  
V,  receptors), provoke  platelet  aggregation  (via its V,  recep-
tors)  and  release  coagulant  factors  (via  its  V2  receptors),  
leading to  an impaired  tissue blood  supply  (2,3,7-14).  
In  the  past  decade  selective  peptide  and  orally  effective  
non-peptide vasopressin  V,  and V2  receptor antagonists  have 
been  developed  and  used  for  receptor  characterization  in  
animal  and  in  human  studies  (15-20).  For  investigations  of  
the  role  of  endogenous  vasopressin  in  the  regulation  of  
physiological  or  pathological  processes,  the  congenitally  
vasopressin-deficient  Brattleboro  homozygous  rat  can  be  
used  (21). The  pituitary/hypothalamic  release  of  vasopressin  
is likewise diminished  in humans with central (also known as  
pituitary,  cranial  or  hypothalamic)  diabetes  insipidus  (2,3,  
22).  These  patients  and  the  Brattleboro  homozygous  rat  
exhibit  the symptoms of  vasopressin  deficiency (i.e.  polyuria  
and  polydipsia)  and  are  sensitive  to  the  administration  of  
exogenous  vasopressin  (2,3,21,22).  
There  is  growing  evidence  that  vasopressin  plays  an  im-
portant role in the regulation of the gastrointestinal  circulation 
under  physiological  and  pathophysiological  circumstances.  
Physiological  doses  of  vasopressin  cause  a  blood  flow  
reduction  in  the  intestinal  tract  and  vasoconstriction  in  the  
superior  mesenteric  artery  (10-13),  the  latter  effect  being  
reversed  by  a  vasopressin  Vi  receptor  antagonist  (13).  The  
existence  of  vasopressin  receptors  (23)  and  the  local  release  
of  vasopressin  from  the  vascular  endothelium  (6)  in  the  
superior  mesenteric  artery  are  also  indicative  of  the  physio-
logical  importance  of  this hormone.  This  artery  is  extremely  
sensitive  to vasopressin:  the minimum  amount  of the  peptide  
required  to  decrease  the  wall  diameter  is  in  the  order  of  
1 pg/ml,  assessed  via  direct  in  vivo  and  in  vitro  techniques  
(24-26).  High doses  of  vasopressin  produce  vasoconstriction  
(27,28), significant ischemia and secondary  mucosal  damage  
in the  stomach  (29).  Gastrointestinal  mucosal  lesions  appear  
following  hemorrhage  (30-32).  On  the  other  hand,  in  the  
hemorrhagic  state  endogenous  vasopressin  produces  mesen-
teric  vasoconstriction  (12)  and  a  gastrointestinal  blood  flow  
reduction (33), an effect blocked by a vasopressin V,  receptor  
antagonist  (33).  Vasopressin  can  cause  the  aggregation  of  
platelets  (7-9),  and  it  may provoke  gastrointestinal  vasocon-
striction,  vasocongestion  or microvascular  damage  through  a  
thromboxane-dependent  mechanism,  since  it  can  release  
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Fig.  1.  Gas t r i c  in t ramucosa l  vasopress in  con ten t  ( uppe r  pane l )  and  
p l a s m a  vasopres s in  level  ( l ower  panel)  f o l l o w i n g  v a r i o u s  ulcero-
g e n i c  cha l l enges ,  i.e.  a f te r  e thano l  (Eth. ;  7 5 % ,  1 ml,  p .o . ,  2 0  min) ,  
i n d o m e t h a c i n  ( Indom. ;  10 m g / k g .  s c.,  4  h) ,  r e se rp ine  (Res . ;  0 .5  mg/  
kg ,  s.c. ,  4  h),  co ld-res t ra in t  s t ress  (Stress;  4 ° C ,  2-h  immobi l i za t ion )  
and  h e m o r r h a g i c  shock  ( S h o c k ;  20-min  shock  +  2 0 - m i n  reper fu-
s ion)  e x p o s u r e  in  the  W i s t a r  rat.  *A  s igni f icant  d i f f e r e n c e  at  a  
s tat is t ical  level  of  p  <  0 .05  as c o m p a r e d  to  the  con t ro l s  (Cont . ) .  Data  
adap ted  f r o m  Refe rence  44 .  
thromboxanes  from  the  vascular  tissue  and  the  platelets  
(8,  34),  the  two  mediators  interacting  synergistically.  The  
thromboxanes  exert  injurious  actions  on  the  gastrointestinal  
mucosal  microcirculation  following  various  challenges;  in  
these  models  there  is  an  elevated  intramucosal  synthesis  of  
thromboxanes,  and  the  mucosal  damage  is  prevented  by  
thromboxane  synthase  inhibitors  (35^)0).  Finally,  vasopres-
sin  may  reduce  blood  flow  by  enhancing  vascular  perme-
ability  (41,42).  
The  generally  accepted  main  pathogenetic  factors  in  the  
development  of  gastroduodenal  ulceration  are  a  lowered  
intramucosal  pH.  an  impaired  natural  defense  mechanism(s),  
acid  hypersecretion,  a  mucosal  energy  deficit  and  gastric  
hypoxia  (32, 43).  Since  vasopressin  exerts  action  that  can  
correspond  with  these  pathways,  we  have  explored  the  
involvement  of  endogenous  vasopressin  in  the  development  
of  gastroduodenal  ulceration.  
INCREASED  INTRAMUCOSAL  AND  PLASMA  
VASOPRESSIN  RELEASE  FOLLOWING  
ULCEROGENIC  CHALLENGE.  INTRAMUCOSAL  
VASOPRESSIN  RECEPTORS  
Our  aim  in  these  investigations  was  to  examine  endogenous  
vasopressin  release  following  various  experimental  ulcero-
genic  challenges.  In  all  of  these  experiments  the  investigated  
species  was  the  Wistar  rat.  
Gastric  and/or  duodenal  mucosal  lesions  were  induced  by  
means  of  ethanol  (75%,  p.o.),  indomethacin  (10 mg/kg,  s.c.),  
reserpine  (0.5 mg/kg,  s.c.),  cold-restraint  stress  (2  h  at  4°C),  
hemorrhagic  shock  (20 min-shock  +  20  min-reperfusion)  and  
endotoxin  shock  (£.  coli  lipopolysaccharide,  50 mg/kg,  i.v.).  
With  the  exception  of  indomethacin  induction,  the  plasma  
vasopressin  level  was found  to be elevated  in all  these  models  
(Fig.  I).  In  contrast,  the  intramucosal  vasopressin  content  
proved  to  be  increased  in  all  the  models  (Fig.  1).  The  
intramucosal  and  plasma  vasopressin  level  elevation  always  
occurred  simultaneously  with,  or  even  preceded,  the  devel-
opment  of  ulceration  (44).  
It  is  likely  that  the  increased  level  of  vasopressin  in  the  
plasma  originates  from the  posterior  pituitary.  The  fact  of  the  
significant  elevation  of  the  intramucosal  vasopressin  content  
in  the  indomethacin-induced  model,  whereas  the  plasma  
vasopressin  level  remained  unchanged,  might  reflect  the  
local,  intramucosal  generation  of  vasopressin,  since  vaso-
pressin-like  immunoreactivity  has  been  observed  in  the  rat  
and  human  gastric  mucosa  (45)  and  vasopressin  release  from  
the  vascular  endothelium  has  also  been  demonstrated  in  
various  vascular  beds  (4-6).  Our  data  are  in  agreement  with  
previous  observations  that  a  high dose  of  orally  administered  
ethanol  causes  vasopressin  release  in  humans  (46)  and  in  rats  
(47),  but  in  apparent  conflict  with  the  established  finding  that  
ethanol  inhibits  the  release  of  vasopressin  (2, 3).  The  para-
doxical response  of vasopressin  release  in the  ethanol-induced  
gastric  erosion  model  might  possibly  reflect  the  different  
doses  of  ethanol  administered,  which  were  high  (46,47).  It  
may  be mentioned  here  that  the magnitude  of the  elevation  of  
circulating  vasopressin  following the  intravenous  administra-
tion  of  graded  doses  of  vasopressin  in  combination  with  oral  
ethanol  has  been  shown  to  correlate  with  the  increasing  
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F i g .  2.  P e r c e n t a g e  i n h i b i t i o n  by  a  v a s o p r e s s i n  a n t a g o n i s t  
( d ( C H 2 ) 5 T y r ( M e ) A V P ,  h a t c h e d  c o l u m n s  in  u p p e r  p a n e l )  a n d  
potent ia t ion  by  a  vasopress in  agonist  ( l y s ine -vasopres s in ,  ha t ched  
c o l u m n s  in  l o w e r  panel )  o n  p re t rea tmen t  ( 3 0  min  b e f o r e  c h a l l e n g e s )  
o f  gastr ic  m u c o s a l  les ions  induced  by  e t h a n o l  (Eth. ;  7 5 % ,  1 ml ,  p .o . ,  
1  h),  i ndome thac in  ( Indom. ;  10 mg/kg ,  s .c. ,  4  h).  r e se rp ine  (Res . ;  
0 . 5  m g / k g ,  s .c . ,  8  h) ,  c o l d - r e s t r a i n t  s t r e s s  ( S t r e s s ;  4 ° C ,  2 -h  
i m m o b i l i z a t i o n )  a n d  h e m o r r h a g i c  s h o c k  ( S h o c k ;  2 0 - m i n  
shock  +  2 0 - m i n  r e p e r f u s i o n )  in  the  W i s t a r  rat.  * A  s igni f icant  
d i f f e r e n c e  at  a  stat ist ical  level  of  p  <  0 . 0 5  b e t w e e n  the  con t ro l  
(Cont . ;  g ray  c o l u m n s )  and  treated  g r o u p s .  Data  adap ted  f r o m  
Refe rences  2 7 , 4 4  and  51 .  
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Fig .  3.  Pro tec t ion  of  t h e  gastric  m u c o s a  ( exp re s sed  as  pe r cen t age  
inh ib i t ion  of  les ions)  b y  a  vasopress in  de f i c i ency  (in  the  Bra t t l eboro  
h o m o z y g o u s  rat;  s h a d e d  co lumns)  aga ins t  d a m a g e  induced  b y  
e thano l  (Eth . ;  7 5 % ,  1 m l .  p.o..  1  h),  i n d o m e t h a c i n  ( Indom. ;  10  m i l  
kg,  s.c. ,  4  h),  r e se rp ine  ( R e s ;  0 .5  m g / k g ,  s.c. ,  8  h),  co ld- res t ra in t  
s t ress  (S t ress ;  4 ° C ,  2 - h  immobi l i za t ion)  and  hemor rhag ic  s h o c k  
( S h o c k ;  2 0 - m i n  shock  — 20-min  r epe r fus ion ) .  *A  signif icant  inh ib i -
t ion  at  a  statistical  level  of  p  < 0 .05  in  c o m p a r i s o n  wi th  the  c o n t r o l s  
(gray  c o l u m n s ) .  Data  a d a p t e d  f r o m  R e f e r e n c e s  2 7  and  44.  
severity  of  the  ethanol-induced  gastric  hemorrhagic  lesions  
(47).  Body  compression  and  restraint  stress  also  increase  the  
vasopressin  level  in  the  plasma  (48,49),  and  the  gastric  
mucosal  vasopressin  content  is elevated  in  the  activity-stress-
induced  ulcer  model  150).  
The  above  findings  led  us  to  suspect  that,  besides  the  
superior  mesenteric  artery  (23),  the  gastric  mucosa  also  
contains  vasopressin  receptors.  Indeed,  by  using  a  radio-
iodinated  vasopressin  Vj  receptor  antagonist,  we  detected  
high-affinity vasopressin  binding  sites  by  receptor  autoradio-
graphy  in  the  intramucosal  vasculature  in  the  rat  stomach  
(44). 
EFFECTS  OF  VASOPRESSIN  AGONISTS  AND  
ANTAGONISTS  IN  ULCER  MODELS  
In this series of studies,  we explored  whether  inhibition  of  the  
action  of  endogenous  vasopressin  (by  vasopressin  antago-
nists)  or  the  administration  of  exogenous  vasopressin  modi-
fies the development  of experimental  gastrointestinal  mucosal  
damage. 
Administration  of  a  vasopressin  V,  receptor  antagonist  
significantly  reduced  the  macroscopic  and  histopathological  
gastric  mucosal  damage  induced  by  ethanol,  indomethacin.  
reserpine,  cold-restraint  stress,  hemorrhagic  shock  and  
endotoxin  shock  (27,44,51-53).  as  demonstrated  in  Fig.  2.  
The  V|  antagonist  was  found  to  have  no  effect  on  the  
intragastric  pH  (27),  which  suggests  that  the  antiulcerogenic  
action  of  V,  antagonists  does  not  relate  to  gastric  acid  
secretion.  It  was  also  demonstrated  that  the  V,  antagonist  
protected  the duodenal  mucosa  in  the hemorrhagic  shock  and  
endotoxin  shock-induced  models  (52. 53).  Finally,  V)  recep-
tor  antagonists  exerted  significant  beneficial  actions  on  
jejunal,  ileal  and  colonic  microvascular  injuries  following  
the  administration  of  high  and  low  doses  of  endotoxin  
(53,54). 
In  contrast  to  the  beneficial  effect  of  vasopressin  antago-
nists,  the  exogenous  administration  of  a vasopressin  agonist,  
lysine-vasopressin  (1 jig/kg,  s.c.).  aggravated  the  gastroduo-
denal  mucosal  injury  provoked  by  ethanol,  indomethacin,  
reserpine,  cold-restraint  stress,  hemorrhagic  shock  and  
endotoxin  shock  (27,44,  52),  as  shown  in  Fig.  2.  Injection  
of this ulcerogenic  dose  of lysine-vasopressin  into rats  caused 
a  significant  reduction  in  gastric  blood  flow  (27)  and  
simultaneously  provoked  an  increase  in  intragastric  pH  (27).  
This  blood  flow  reduction  in  the  stomach  might  originate  
from  a  vasopressin-mediated  vasoconstriction  and/or  vaso-
congestion  (2, 3 ,7-14)  and may  explain  the decreased  gastric  
acid  secretion  observed  following  vasopressin  administration  
(27,  55,56).  
VASOPRESSIN-DEFICIENT  RATS  ARE  LESS  
SENSITIVE  TO  ULCEROGENIC  STIMULI  
Apart  from  the  use  of  vasopressin  antagonists,  the  role  of  
endogenous  vasopressin  in  various  physiological  or  patholo-
gical  processes  can  be  investigated  in  the  congenitally  
vasopressin-deficient  Brattleboro  homozygous  rat  (21).  Fol-
lowing  the  oral  administration  of  ethanol,  we  found  that  the  
extent  of  macroscopic  and  histologic  mucosal  injury  was  
significantly  less  in  the  stomach  of  the  Brattleboro  homo-
T a b l e  I.  Da ta  on  the  inc idence  of  g a s t r o d u o d e n a l  ulcerat ion  a m o n g  the  no rma l -vasop re s s in  popu la t ion  a n d  among  vasopress in -de f i c i en t  
sub jec t s  wi th  central  d i a b e t e s  ins ip idus  in  the  2 0 - 7 0  years  age  g r o u p  in  H u n g a r y  
Dis t r ibut ion  o f  gas t roduodena l  N o .  of  normal -vasopress in  N o .  of  d i abe t e s  ins ipidus  
u l ce ra t ion  ( G D U ) a  sub jec t s b  pa t i en t s  
No .  of  G D U - n e g a t i v e  s u b j e c t s  6  5 3 2  0 0 7  811  
No .  of  G D U - p o s i t i v e  c a s e s  148  198  4  
Pe rcen tage  inc idence  2 . 2 2  0 . 4 9 *  
a  A c u t e  or  chronic  g a s t r i c  and/or  d u o d e n a l  u lcera t ion ,  with  o r  wi thout  a c o m p l i c a t i o n  (b l eed ing  and/or  pe r fo ra t ion) ,  cu r ren t ly  ex i s t ing  or  
f ea tu r ing  in  the  case  h i s t o ry .  
b  T h e  total  popu la t i on  in  Hungary  wi thou t  d i a b e t e s  insipidus  in  the  2 0 - 7 0  yea r s  a g e  g r o u p  ( n u m b e r s  o n  1 January  1995).  S ign i f ican t ly  
d i f f e r en t  at  a  statistical  l eve l  of  *p  <  0 .005 .  
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zygous  rat  than  in  the  normal  Wistar  rat  (Fig.  3).  The  
vasopressin  deficiency  in  the  former  strain  protected  the  
deeper  layer  of  the  gastric  mucosa  and  inhibited  mucosal  
microvascular  injury (assessed  by the Monastral  blue  techni-
que) following ethanol  challenge.  Administration  of  exogen-
ous  vasopressin  to  the  Brattleboro  rat  enhances  the  gastric  
mucosal injury to the level found in a normal strain with intact 
vasopressin secretion. This dose of vasopressin also provoked 
a  significant  reduction  in  gastric  blood  flow.  The  protection  
against ethanol  damage  in the Brattleboro rat was  not  related  
to an unusual gastric emptying or gastric acid secretion  in this 
special  strain,  since  there  were  no  differences  in  these  
parameters  between  normal  and  vasopressin-deficient  rats  
(27). 
Further  studies  revealed  that  the  gastric  mucosa  of  the  
Brattleboro  homozygous  rat  is  less  sensitive  to  other  
ulcerogenic  stimuli:  the  gross  and  microscopic  gastric  
damage  was  significantly  attenuated  following  reserpine  or  
indomethacin  administration,  and during cold-restraint  stress,  
hemorrhagic  shock and  endotoxin  shock (44,51),  as  demon-
strated in Fig. 3. Similarly, as observed in the ethanol-induced 
model,  the  congenital  vasopressin  deficiency  protected  the  
deeper  layer  of  the  mucosa  after  these  stimuli  (44,51).  
Moreover,  the  vasopressin  deficiency  had  a beneficial effect 
during the generation  of  macroscopic and histologic  mucosal  
damage  and  microvascular  injury  induced  by  hemorrhagic  
shock  and  endotoxin  shock  in  the  duodenum  and  jejunum  
(52,53). 
LOWER  INCIDENCE OF  GASTRODUODENAL  
ULCERATION  AMONG  VASOPRESSIN-DEFICIENT  
HUMANS 
The  observations  that  various  ulcerogenic  challenges  in-
creased the intramucosal  vasopressin level in normal rats (44), 
whereas  the  gastroduodenal  mucosa  of  the  congenitally  
vasopressin-deficient  Brattleboro  homozygous  rat  was  less  
sensitive to these stimuli (27,44,52,53),  led us to seek a link 
between our experimental  findings and human  ulcerogenesis.  
Accordingly,  we  evaluated  the  incidence  of  gastroduodenal  
ulceration  among central  diabetes  insipidus patients  (persons  
with an impaired vasopressin release) in comparison  with that 
in the normal population  (in whom the release of  endogenous  
vasopressin  is  presumed  to  be  intact)  by  performing  a  
hospital-  and  population-based  case-control,  age-matched  
retrospective  study  (57).  Data  on  all  patients  (with  gastro-
duodenal  ulceration  and/or  with  a  vasopressin  deficiency)  
aged 20-70 years who were hospitalized  in Hungary  between  
1 January  1992 and  1 October  1995 were compared  with  the  
data  on  the  normal  Hungarian  population  in  the  same  age  
group (number  on  1 January  1995).  
The  incidence  of  gastroduodenal  ulceration  was  signifi-
cantly  higher  in  the normal  population  than  in  the  vasopres-
sin-deficient  one  (odds  ratio:  4.60  with  95%  confidence  
interval:  1.9-11.2; p  = 0.001), as demonstrated  in Table I. An 
intact  endogenous  vasopressin  release  therefore  appears  to  
favour  the  development  of  ulceration  of  the  human  gastro-
duodenal  mucosa  relative  to  that  in  a  vasopressin-deficient  
state,  as  in  the  Brattleboro  rat  (27,44,52,53).  
CONCLUSIONS 
The  release  of  vasopressin  into  the  circulation  has  been  
demonstrated  in animal  models of gastroduodenal  ulceration,  
and  there  are  also  strong  grounds  for  suspecting  the  local  
intramucosal  secretion  of  the  hormone.  The  existence  of  
intramucosal  vascular  vasopressin  receptors  in  the  stomach  
lends  further  support  to  the  physiological  and  pathophysio-
logical  actions  of  the  peptide  in  regulation  of  the  gastro-
intestinal  circulation.  This  vasopressin  release  mediates  
pathological  processes  in  the  generation  of  gastrointestinal  
mucosal  injury,  since  vasopressin  antagonists  and  a  vaso-
pressin  deficiency  provide  a  protective  effect  in  various  
experimental  models  of  gastrointestinal  ulceration.  Although  
endogenous  vasopressin  seems  to  have  an  important  role  in  
the generation  of  the gastrointestinal  mucosal  injury  induced  
by  various  ulcerogenic  challenges,  this  hormone  is  not  the  
only factor involved: the macroscopic  and histologic  severity  
of  the  lesions  was  not  related  to  the  plasma  or  intramucosal  
vasopressin  levels  in  the  ethanol  and  cold-restraint  stress  
models  (44).  It  is  strongly  suspected  that  endogenous  
vasopressin interacts with other damage-provoking  mediators  
(thromboxanes,  leukotrienes,  platelet-activating  factor,  etc.)  
in  the  pathogenesis  of  ulceration  of  the  gastrointestinal  
mucosa  (40,54,58).  
The  lower  incidence  of  gastrointestinal  ulceration  among  
vasopressin-deficient  patients  suggests  the  pathological  im-
portance  of  endogenous  vasopressin  release  in  the  develop-
ment  of  human  mucosal  damage.  Gastrointestinal  mucosal  
stress erosions commonly  appear among critically  ill  patients  
in intensive care units after a number of acute conditions, such 
as severe trauma, burns, septic shock, hemorrhagic shock and  
cardiogenic  shock  or  injury  to  the  central  nervous  system.  
Once  hemorrhage  becomes  manifest,  the  severity  of  the  
condition  is reflected in  the mortality  rate, which  approaches  
50%  (32).  Although  it  would  be  of  high  significance,  the  
problem of how to prevent  the development  of  such  erosions  
is  unsolved  (59).  In  these  hypovolemic  states  the  release  of  
endogenous  vasopressin  is  highly  probable  (2,3,22).  The  
experimental  and  clinical  observations  lead  us  to  conclude  
that  vasopressin  antagonists  might  be  of  therapeutic  impor-
tance  in  the  prevention  of  the  generation  of  gastrointestinal  
stress  erosions.  
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Abstract  —  Vasopress in  is  a  s t ress  h o r m o n e  re leased  f rom  the  poster ior  pituitary.  In  h u m a n s  su f fe r ing  f rom  central  d iabetes  insipidus,  
this  release  of  vasopress in  is  d imin i shed .  It  w a s  s h o w n  previous ly  that  the  congenu ta l ly  vasopress in-def ic ien t  Bra t t leboro  h o m o z y g o u s  
rat  is  less  sensi t ive  to  va r ious  u lce rogen ic  s t imuli .  In  this  study,  w e  invest igated  the  inc idence  o f  gas t roduodena l  ulceration  in  
vasopress in  def ic ient pa t ients .  Da ta  on  pat ients  aged  2 0 - 7 0 ,  hospi ta l ized  in  Hungary  be tween  1992  and  1995  were  c o m p a r e d  with  those  
on  the  total  popula t ion  in  this  age  g roup  (6  681  020  in  1994).  Subjec ts  wi th  central  d iabetes  ins ip idus  were  se lec ted  separate ly  (815  
cases) .  Gas t roduodena l  ulcerat ion  was  c o m p a r e d  in  sub jec t s  with  an  intact  vasopress in  re lease  and  vasopress in-def ic ien t  pat ients .  T h e  
f requenc ies  of  gas t roduodena l  u lcera t ion  were  a lso  examined  separately  in  male  and  f ema le  subjec ts .  In  the  total  popula t ion ,  the  
f r equency  of  gas t roduodena l  u lcera t ion  w a s  lower  in  vasopress in-def ic ien t  cases  ( 2 . 2 2 %  versus  0 . 6 1 % ;  P <  0.005) .  A m o n g  
normal -vasopress in  subjects ,  m a l e s  have  a  h ighe r  r isk  o f  gas t roduodena l  ulcerat ion  than  f ema le s  ( 3 . 0 4 %  versus  1 .46%,  respect ive ly ;  
P<  0 .001) .  A m o n g  vasopress in -def ic ien t  subjec ts ,  a  s imilar  ma le : f ema le  ratio  w a s  observed ,  but  it  was  not  s ignif icant  (P  0 .36) .  In  
compar i son  to  the  no rma l -vasopres s in  popula t ion ,  the  inc idence  of  gas t roduodena l  ulcerat ion  was  reduced  a m o n g  vasopress in-def ic ien t  
males  and  females  by  7 7 %  ( P < 0 . 0 1 )  and  by  8 2 %  ( P c  0.05) ,  respectively.  In  conc lus ion ,  e n d o g e n o u s  vasopress in  has  a  s ignif icant  
ha rmfu l  act ion  t owards  the  h u m a n  gas t roduodena l  m u c o s a .  Pept ide  and  non-pep l ide  vasopress in  receptor  an tagonis t s  migh t  have  a  
potent ial  therapeut ic  benef i t  in  the t r ea tmen t  (as  an  ad juvan t )  and  prevent ion  o f gas t roduodena l  u lcera t ion .  ©  2 0 0 0  Elsevier  Sc ience  Ltd.  
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1.  Introduction  
Gastroduodenal  ulceration  is  a  common  disease.  It  
is known  that aggressive  (e.g., gastric  acid, pepsin)  and  
protective  (e.g.,  mucosal  blood  flow,  prostaglandins)  
factors  act  in  the  development  of  acute  or  chronic  
mucosal  lesions,  and  an  imbalance  between  them  plays  
a  key  role  in  the  occurrence  of  the  disease  [15],  
In  animals,  endogenous  vasopressin  has  been  dem-
onstrated  to  act  as  an  aggressive  factor  towards  the  
gastroduodenal  mucosa,  since  the  vasopressin-
deficient  Brattleboro  homozygous  rat  [16]  is  less  sen-
sitive  to  various  ulcerogenic  stimuli  than  the  rat  with  
normal-vasopressin  secretion  [5,  6,  8],  
In  humans,  suffering  from  central  diabetes  insipi-
dus,  the  secretion/release  of  vasopressin  from  the  
hypothalamus/posterior  pituitary  is  impaired.  These  
patients  are  ideal  subjects  of  the  investigation  of  the  
role  of  endogenous  vasopressin  in  generation  of  vari-
ous  diseases,  in  which  this  stress  hormone  might  
possibly  have  a  pathogenetic  action.  Accordingly  the  
aim  of  the  present  study  was  to  evaluate  the  incidence  
of  gastroduodenal  ulceration  among  vasopressin-
* Correspondence  and  reprints  
deficient  human  subjects  in comparison  to  the  normal-
vasopressin  population.  
2.  Materials  and  methods  
2.1.  Study  groups  
Two groups  of human  subjects aged  between  20  and  
70 years  were  selected:  the  vasopressin-deficient  and  
the  non-deficient  groups.  The  vasopressin-deficient  
cases  suffered  from  central  diabetes  insipidus,  while  
the non-deficients were  taken  as the normal  population  
in  Hungary  in  1994  (data  on  01.01.1995).  All  central  
diabetes  insipidus  cases  hospitalized  in  Hungary  be-
tween  01.01.1992  and  01.10.1995  were  selected.  Ad-
ditionally,  the  subjects  in  the  two  groups  were  exam-
ined  on  the  basis  of  their  sex.  
2.2.  Cases  with  gastroduodenal  ulceration  
All  patients  aged  20-70  years  hospitalized  in  Hun-
gary  between  01.01.1992  and  01.10.1995  with  gas-
troduodenal  ulceration  (including  acute  or  chronic  
gastric  and/or  duodenal  ulceration  with  or  without  
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Table  I.  Data  on  normal-vasopressin  and  vasopressin-deficient  humans  aged  20-70 years  in  Hungary.  
Male Female Male  + female 
N o r m a l DI N o r m a l DI N o r m a l DI 
N u m b e r 3  213  6 1 3  4 2 4 3 4 6 7  407  391 6  681  0 2 0  815 
Hosp . 1  972  0 0 0  562 2 977  599  507 4  949  5 9 9  1069 
Normal,  subjects  with  intact  vasopressin  release.  
Dl,  subjects  with  diabetes  insipidus  (vasopressin-deficient).  
Number,  number  of  persons  in  this  age  group  in  Hungary  in  1994 (data  on  01.01.1995).  
Hosp.,  total  number  of  hospitalizations  of  subjects  in  this  age  group  in  Hungary  between  01.01.1992  and  01.10.1995.  
complication  (bleeding and/or perforation) currently  or  
in  the  case  history)  were  selected.  In  each  group,  
patients  were  taken  as  vasopressin-deficient  if  the  
appearance  of  diabetes  insipidus  preceded  the  onset  of  
gastroduodcnal  ulceration.  
2.3.  Comparisons  
The  frequencies  of  gastroduodenal  ulceration  were  
compared  in the vasopressin-deficient  (central  diabetes  
insipidus)  patients  and  the  non-deficient  population.  
The  male  and  female populations  were  also  compared.  
2.4.  Statistics  
For  statistical  comparisons  the  Mantel-Haenszel  
Chi-square  test  and  for  relative  risks  the  odds  ratio  
(OR)  with  95%  confidence  interval  (CI)  were  used,  
where  appropriate.  P  < 0.05%  was  taken  as  indicating  
statistical  significance.  
3.  Results  
3.1.  Study  groups  
The  male:female  ratio  is  demonstrated  in  table  I.  
The  male:female  ratio  in  the  vasopressin-dcficient  and  
normal-vasopressin  population  was  approximately  
50%,  being  48  versus  52%,  respectively  among  
vasopressin-deficients and  52 versus 48%,  respectively  
among  cases  with  intact  vasopressin  release.  
3.2.  Cases  with  gastroduodenal  ulceration  
The  risk  of  gastroduodenal  ulceration  was  signifi-
cantly  higher  in  the  normal-vasopressin  population  as  
compared  to the vasopressin-deficient  population  (OR:  
4.60  with  95%  CI:  1.88-11.24; P <  0.005),  as  demon-
strated  in  figure  1.  Among  normal-vasopressin  sub-
jects,  males  have  a  higher  risk  of  gastroduodenal  
ulceration  than  females  (OR:  2.12  with  95%  CI:  
2.10-2.15;  P  < 0.001).  A higher  male:female  ratio  was  
observed  in  vasopressin-deficient  cases,  but  it was  not  
significant  (OR:  2.78  with  95%  CI:  0.32-24.44;  
P  = 0.36).  In  comparison  to  the  nonnal-vasopressin  
population,  the  incidence  of gastroduodenal  ulceration  
was  reduced  among  vasopressin-deficient  males  and  
females  by  77%  ( £ < 0 . 0 1 )  and  by  82%  (£<0 .05) ,  
respectively,  as  shown  in  figure  1.  The  risk  to  acquire  
gastroduodenal  ulceration  was 4.40  (OR  with  95%  CI:  
1.56-12.43)  and  5.76  (OR  with  95%  CI:  1.02-32.59)  
among  normal-vasopressin  males  and  females,  respec-
tively,  compared  to  vasopressin-deficient  ones.  
4.  Discussion  
In  this  work,  the  incidence  of  acute  and  chronic  
gastric  and/or  duodenal  ulceration  has  been  found  to  
be  lower  in  vasopressin-deficient  humans  than  in  the  
normal-vasopressin  population  aged  20-70  years.  This  
result  might  indicate  the  pathogenic  role  of  endog-
enous  vasopressin  in  development  of  gastroduodenal  
ulceration. 
In  various  rat  models  of  gastroduodenal  ulceration  
(i.e.,  in  the  ethanol-,  reserpine-,  stress-  and  
indomcthacin-induced  gastric,  and  in  the  hemorrhagic  
shock-provoked  gastroduodenal  one), the  intramucosal  
and  plasma  vasopressin  levels  were  detected  to  be  
elevated  [3,  7,  8].  It  should  be  noted  here,  that  the  
measurement  of  intramucosal  and  plasma  vasopressin  
looks  like  indicated  in humans  with  and  without  acute  
or  chronic  gastroduodenal  ulceration.  Endogenous  va-
sopressin  may  act  on  its  intramucosal  pressor  (V,)  
receptors,  since  previously  on  gastric  microvessels  of  
the  rat  such  kind  of  receptors  have  been  demon-
strated  [8].  The  existence  of  vasopressin  receptors  in  
the  superior  mesenteric  artery  [17],  in  conjunction  
with  the  finding  that  this  blood  vessel  is  highly  
sensitive for vasopressin  both  in vitro and  in vivo  [1,2,  
4,  13],  suggests  that  this  hormone  can  also  act  in  the  
macrocirculation  of  the  gut.  Finally,  it  is  known  that  
administration  of exogenous  vasopressin  derivatives  is  
useful  in  the  treatment  of  gastrointestinal  bleeding  of  
humans  [15],  
Endogenous  vasopressin,  released  from  the  poste-
rior  pituitary  and  from  the  vascular  endothelium  [10-
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Figure  1.  Incidence  (per  1 000 subjects)  of  gastroduodenal  ulceration  (including  acute  and  chronic  gastric  and/or  duodenal  
ulceration  with  or  without  complication,  such  as  bleeding  and/or  perforation)  among  the  normal  Hungarian  population  aged  
20-70 years  (males,  females  and  total  population)  with  an  intact  vasopressin  release  (gray  column)  or  with  a  vasopressin  
deficiency (hatched  column).  Statistical  significance:  * P < 0.05;  ** P < 0.01:  and  ***  P < 0.005 for normal-vasopressin  versus  
vasopressin-deficient  cases,  and  #mn  P < 0.001  for males  versus  females.  
12], may  generate  vasoconstriction  and  platelet  aggre-
gation  (via  its  V,  receptors),  and  release  coagulant  
factors  (via  its  antidiuretic  V2  receptors),  leading  to  a  
reduced  blood  flow  and  a  consequent  hypoxia  in  the  
gastroduodenal  mucosa.  The  reduction  of  mucosal  
oxigenation  might  attenuate  the  protective  mecha-
nisms  of  the  gut  and  sensitize  it  to the  damaging  effect  
of other well-known  aggressive  factors, such  as  gastric  
acid  and  pepsin  [15].  Indeed,  administration  of  vaso-
pressin  V,  receptor  antagonists  elevates  blood  flow  in  
the superior  mesenteric  artery  [14] and  protects  against  
various  ulcerogenic  challenge  [5,  6,  8.  9]. Although  in  
a previous  study,  a selective  V2  receptor  antagonist  has  
been  reported  to be  ineffective against  cthanol-induccd  
gastric  hemorrhagic  erosions  in  the  rat  [6],  but  the  
involvement  of this  type  of vasopressin  receptor  seems  
not  to  be  excluded  in  generation  of  gastroduodenal  
ulceration,  since  a  non-selective  vasopressin  receptor  
antagonist  (V,/V2  antagonist)  was  shown  to  be  more  
potent  in  the  ethanol  model  than  the  selective  V,  
receptor  antagonist  alone  (our  unpublished  result).  
In  conclusion,  endogenous  vasopressin  seems  to  
have  a  significant  harmful  action  towards  the  human  
mucosa  in  generation  of  gastroduodenal  ulceration.  
Peptide  and  orally  effective  non-pcptide  vasopressin  
receptor  antagonists  may  have  a  potential  therapeutic  
benefit  in the prevention  and  treatment  (as an  adjuvant)  
of  gastroduodenal  ulceration.  
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ABSTRACT.  Rats  transgenic  for HLA-B27/human  /^-microglobulin  develop  a spontaneous  multisystem  inflam-
matory disorder that  closely mimicks human spondyloarthropathies.  Prominent features of this disorder  are  gut  
inflammation that predominates  in the colon,  and arthritis.  Several  mediators  such as IFN-y, IL - ip ,  TNF-a,  and  
inducible  nitric  oxide  synthase  (iNOS)  have  been found  increased  in  the  inflamed  colonic  mucosa.  In  the  colon  
of  HLA-B27  transgenic  rats,  iNOS  is  predominantly  expressed  by  epithelial  cells,  and  iNOS  transcripts  are  
detected  in the hip cartilage of  those  rats, but not in nontransgenic  littermates.  The role of iNOS in this  disorder  
was  evaluated  by  administer ing  the  cort icosteroid  dexamethasone ,  or  the  NOS  inhibi tor  L-N 6 - ( l -
iminoethyl)Iysine  (L-NIL)  to HLA-B27  transgenic  rats  with  established  disease.  Treatment  with  dexamethasone  
attenuated  some  aspects  of  gut  inflammation,  although  it  had  no  effect on  iNOS  expression.  In  contrast,  treat-
ment  with  L-NIL  effectively  inhibited  iNOS  activity,  and  resulted  in  an  increase  in  colitis.  Cytokine  transcripts  
in  the  colon  were  modified  by  these  treatments:  IFN-y  and  I L - i p  were  decreased  after  dexamethasone  treat-
ment,  whereas administration  of  L-NIL resulted  in decreased  IFN-y,  and TNF-a.  A trend towards  increased  IL-
IP expression  was  observed  which  could  have  contributed  to the  L-NIL  pro-inflammatory  effect.  These  results  
suggest that iNOS exerts  a protective effect on colitis,  in the inflammatory disorder  of HLA-B27  transgenic  rats.  
Keywords:  rodent,  inflammation, nitric  oxide,  cytokines,  in  vivo  animal  models.  
INTRODUCTION 
The  HLA-B27  class  1 major  histocompatibility  com-
plex  allele  is  strongly  associated  with  the  spondyloar-
thropathies,  a  group  of  human  disorders  characterized  
by  the  combination  of  osteoarticular,  skin  and  gut  
inflammatory  manifestations [1].  Several  lines  of  rats  
transgenic  for HLA-B27  and  human  /^-microglobulin  
develop  a  spontaneous  multisystem  inf lammatory  
disease  that  strikingly  resembles  human  spondyloar-
thropathies,  by combining  arthritis  with  colitis  and  pso-
riatic  skin  lesions  [2],  The  immune  system  is  critically  
involved  in  the  pathogenesis  of  this  disease  in  HLA-
B27 transgenic  rats,  which  is transmittable  to  nontrans-
genic  rats  by  bone  marrow  graft,  and  requires  the  pre-
sence  of  mature  T  cells  for  its  development  [3,  4],  
Based  on  these  findings,  it  is  hypothesized  that  disease  
in  HLA-B27  transgenic  rats  arises  as  a  consequence  of  
interaction  between  an  antigen-presenting  cell  expres-
sing high  levels  of HLA-B27,  and  peripheral  T  lympho-
cytes  [3,  4],  The  presence  of  a  normal  gut  flora  is  also  
required for the gut and the joint disease to develop  [2].  
Mediators  implicated  in  the  pathogenesis  in  the  HLA-
B27  transgenic  rat  model  have  been  most  extensively  
studied  in  the  gut  mucosa.  The  profile  of  cytokines  
expressed  in  the  inflammed  colonic  mucosa  is  charac-
terized  by  a  prominent  early  increase  in  IFN-y  and  
IL-2,  suggesting  a  Thl-mediated  predominant  res-
ponse  [2].  In  established  disease,  pro-inflammatory  
mediators  such  as  IL- la ,  IL-lp,  TNF-a,  macrophage  
inflammatory  protein  2,  and  myeloperoxidase  (MPO)  
are  a l s o  expressed  in  the  i n f l a m m e d  co lon ic  
mucosa  [5,  6].  Elevated  plasma  levels  of  nitrite/nitrate  
are  consistent  with  an  increased  production  of  nitric  
oxide  (NO)  in  this  model  [7]  and  the  inducible  nitric  
oxide  synthase  isoform  (iNOS)  was  detected  in  the  
colonic  mucosa  of  affected  B27  transgenic  rats  by  
reverse  transcriptase-polymerase  chain  reaction  (RT-
PCR)  and  by  enzymatic  activity  assay  [5,  6].  
We  previously  reported  that  administration  of  murine  
recombinant  IL-10  to  HLA-B27  transgenic  rats  with.,  
established  disease  had  no  influence  on  the  clinical .or-' 
histopathological  course  of  the  disease.  However,  
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IL-10  e f f i c i e n t l y  inh ib i ted  p roduc t ion  of  IFN-y,  
TNF-oc,  and  IL-ip  in  the  gut  mucosa,  and  conversely  
increased  colonic  iNOS  expression  (5;  M.  Breban  and  
D.  Lamarque,  unpublished  results).  This  result  sugges-
ted  that  iNOS  could  play  a  pathogenic  ro le  in  this  
model,  by  the  production  of  NO-derived  injurious  pro-
ducts  such  as  peroxynitrites,  or  by  altering  the  balance  
between  pro-  and  anti-inflammatory  cytokine  produc-
tion [8,9] .  In  the  present  study,  we  tested  this  hypothe-
sis  by  administering  to  HLA-B27  transgenic  rats  with  
established  disease,  dexamethasone,  which  can  prevent  
the  expression  of  iNOS  [10,  11],  and  the  iNOS  inhibi-
tor,  L-N6-( 1 -iminoethyl)lysine  (L-NIL)  [12].  conside-
red  to offer selectivity  for the iNOS  isoform.  
MATERIALS  AND  M E T H O D S  
Rats.  The  HLA-B27  transgenic  rat  line  33-3 ,  on  a  
Fisher  (F344)  background  [2],  was  mainta ined  by  
breeding  33-3 females  with  nontransgenic  F344  males,  
and  typing  offsprings  for  the  B27/h/J,m  transgene  by  
PCR  amplification  of  tail genomic  DNA with  an  HLA-
B27  specific  pair  of  primers  RT11  and  RT12  [13].  All  
rats  were  maintained  under  conventional  conditions  at  
Cochin  University  Hospital  animal  facility.  
Treatment.  Dexamethasone  was  administered  s.c.  daily  
(study  1).  L-NIL  (Alexis,  Paris,  France)  was  adminis-
tered  s.c.  twice  daily  (study  2).  Sex-  and  age-matched  
rats  of  the  33-3 line  with  overt  disease  (6 rats  per  
group,  11-39 weeks  old:  study  1;  8 rats  per  group,  17-
21 weeks  old:  study  2),  and  control  F344  littermates  
(4 rats  per  group  in  each  study)  received  either  active  
compound  or  vehicle.  
Clinical  evaluation.  Rats  were  scored  three  times  each  
week for diarrhea  and  arthritis,  on  a scale ranging  from  
0  (normal)  to  4 for  each  of  these  symptoms,  by  the  
same  examiner  unaware  of  the  treatment.  The  average  
daily  total  of  these scores  was  calculated  each  week.  
Macroscopic  and  histological  evaluation  of  organs.  
After  completion  of  treatment,  rats  were  sacrificed.  
Mesenteric  lymph  nodes  (MLN)  were  weighed  and  
colon  weight/length  was  measured.  Tissue  samples  
from  the  caecum,  proximal  colon  and  distal  colon,  
were  fixed  in  formalin,  embedded  in  paraffin,  sectio-
ned,  stained  with  hematoxylin,  eosin,  saf ran,  and  
coded  for  blind  examination.  Sections  were  scored  for  
ulceration  density  (absent:  0;  covering  <  1/3  of  exami-
ned  area:  1;  covering  1/3  to  2/3  of  examined  area:  2;  
covering  >  2/3  of  examined  area:  3),  ulceration  depth  
(limited  to  mucosa:  1;  reaching  submucosa:  2;  rea-
ching  muscularis  propria:  3)  and  extent  of  polymor-
phonuclear  and  mononuclear  cells  infiltration  in  the  
chorion  (absent:  0;  limited  to  mucosa:  1; reaching  sub-
mucosa:  2;  reaching  muscularis  propria:  3). The  global  
histological  score  was  the  sum  of  the  values  obtained  
for  the  caecum,  the  proximal  colon,  and  the  distal  
colon  per  rat.  
Immunohistochemistry.  An  antigen  retrieval  method  
was  performed  on  5  pm  thick,  deparaffinized  sections  
of  colon,  using  micro-wave  oven  heating  ( 3 x 5  min)  
in  6 mM  citrate  buffer  pH  6.  Sections  were  then  incu-
bated  for  10 min  in  39b  hydrogen  peroxide  to  block  
endogenous  peroxidase  activity,  followed  by  1 hour 
with  anti-iNOs  monoclonal  antibody,  dilution  1/40  
(Transduction  Laboratories,  Lexington,  UK).  A  three-
step  indirect  process  based  on  avidin-biotinylated  per-
oxidase  complex  (Vectastain  Elite  ABC  kit,  Vector  
Laboratories,  Burlingame,  CA,  USA)  and  3,3-diami-
nobenzidine  (Sigma,  St-Quentin  Fallavier,  France)  as  
chromogen,  was  applied  to  reveal  as  a  brown  precipi-
tate  the  positive  reaction.  Negat ive  controls  were  
obtained  by omitting  the  primary  antibody.  
Western  immunoblot  analysis.  The  whole  colonic  
mucosa  or  colonic  epithelial  cells,  isolated  by  the  
standard  method  [14],  were  homogenized  in  buffer  
(2 mM  Tris  7-9,  50 mM  mannitol,  100 p M  phenylme-
thylsulfonyl,  2 p M  leupeptin,  0.5  mu/ml  aprotinin,  
0.5%  triton  X100).  Spleen  homogenate  from  rat  chal-
lenged  i.v.  with  Escherichia  coli  lipopolysaccharide  
(LPS  serotype  0111:B4;  Sigma)  was  used  as  a  posi-
tive  control  for  iNOS.  Homogenates  were  sonicated  
twice  for  10 sec  on  ice  and  spun  (21,000  g  at  4°  C,  
15 min).  Aliquots  of  20 pg  of  total  cellular  protein  
were  denatured  by  boiling  v/v  with  20 mM  Tris  7-9,  
2 mM  EDTA,  2%  SDS,  10%  P-mercaptoethanol,  20%  
glycerol.  Samples  were  electrophoresed  on  7.5%  SDS-
polyacrylamide  gel,  and  transferred  to  nitrocellulose  
membrane  (Amersham,  Little  Chalfont,  UK).  After  
blocking  with  PBS  (pH  7.4),  0.25%  tween  20  (v/v)  
and  5%  non-fat dried  milk,  the  membrane  was  probed  
with  anti-iNOS  polyclonal  antibody  (sc-651;  Santa  
Cruz,  Santa  Cruz,  CA,  USA)  for  1 hour,  washed  with  
PBS-tween  20 and  then  incubated  with  horseradish  
peroxidase-conjugated  second  antibody  for  1 hour  at  
room  temperature.  Membranes  were  developed,  using  
an  enhanced  chemiluminescence  system  (Amersham)  
and  exposed  to  Hyperfilm  (Amersham).  Films  were  
scanned  on  a GS-700 Imaging  Densitometer  (Bio-Rad,  
Hercules,  USA)  and  analysed  using  the  Molecular  
Analyst  Software  (Bio-Rad).  
MPO  assay.  M P O  activity  was  determined  as  des-
cribed,  with  minor  modifications  [15].  Segments  of  
colon  were  homogenized  in  ice-cold  phosphate  buf-
fer  containing  0 .5%  hexadecyltrimethylammonium-
bromide,  freeze-thawed  three  times  and  centrifuged  
(10,000  g,  15 min,  4°  C).  Supernatant  was  mixed  
with  phosphate  buf fe r  containing  0.167  mg/ml  of  
O-adenosine  dihydrochloride  and  5  X  10" 4%  hydro-
gen  peroxide  and  assayed  spectrophotometr ical ly  
(500  nm).  MPO  activity  was  expressed  in  mU/g  of  
tissue. 
Determination  of  iNOS  enzymatic  activity.  Activity  of  
iNOS  was  estimated  by  measuring  the  conversion  of  
L-[ l4C]-arginine  monohydrochloride  to  L-[ l4C]-citrul-
line,  based  on  a  previously  described  method  [16].  
Briefly,  a  colon  sample  was  homogenized  in  HEPES  
buffer containing  protease  inhibitors.  After  centrifuga-
tion  (10,000 g,  30  min,  4° C),  an  aliquot  of  superna-
tant  was  added  to  prewarmed  buffer  containing  (final  
c o n c e n t r a t i o n )  p o t a s s i u m  p h o s p h a t e  (50  m M ;  
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pH  =  7.4),  valine  (50 mM),  MgCl ,  (1  mM),  CaCl ,  
(200  | iM) ,  D L - D T T  (1  mM),  L-ci t rul l ine  (1  m M ) j  
NADPH  (0.3 mM),  FAD  (3 | iM),  FMN  (3 pM),  BH4  
(3  p M ) ,  L - [ l 4 C ] - a r g i n i n e  m o n o h y d r o c h l o r i d e  
(15.5 nM;  Amersham,  Les  Ulis,  France)  and  incubated  
for  10 min  at  37°  C.  The  incubation  was  terminated  by  
the  binding  of  arginine,  by  addition  of  a  1:1  suspen-
sion  of  Dowex  (AG  50W-8:  Sigma)  in  water.  Superna-
tant  was  taken  for  scintillation  counting.  Activity  of  
iNOS  was  that  which  was  inhibited  by  in  vitro  incuba-
tion  with  the  NO  synthase  inhibitor  NG-monomethyl-
L-arginine  (300  p M ;  Sigma)  but  not  with  EGTA  
(1 mM),  and  was  expressed  as  pmol.min"  ' .mg~'  pro-
tein  [17].  
RT-PCR.  Total  RNA  was  isolated  with  the  TRI  Rea-
gent  (Molecular  Research  Center ,  Cincinnat i ,  OH,  
USA)  and  reverse  transcribed  into  complementary  
DNA  ( c D N A )  us ing  AMV  reverse  t r ansc r ip t a se .  
Amplification  was  carried  out  in  a  100  pi  volume  
containing  100 ng  cDNA,  125 p M  of  each  2 '-deoxy-
nucleoside  5'-triphosphate,  2  U  of  Taq  DNA  polyme-
rase,  50  ng  of  each  primei  and  10 pi  of  10 X  PCR  
buffer.  Primer  sequences  and  the  annealing  tempera-
ture  used  for  (3-actin,  CD3,  IL-1(3,  TNF-a ,  and  IFN-y  
were  as  described  [5];  other  primers  were:  IL-10  sense  
5 ' -TGC  CTT  CAG  TCA  AGT  GAA  GAC  T - 3 \  anti-
sense  5 ' -AAA  C T C  ATT  CAT  GGC  CTT  GTA-3 ' ,  
Tm  =  55° C;  iNOS  sense  5 ' -CAA  TCC  ACA  ACT  
CGC  TCC  AA-3' ,  antisense  5 ' -GCT  ACA  CTT  CCA  
ACT  CAA  CA-3' ,  Tm  =  57° C.  Amplification  condi-
t ions  c o n s i s t e d  of  3  min  at  92°  C  f o l l o w e d  by  
35 cycles  of  denaturation  at  94°  C  for  30  sec,  annea-
ling  for  30  sec,  extension  at  72°  C  for  40  sec,  and  by  
final  elongation  at  72°  C  for  10 min.  Fifty  microliters  
of  PCR  product  were  electrophoresed  on  agarose  gel.  
Negative  pictures  of  the  gels  were  taken  for  quantita-
tion  with  a  Personal  Densi tometer  and  the  Image  
Quant  3.3 software  (Molecular  Dynamics,  Sunnyvale,  
CA,  USA).  Data  are  expressed  in  arbitrary  units,  as  
the  ratio  between  optical  densi ty  for  the  speci f ic  
cDNA  and  the  one  for  [3-actin  on  the  same  sample.  
Statistics.  The  data  are  expressed  as  mean  ±  SEM,  
unless  otherwise  stated.  The  statistical  significance  of  
differences  was  tested  with  the  Mann  Withney  non-
parametric  U  test.  P  values  less  than  0.05  were  consi-
dered  significant.  
RESULTS 
Localization  of  iNOS  expression  in  HLA-B27  transge-
nic  rats.  Expression  of  iNOS  was  reproducibly  detec-
ted  by  Western  Blot  analysis  (Figure  1),  and  by  immu-
nohis tochemis t ry  (Figure  2)  in  the  whole  colon  of  
HLA-B27  transgenic  rats  with  established  colitis,  but  
not  in  the  colon  of  nontransgenic  F344  l i t termates.  
Immunohistochemistry  performed  on  the  colon  of  33-3  
rats,  demonstrated  the  predominance  of  iNOS  expres-
sion  in  the  epithelium  over  the  chorion  (Figure  2).  This  
result  was  consistent  with  the  strong  detection  of  iNOS  
in  isola ted  co lon i c  epi the l ia l  ce l ls  f r o m  33-3  ra ts  
(Figure  1).  In  addition,  RT-PCR  analysis  of  several  tis-
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F i g u r e  1  
W e s t e r n - b l o t  a n a l y s i s  of  i N O S  in  t h e  w h o l e  c o l o n  a n d  i n  i so -
l a t e d  c o l o n i c  e p i t h e l i a l  ce l l s  f r o m  t h e  H L A - B 2 7  t r a n s g e n i c  
r a t  o f  t h e  3 3 - 3  l i n e  w i t h  e s t a b l i s h e d  d i s e a s e ,  a n d  f r o m  a  n o n -
t r a n s g e n i c  ( N t g )  F 3 4 4  l i t t e r m a t e .  
S p l e e n  h o m o g e n a t e  f r o m  rat  c h a l l e n g e d  i.v.  w i t h  L P S  w a s  u s e d  
as  a  p o s i t i v e  con t ro l  of  i N O S  e x p r e s s i o n .  T h i s  result  is  r e p r e -
s e n t a t i v e  of  4  s epa ra t e  e x p e r i m e n t s .  
F i g u r e  2  
D e t e c t i o n  of  i N O S  b y  i m m u n o h i s t o c h e m i s t r y  p e r f o r m e d  o n  
t h e  c o l o n i c  m u c o s a .  
A :  c o l o n  f r o m  an  H L A - B 2 7  t r a n s g e n i c  rat  of  t h e  3 3 - 3  l ine  w i t h  
e s t a b l i s h e d  d i sease .  T h e  s ec t i on  s h o w s  c h r o n i c  co l i t i s  wi th  u l c e -
ra t ion ,  c r y p t i c  a b c e s s  and  m a r k e d  in f i l t r a t ion  of  i n f l a m m a t o r y  
cel ls ,  a n d  i m m u n o h i s t o c h e m i c a l  loca l i sa t ion  o f  i N O S  as  d i f f u s e ,  
da rk  s t a i n i n g ,  loca l i zed  m a i n l y  in  the  ap ica l  e p i t h e l i u m  (o r ig ina l  
m a g n i f i c a t i o n  x  4 0 ) .  Pos i t ive  d e t e c t i o n  of  i N O S  was  o b s e r v e d  
in  c o l o n  f r o m  8 d i f f e r e n t  3 3 - 3  r a t s  e x a m i n e d .  B :  no rma l  c o l o n  
f r o m  n o n - t r a n s g e n i c  F 3 4 4  l i t t e r m a t e .  T h e  s e c t i o n  s h o w s  n o  e p i -
thel ia l  ce l l s  o r  l a m i n a  p r o p r i a  s t a in ing  ( o r i g i n a l  m a g n i f i c a t i o n  
x  100) .  A  pos i t ive  s t a in ing  of  g a n g l i o n i c  c e l l s  f r o m  M e i s s n e r ' s  
p l e x u s  c a n  be  no t ed  ( a r rows ) .  
sues  was  performed  in  HLA-B27  t ransgenic  rats  in  
parallel  with  nontransgenic  littermates.  These  experi-
ments  demonstrated  the  presence  of  iNOS  mRNA  in  
the  hip  cartilage  of  7  out  of  10 HLA-B27  transgenic  
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rats  studied,  in  addition  to  the  colon  (data  not  shown),  
but  not  in  this  tissue  f rom  nontransgenic  littermates,  
nor  in  any  the  following  tissues  from  affected  33-3  or  
from nontransgenic  F344  rats  that  were  examined:  sto-
mach,  ileum,  heart,  eye,  synovial  tissue  f rom  arthritic  
and  nonarthritic  knees  (specimens  from  2  to  5 rats  for  
each  tissue  were examined;  data  not  shown).  
Dexamethasone  improves  spontaneous  disease  in  
HLA-B27  transgenis  rat  but  fails  to  inhibit  INOS  
expression.  In  study  1,  groups  of  33-3 rats  and  non-
transgenic  littermates  were  treated  for  4  weeks  with  
e i t h e r  d e x a m e t h a s o n e  ( 0 . 2 5  mg .kg"  ' . d a y "  ' ) ,  or  
vehicle.  None  of  the  33-3 rats  used  in  this  experiment  
had  cl inical  arthritis,  but  all  had  chronic  diarrhea.  
Administration  of  dexamethasone  decreased  diarrhea  
in  33-3 rats  (Table  1,  study  1).  Consistent  with  this  
observation,  gross  examination  of  MLN  and  the  colon  
at  autopsy  demonstrated  reduced  MLN  hyperplasia,  
and  weight/length  ratio  of  the  colon  in  dexametha-
sone-treated  33-3 rats  (Table  2,  study  1). M L N  weight  
was  also  reduced  in  dexamethasone-treated  nontrans-
genic  F344  rats.  Histological  examination  of  the  colo-
n i c  m u c o s a  r e v e a l e d  c h r o n i c  i n f l a m m a t i o n  in  
33-3 rats.  However,  the  histological  score  of  lesions  
was  unchanged  in  dexamethasone-treated  33-3 rats,  as  
compared  to  vehicle-treated  rats  (Table  2,  study  1).  An  
inhibitory  effect of  dexamethasone  was  detected  in  the  
colon  on  several  markers  linked  to  gut  inflammation,  
i.e.  M P O  enzymatic  activity  (Table  3,  study  1),  and  
IFN-y,  I L - i p  and  CD3  transcripts  evaluated  by  semi-
quantitative  RT-PCR  (Figure  3A).  However,  neither  
iNOS  enzymatic  activity  (Table  3,  study  1),  nor  iNOS  
m R N A  expression  (Figure  3A),  examined  in  the  colo-
nic  mucosa  were  modified  in  dexamethasone-treated  
33-3  rats.  
L-NIL  decreases  iNOS  activity,  and  aggravates  the  
spontaneous  inflammatory  disease  of  HLA-B27  trasn-
genic  rat.  We  further  addressed  the  role  played  by  
iNOS  in  the  disease  process  of  HLA-B27  transgenic  
rat,  by  administering  L-NIL  (10 mg.kg"  ' . d a y  ')  or  
Table 1 
Effect of  dexamethasone  (study  1) and L-NIL (study  2) on the scores of diarrhea  and  arthritis  in HLA-B27  transgenic  rats  
Group of  rats  
Week of  treatment  
0 1 2 3 4 
Study  I  
Score of  diarrhea  
33-3: vehicle  (n = 6) 1.7 ±0.5 2 ±0.6 2.3 ± 0.6 2.5 ± 0.8 2.9 ± 0.8 
33-3: dexamethasone  (n = 6) 2.3 ± 0.3 2.5 ± 0.4 2.1  ±0.4"  1.6 ±0.2» 1.3 ±0.5' 
Study  2  
Score of  dian-hea  
33-3: vehicle  (n = 8) 1.6 ±0.3 2 ±0.2 1.9 ±0.1 2 ±0.1 
33-3: L-NIL  (n = 8) 2.3 ± 0.2 2.4 ± 0.2 2.3 ± 0.2 2.1  ±0.2  
Arthritic  score  
33-3:  vehicle  (n = 8) 0.5 ± 0.5 1.1 ±0.7 1 ±0.6 0.9 ± 0.5 
33-3: L-NIL  (n = 8) 0.8 ± 0.4 1.6 ±0.5 2 ±0.5 2 ±0.6 
Study  I:  HLA-B27  transgenic  rats  of  the  33-3  line  with  established  disease  received  dexamethasone  (0.25 mg.kg" '.day- ')  or  vehicle  for  
4 weeks.  Dexamethasone-  and  vehicle-treated  nontransgenic  F344 littermates  had  no  diarrhea.  '  P  =  0.015 dexamethasone  vs  vehicle:  week  2  
and  week 4 minus week 0.b  P < 0.01  dexamethasone  vs  vehicle: week 3 minus week 0. 
Study 2: HLA-B27  transgenic rats of  the  33-3 line with  established  disease  received  L-NIL (10 mg.kg" '.day-')  or  vehicle  for 3 week. L-NIL-
and vehicle-treated  nontransgenic F344 littermates  had no detectable diarrhea or arthritis.  
Table 2 
Effect of dexamethasone  (study  1) and  L-NIL (study  2) on MLN weight,  colon weight/length  and quantitative  histological  score  
of  HLA-B27  transgenic  rat  colon 
Group of  rats  MLN wt (mg) Colon wt/length  (mg/cm)  Histologic  score  
Study  I  
33-3: vehicle  (n = 6) 1,180 ±  184  239  ±31  16.5 ± 1 
33-3: dexamethasone  (n = 5) 413 ±88" 158 ±  12b  17 ±  1.1  
Ntg: vehicle  (n = 4) 126 ±26 98 ±  19  0 
Ntg: dexamethasone  (n = 4) 27 ±  5C  90 ± 1 0 
Study  2  
33-3: vehicle  (n = 8) 863 ± 49 217  ±22  8.3 ±  1.5  
33-3: L-NIL  (n = 8) 1055 ±69" 224 ±  18  11,5C ± 0.4 
Ntg:  vehicle  (n = 4) 188 ± 34 99  ± 9  1.9 ±  1.5  
Ntg: L-NIL  (n = 4) 163 ± 36 117 ± 3 0 
HLA-B27  transgenic  rats of  the  33-3 line  and  nontransgenic  (Ntg)  F344 rats were  treated  with  dexamethasone  (0.25 mg.kg" '.day')  or  vehicle 
for 4 weeks  (study  I), or  with  L-NIL (10 mg.kg" '.day ')  or  vehicle for 3 weeks (study  2). MLN  weight  and  weight/length  of  colon  were  mea-
sured at sacrifice. 
Study I: 33-3: dexamethasone  vs vehicle; 'P  < 0.005; " P < 0.04 
Ntg: dexamethasone  vs vehicle;'  P < 0.03 
Study 2: 33-3:  L-NIL vs vehicle:d  P < 0.04;'  P < 0.03. 
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Figure  3  
Semi-quantitative  RT-PCR  evaluation  of  iNOS  and  cyto-
kines  transcripts  in  the  colonic  mucosa  f rom  HLA-B27  
transgenic  rats.  Individual  rat  values  and  medians  a re  
shown. 
A :  study  1:  i N O S ,  C D 3 ,  IFN-y ,  a n d  IL-lfS  t r a n s c r i p t s  in  t h e  
co lon ic  m u c o s a  f r o m  v e h i c l e - t r e a t e d  B 2 7  t r a n s g e n i c  ra t s  ( c l o s e  
s y m b o l s ) ,  a n d  f r o m  d e x a m e t h a s o n e - t r e a t e d  B 2 7  t r a n s g e n i c  r a t s  
(open  s y m b o l s ) .  *  P  <  0 .05 ,  d e x a m e t h a s o n e -  vs  v e h i c l e - t r e a t e d  
g roups .  In  the  c o l o n  o f  d e x a m e t h a s o n e -  (n  =  4 )  o r  v e h i c l e - t r e a -
ted  (n  =  2 )  n o n t r a n s g e n i c  F 3 4 4  l i t t e rma te s ,  t r a n c r i p t s  f o r  i N O S ,  
I F N - y  o r  I L - i p  w e r e  n o t  de tec ted  a n d  t r ansc r i p t s  f o r  C D 3  w e r e  
nega t i ve  o r  <  10 - fo ld  b e l o w  the  l eve l  of  d e t e c t i o n  a c h i e v e d  in  
B 2 7  t r a n s g e n i c  ra ts .  B :  study  2:  I F N - y ,  T N F - a  ( l e f t  sca le ) ,  a n d  
IL-10 ,  I L - i p  ( r ight  s c a l e )  t r ansc r ip t s  in  the  c o l o n i c  m u c o s a  f r o m  
v e h i c l e - t r e a t e d  ( c l o s e  s y m b o l s ) ,  a n d  f r o m  L - N I L - t r e a t e d  B 2 7  
t r a n s g e n i c  ra t s  ( o p e n  s y m b o l s ) .  *  P  <  0 .05 ,  L - N I L -  vs  v e h i c l e -
t rea ted  g r o u p .  **  P  <  0 . 0 1 ,  L-NLL-  vs  v e h i c l e - t r e a t e d  g r o u p .  In  
the  c o l o n  of  L - N I L -  (n  =  2)  or  v e h i c l e - t r e a t e d  (n  =  3)  n o n t r a n s -
gen ic  F 3 4 4  l i t t e rma te s ,  t r ancr ip t s  f o r  IFN-y,  T N F - a ,  o r  I L - i p  
were  n o t  de t ec t ed ,  a n d  t ransc r ip t s  f o r  I L - 1 0  w e r e  e i t h e r  n e g a t i v e  
or  <  7 - f o l d  b e l o w  t h e  a v e r a g e  level  o f  d e t e c t i o n  in  v e h i c l e - t r e a -
ted  B 2 7  t r a n s g e n i c  r a t s .  
veh ic le  f o r  3 w e e k s  to  3 3 - 3  ra t s  w i th  e s t a b l i s h e d  
disease  (study  2).  In  this  exper iment ,  bo th  d ia r rhea  
and  a r t h r i t i s  w e r e  p r e s e n t .  A d m i n i s t r a t i o n  o f  
L-NIL  had  no  detectable  ef fec t  on  diarrhea  (Table  1,  
study  2);  arthritis  was  exacerbated  in  the  L-NIL- t rea-
ted  group,  as  compared  to  the  vehicle-treated  g roup  
although  the  d i f fe rence  was  not  statistically  s ignif icant  
(Table  1,  study  2).  Evidence  f o r  a  detr imental  ef fec t  of  
L - N I L  on  the  c o u r s e  of  i n f l a m m a t o r y  d i s e a s e  in  
33-3  rats  was  fu r ther  provided  by  gross  organ  exami -
nation;  M L N  hyperplasia  was  increased  in  L-NIL- t rea-
ted  33-3  rats,  as  compared  to  vehicle- t reated  g roup ,  
whereas  the  colon  weight/ length  ratio  was  no  d i f ferent  
between  the  two  groups  (Table  1,  s tudy  2).  Finally,  
h i s to log ica l  e v a l u a t i o n  of  t h e  co lon  d e m o n s t r a t e d  
increased  lesions  in  L-NIL-t reated  33-3  rats,  as  corn-
Table  3  
Effect  of dexamethasone  (study  1) and  L-NIL  (study  2)  
on  MPO  and  iNOS enzymatic  activities  in  the  colon  
of  HLA-B27  transgenic  rats  
G r o u p  of  rats  M P O i N O S 
( m U / g  of  c o l o n )  (pmol . 
min"  ' . m g " 1  
pro te in) 
Study  I  
3 3 - 3 :  veh i c l e  (n  =  6)  1,451  ± 4 5 5  2.2  ±  0 . 6  
3 3 - 3 :  d e x a m e t h a s o n e  (  n  =  5 )  4 7 5  ±  112  2 .2  ±  0 . 5  
N t g :  veh ic le  (n  =  4 )  6 9 0  ±  1 2 6  0 
N t g :  d e x a m e t h a s o n e  (n  =  4 )  7 6  ±  25'  0 
Study  2  
3 3 - 3 :  veh ic le  (n  =  8)  4 7 7  ±  113  1.4  ± 0 . 4  
3 3 - 3 :  L - N I L  (n  =  6)  6 4 9  ± 2 1 2  0 .4  ± 0 . 1 "  
N t g :  veh ic le  (n  =  4 )  3 1 9  ± 7 0  0 .2  ± 0 . 1  
N t g :  L - N I L  (n  =  4 )  351  ±  1 0 5  0 .1  ± 0 . 2  
H L A - B 2 7  transgenic  rats  of  the  33-3  line  and  nontransgenic  (Ntg)  
F344  rats  were  treated  with  dexame thasone  (0 .25  mg.kg" ' . d a y " ' )  or  
vehicle  for  4  weeks  (study  1),  o r  with  L - N I L  ( 1 0  mg.kg" ' . d a y  ' )  o r  
vehicle  for  3 weeks  (study  2).  M P O  and  i N O S  enzymat ic  activity  
were  measured  in  samples  of  co lon  harvested  at  sacrif ice.  
'  P  <  0 .05,  Nig:  dexamethasone  vs  vehicle  (study  I).  
"  P  =  0 .05,  33-3:  L.-NIL  vs  vehic le  (study  2).  
pared  to  the  vehicle-treated  group  (Table  2,  study  2).  
Variations  in  M L N  weight ,  histological  score,  M P O  
and  iNOS  activity  of  vehicle-treated  33-3  groups  bet-
ween  study  1 and  2  (Tables  1  and  2)  merely  reflects  
the  d i f ference  in  the  overal l  degree  of  gut  in f l amma-
tion  between  the  2  studies.  
Influence  of  L-NIL  treatment  on  cytokine  production  
in  the  colon  of  B27-transgenie  rats.  Inh ib i t ion  of  
iNOS  enzymat ic  activity  by  L-NIL  w a s  conf i rmed  in  
the  colon,  whereas  M P O  activity  was  not  significati-
vely  modif ied  by  L-NIL  t reatment  (Table  3,  s tudy  2).  
RT-PCR  analysis  detected  comparab le  levels  of  C D 3 ,  
iNOS,  and  IL-10  transcripts  in  the  co lonic  mucosa  of  
33-3  rats  treated  with  L - N I L  or  with  vehicle  (Figure  
3B,  and  data  not  shown) .  As  regards  cytokine  trans-
cripts,  a  significant  decrease  was  obse rved  for  IFN-y,  
and  T N F - a  in  L-NIL-t rea ted  33-3  rats,  in  compar ison  
to  v e h i c l e - t r e a t e d  g r o u p  (F igu re  3 B ) .  In  c o n t r a s t ,  
IL-1J3  m R N A  t r a n s c r i p t s  w e r e  i n c r e a s e d  in  t h e  
L-NIL-t reated  group,  as  compared  to  vehicle-treated  
33-3  rats,  but  this  d i f fe rence  did  not  reach  statistical  
s ignif icance.  N o  consistent  d i f ference  in  pathology  or  
M P O  activity  w a s  de tec ted  be tween  a  subgroup  of  
4  r a t s  w i th  h i g h  I L - i p  t r a n s c r i p t  v a l u e s  and  the  
3  r ema in ing  ra ts  with  l o w e r  values ,  a m o n g  L - N I L -
treated  33-3  rats  (data  not  shown) .  
D I S C U S S I O N 
Expression  of  iNOS  was  detected  in  two  prominent  
target  organs  of  H L A - B 2 7  transgenic  rat  inf lammatory  
disorder,  namely  the  colonic  mucosa  and  joint.  Induc-
tion  of  iNOS  was  reproducibly  detected  in  the  hip  car-
t i l age  of  33 -3  ra ts ,  e v e n  t h o u g h  a r th r i t i s  w a s  not  
observed  at  this  site.  In  contrast ,  iNOS  was  not  detec-
ted  in  the  synovium,  even  f r o m  arthrit ic  joints,  which  
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may  suggest  that  chondrocytes  are  specifically  trigge-
red  to  produce  iNOS  in  this  model.  Conceivably,  a  
common  mechanism  may  result  in  iNOS  expression  in  
both  gut  and  joint,  since  inflammation  of  these  two  
organs  is  closely  linked  in  the  HLA-B27  transgenic  
rat  [2],  In  the  colonic  mucosa,  iNOS  expression  was  
predominantly  localized  in  the  epithelial  cells,  with  
only  limited  expression  in  the  inflammatory  cells  infil-
trating  the  lesions.  Among  possible  triggers  of  iNOS  
expression,  cytokines  produced  locally  in  the  setting  
of  chronic  inflammation  and  luminal  bacterial  pro-
ducts,  such  as  LPS,  are  likely  candidates  [18,  19].  
We  examined  in  vivo  the  role  played  by  iNOS  in  the  
HLA-B27  transgenic  rat  model  by  administering  dexa-
methasone,  which  may  prevent  the  expression  of  
iNOS  [20]  and  the  putative  iNOS  inhibitor,  L-NIL.  
Dexamethasone  treatment  improved  chronic  diarrhea,  
and  r e d u c e d  M L N  h y p e r p l a s i a ,  a n d  co lon  
weight / length  rat io  in  33-3  rats  with  establ ished  
disease.  It  also  decreased  MLN  weight  and  MPO  acti-
vity  in  the  colon  of  nontransgenic  control  F344rats.  
All  these  changes  are  suggestive  of  an  anti-inflamma-
tory  effect.  Nevertheless  the  efficacy  of  dexametha-
sone  on  33-3 gut  lesions  was  not  confirmed  when  exa-
mined  histologically.  We  also  observed  a  lack  of  
influence  of  dexamethasone  on  iNOS  expression.  This  
latter  result  is  consistent  with  a  study  carried  out  in  
human  inflammatory  bowel  disease  [21],  although  it  is  
at  variance  with  reports  showing  inhibition  by  corti-
cos tero ids  of  cytokine-  and  LPS-media ted  iNOS  
induction  [11,  14],  Such  inhibitory  effects  of  dexame-
thasone  are  thought  to  involve  inhibition  of  nuclear  
factor-kappaB  (NF-KB)  activation,  which  is  important  
for  induction  of  the  iNOS  gene  [22].  However,  inhibi-
tion  of  NF-KB  by  dexamethasone  is  not  uniformly  
observed  [23],  and  dexamethasone-insensitive  path-
ways  of  iNOS  induction,  other  than  NF-KB  have  been  
described  in  epithelial  cells  [24],  In  the  present  study,  
the  decrease  of  CD3  and cytokine  transcripts  in  colon,  
observed  after  dexamethasone  treatment,  was  not  
associated  with  a  striking  inhibition  of  gut  inflamma-
tion.  This  result  is  consistent  with  our  previous  work,  
in  which  administration  of  IL-10  to  33-3 rats  failed  to  
improve  colonic  inflammation,  although  it  did  reduce  
CD3,  IFN-y,  T N F - a .  and  IL-1(3,  and  conversely  
increased  iNOS  expression  in  the  colon  (5;  M.  Breban  
and  D.  Lamarque,  unpublished  results).  Altogether,  
these  results  argue  for  a  dispensable  role  of  this  set  of  
p r o - i n f l a m m a t o r y  cy tokines  in  perpe tua t ing  the  
disease  process  and  in  the  induction  of  iNOS.  It  is  
likely  that  other  mediators  are  critically  involved  in  
the  sustained  colonic  inflammation  of  HLA-B27  trans-
genic  rats.  However,  since  dexamethasone  had  no  
effect  on  iNOS,  this  study  could  not  properly  address  
the  role of  iNOS  in  this  model  of  colitis.  
In  a further  study,  L-NIL  was  used  as  a  selective  inhi-
bitor  of  iNOS  [12].  Enzymatic  inhibition  of  iNOS  was  
achieved  with  this  compound.  L-NIL-treatment  was  
associated  with  aggravation  of  several  markers  of  
disease  severity,  Le.  arthritis,  MLN  hyperplasia,  and  
colonic  histological  inflammation.  Another  noticeable  
effect of  L-NIL  administration  was  a decrease  of  seve-
ral  cytokine  transcripts  in  the  colon,  i.e.  IFN-y  and  
T N F - a .  However,  a  trend  towards  increased  I L - i p  
was  conversely  observed  in  the  same  tissue.  Hence,  
this  result  suggests  that  NO  produced  by  epithelial  
cells  in  the inflammed  colonic  mucosa  results  in  either  
stimulatory  (IFN-y,  T N F - a )  or  inhibitory  ( IL-IP)  
effects  on  cytokine  production.  Depending  on  the  site  
of  production,  the  amount  produced,  and  the  targets  
within  the  local  environment,  NO  has  indeed  been  
shown  to  display  opposite  effects,  including  those  on  
cytokine  production  [2.5-27].  In  the  colitis  of  HLA-
B27  transgenic  rats,  it  is  not  yet  known  which  cells  
produce  specific  cytokines,  and  N O  may  exert  an  
effect  on  different  target  cells,  such  as  T  cells,  macro-
phages  or  epithelial  cells,  resulting  in  distinct  varia-
tions  of  cytokine  transcripts.  In  any  case,  stimulation  
of  I L - i p  transcription  may  provide  an  explanation  for  
the  damaging  consequence  of  iNOS  inhibition  in  the  
present  model.  In  a  study  by  Aiko  and  colleagues,  two  
other  NO  synthase  inhibitors,  i.e.  aminoguanidine  and  
L-NAME,  were  used  in  this  HLA-B27  transgenic  rat  
model  [28].  The  major  effects  of  NO  synthase  inhibi-
tors  reported  by  these  authors  were  decreased  MPO  
activity  in  the  colonic  mucosa  and  decreased  bowel  
mucosal  permeability.  Increased  colonic  lesions  were  
not  described.  However,  no  quantitative  histological  
analysis  of  colonic  ulceration  and  infiltration  by  
inflammatory  cells  was  performed.  Hence,  differences  
with  the  present  study  could  be  related  to  different  
inhibitory  activity  of  the  inhibitors  used  in  their  study,  
as  compared  to  L-NIL,  or  to  a  differences  in  study  
protocols. 
Induction  of  iNOS  has  been  described  in  a  variety  of  
inf lammatory  diseases,  in  humans  and  in  animal  
models,  including  colitis,  arthritis  and  psoriasis  which  
are  features  of  the  HLA-B27  transgenic  rat  model  [25,  
29,  30].  Interestingly,  expression  of  iNOS  in  human  
ulcerative  colitis  was  shown  to  predominate  in  epithe-
lial  cells  rather  than  in  infiltrating  leukocytes  of  the  
colonic  mucosa,  a  finding  similar  to  our  observation  
in  HLA-B27  transgenic  rat  [31].  Investigating  the  
potential  implication  of  iNOS  induction  in  the  patho-
genic  mechanism  of  this  model  is  of  considerable  
interest,  since iNOS  has been  shown  to  exert  both  pro-
tective  and  detrimental  effects  on  several  inflamma-
tory  processes,  including  chronic  gut  inflammatory  
situations  and  arthritis  [9,  32].  NO  from  iNOS  seems  
to  contribute  to  tissue  destruction  in  acute  inflamma-
tory  disease  through  the  generation  of  its  cytotoxic  
derivative  peroxynitrite,  when  produced  by  macro-
phages  and  neutrophils  in  combination  with  oxygen  
free  radicals  [33].  Such  a  consequence  is  less  likely  to  
happen  if  NO  production  takes  place  in  epithelial  
cells,  such  as  in  chronic  colitis  of  HLA-B27  transge-
nic  rat.  Local  production  of  NO  in  the  epithelium  may  
rather  display  antibacterial  effects  that  could  be  bene-
ficial  in  this  model,  in  which  gut  bacterial  flora  is  cri-
tically  involved  in  the  induction  of  both  gut  and  joint  
inflammation  [2],  NO  may  also  display  immunoregu-
latory  activities  which  are  mediated  by  the  modulation  
of  cytokine  product ion  and  apoptosis  of  effector  
T  cells,  resulting  in  a  decrease  of  Thl -dependant  
autoimmune  diseases  [9].  Regarding  a  putative  immu-
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noregulatory  mechanism,  it  is  worth  noting  that  IL- ip ,  
which  has  been  repeatedly  implicated  in  the  pathoge-
nesis  of  IBD  was  rather  increased  in  the  colon  after  
L-NIL  treatment  [34-36].  
Our  results  provide  a  strong  suggestion  that  iNOS  is  
protective,  at  least  in  colitis  and  presumably  in  arthritis  
in  the  HLA-B27  transgenic  rat  model.  To  our  know-
ledge,  this  is  the  first  evidence  that N O  is  protective  in  
a  spontaneous  animal  model  of  chronic  colitis  or  arthri-
tis.  It  will  be  important  to  consider  this  result  when  
discussing  the  therapeutic  prospect  of  selective  iNOS  
inhibitors  in chronic  inflammatory  disorders  [25,  37],  
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ABSTRACT.  Objective. In  pa t ien ts  with  anky los ing  spondyl i t i s  (AS) ,  i n f l a m m a t o r y  p rocesses  h a v e  been  de tec ted  
in  the  ileal  and  co lonic  m u c o s a .  T h e  inducible  i so form  of  nitric  ox ide  syn thase  ( i N O S )  m a y  be  
expres sed  early  in  the  i n f l a m m a t o r y  process .  We  invest igated  i N O S  act ivi ty  and  lymphocy t i c  inf i l -
trat ion  in  the d u o d e n u m  and  co lon  in  pat ients  with  A S  and  ulcerat ive  coli t is c o m p a r e d  wi th  contro ls .  
Methods.  G a s t r o s c o p y  with  duodena l  b iops ies  and/or  co lonoscopy  with  b iops ies  w e r e  conduc ted  in  
4 2  pa t ien ts  with  A S  treated  or  not  treated  with  nonsteroidal  an t i i n f l ammato ry  d rugs  (NSA1D) ,  in  15  
with  u lcera t ive  coli t is ,  and  in 4 6  contro ls .  Lymphocy t i c  infi l trat ion  in the  l amina  propr ia  and  intraep-
ithelial  inf i l t ra t ion  were  quan t i f i ed  by  histological  score.  i N O S  express ion  was  assessed  by  i m m u n o -
h i s tochemis t ry  with  m o n o c l o n a l  an t ibodies ,  and  i N O S  activity  w a s  de t e rmined  by  rad iochemica l  
assay. 
Results.  E n d o s c o p i c  examina t i on  of  the  gas t roduodena l  or  co lon ic  m u c o s a  did  not  reveal  m a c r o -
scopic  les ions  in  the  A S  pat ients .  In  the  d u o d e n u m ,  mucosa l  l ymphocy t i c  inf i l t ra t ion  was  f o u n d  in  
8 3 . 3 %  of  the  A S  g r o u p  c o m p a r e d  to  4 8 . 6 %  of  cont ro ls  (p  =  0 .02) ,  and  was  i ndependen t  of  the  
N S A I D  intake.  Int raepi thel ia l  l y m p h o c y t e  infi l t rat ion  was  increased  in  both  d u o d e n u m  and  co lon  in  
A S  pa t ien t s  c o m p a r e d  to  cont ro ls .  i N O S  activity  in  d u o d e n u m  and  colon  and  express ion  of  i N O S  
prote in  in  l amina  p ropr ia  i n f l a m m a t o r y  cells  was  increased  in A S  pat ients  c o m p a r e d  to  cont ro ls .  
Conclusion.  L y m p h o c y t i c  infi l t rat ion  and  i N O S  express ion  and  act ivi ty  were  de tec ted  in  duodena l  
and  co lon ic  m u c o s a  f r o m  pat ients  with  AS.  Such  f ind ings  m a y  indicate  an  i n f l a m m a t o r y  p rocess  in  
the  smal l  in tes t ine  and  co lon  of  pat ients  wi th  A S .  (J  R h e u m a t o l  2 0 0 3 ; 3 0 : 2 4 2 8 - 3 6 )  
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Histologic  features  of  inflammation  have  been  described  in  
ileal  and  colonic  mucosa  from  patients  with  ankylosing  
spondylitis (AS).  Up to 56% of those patients have  exhibited  
lymphocytic  infiltration  in  the  colonic  lamina  propria,  
suggesting  inflammatory  bowel  disease'-2.  Inflammation  of  
the  gut  has  been  proposed  to  be  linked  to  the  pathogenesis  
of AS  by provoking  a break  in the epithelial  barrier,  permit-
ting  luminal  antigens,  especially  bacteria,  to  penetrate  into  
the  mucosa  and  subsequently  to  activate  an  immune  
process1.  One  consequence  of  such  a  process  involving  
epithelial  dysfunction would  be the release  of  local  bacterial  
products  that  cause  expression  of  mediators  and  markers  of  
inflammation. 
Expression  of  inducible  nitric  oxide  synthase  (iNOS)  
could  be  such  a  marker,  as  it  appears  in  the  initial  phase  of  
inflammation  in many  animal  models  of  gut  inflammation3.  
Thus,  after systemic  low  dose  administration  of  endotoxin,  
iNOS  is  expressed  within  3  hours  in  duodenal  or  colonic  
tissue  and  epithelial  cells  and  is  associated  with  epithelial  
cytotoxicity  and  microvascular  leakage  of  albumin4'7.  
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Expression  of  iNOS  in the colon  is also observed as an  early  
event  in  experimental  colitis  induced  by  trinitrobenzene  
sulfonic acid  in the  rat and  in an HLA-B27  transgenic  model  
of  AS8-9.  Induction  of  iNOS  is  stimulated  by  the  proinflam-
matory  cytokines  interferon-y (IFN-y)  and  interleukin  2  (IL-
2 ) 1 0 " ,  whereas  IL-10  is  known  to  modula te  the  
inflammatory  response  and  reduce  iNOS  expression'2 .  
To  explore  the  possibility  that  gut  inflammation  in  
patients  with  AS  extends  to  other  regions  of  the  gastroin-
testinal  (GI)  tract,  we  invest igated  the  infiltration  of  
lymphocytes  into  the  epithelium  and  lamina  propria,  along  
with  iNOS  activity  and  expression  in  mucosa  of  both  the  
duodenum  and  the  colon  in  patients  with AS.  These  factors  
in  the  duodenal  and  colonic  mucosa  were  compared  with  
control  patients  or  patients  with  ulcerative  colitis,  respec-
tively. Moreover,  the expression  of m R N A for other  markers  
of  inflammation,  the  cytokines  IFN-y,  IL-2,  and  IL-10,  was  
also  evaluated  in  duodenum  f rom  patients  with  AS  and  
control  patients.  
MATERIALS AND METHODS 
Patients.  Patients  who  had  dyspepsia,  abdominal  pain,  or  diarrhea  were  
referred  for  csophago-gastroduodcnoscopy  or  colonoscopy  in  the  Henri  
Mondor  Hospital  endoscopy  unit and  were  considered  for inclusion  in  the  
study.  Patients  with  concomitant  known  intestinal  or  significant  hepatic,  
respiratory, cardiovascular,  or renal disease or  malignancy, or  those  taking  
medications other than nonsteroidal  antiinflammatory drugs (NSAID) were 
excluded.  Patients treated for Helicobacter  pylori  infection were excluded. 
Forty-two  patients  with AS  were  recruited  from  rheumatology  depart-
ments  at  Henri  Mondor  Hospital  and  Cochin  Hospital  over  a  36  month  
period.  All  patients  were  diagnosed  with  AS,  according  to  the  New  York  
criteria,  and  all  except  3  had  the  HLA-B27  antigen11.  Axial  involvement  
was present  in all patients. According  to the exclusion  criteria,  none of  the  
AS  patients  were  treated  with  sulfasalazine.  Patients  were  divided  into  2  
groups:  14 patients  who  had  used  NSAID  at  least  once  per  week  in  the  
previous month and 28 patients whose NSAID treatment was interrupted  in  
the previous week for the purpose of  the  study.  
A group  of  15  patients  having  clinically  active  ulcerative  colitis  not  
associated  with  AS  or  peripheral  arthritis  or  other  inflammatory  diseases  
were also recruited. 
Finally. 46  palients  were  selected  for  the  control  group  from  patients  
referred  to our  endoscopy  unit  for  polyp  screening  or  dyspepsia.  Patients  
with  GI  disease  or  taking  antisecretory  drugs  were  excluded  from  these  
groups. Nine of  the control  patients  had  taken NSAID for osteoarthritis.  
All  patients  signed  an  informed  consent  approved  by  the  institutional  
ethics  committee.  
Tissue  samples.  All  tissues  evaluated  in  this  study  were  obtained  from  
endoscopic  biopsy  specimens.  In  patients  having  esophago-gastroduo-
denoscopy.  2  biopsies  were  taken  from  the  antrum  and  6  from  the  
duodenum  for  histology.  In  patients  having  colonoscopy.  6  samples  were  
taken  from  the  ascendant  colon.  For  measurement  of  iNOS  and  mRNA  
analysis.  8 additional  biopsies obtained  from the duodenum  or colon  were  
snap-frozen  in  liquid  nitrogen.  
Histological  inflammation  grading.  After  fixation  in  buffered  formalin,  
tissues  were  embedded  in  paraffin,  sectioned,  and  stained  with  hema-
toxylin,  cosin,  and  safran.  All  histological  sections  were  reviewed  by  a  
single GI pathologist  (JTVN), who was blinded  to the other  characteristics  
studied.  Sections  were  scored  for  lymphocytic  infiltration  in  the  lamina  
propria  (absent:  0,  mild:  1,  moderate:  2,  severe:  3)  or  the  intraepithelial  
lymphocytic infiltration (for duodenum: < 20%: 0, from 20% to s  50%:  1,  
more than 50%: 2; for colon: <  10%: 0,  10% to 30%: I, >30%: 2). It.  pylori  
infection was diagnosed  by examination  of  antral  mucosal  samples stained 
with cresyl  fast violet. 
Immunohisrocliemistry.  An  antigen  retrieval  method  was  performed  on  5  
pm deparaffinized sections  of duodenum  or  colon,  using  microwave  oven  
heating ( 3 x 5  min) in 6 mM citrate  buffer, pH 6. Sections  were then  incu-
bated  10  min  in  3%  hydrogen  peroxide  to  block  endogenous  peroxidase  
activity,  followed  by  1  h  with  anti-iNOS  monoclonal  antibody,  dilution  
1/40 (Transduction  Laboratories. Lexington,  KY, USA). Cross-reactivity of  
these antibodies to human  iNOS has been described  by  iinmunohistochem-
istry'4. This antibody  has previously  been  used  to determine  iNOS expres-
sion  in gastric  mucosa from patients  with  H. pylori  infection11. That  study  
has  shown  that  the  immunostaining  was  in  agreement  with  the  mRNA  
expression  of iNOS. A 3-step indirect process, based on avidin-biotinylated  
peroxidase  complex  (Vectastain  Elite  ABC  kit,  Vector  Laboratories.  
Burlingame,  CA.  USA)  and  3,3-diaminobenzidine  (Sigma,  St-Quentin  
Fallavier,  France) as chromogen, was applied  to reveal staining as a brown 
precipitate.  Negative controls  were obtained  by omitting  the primary  anti-
body  and  by staining  after incubating  the  antibody  for 2  h with  the  iNOS  
peptide  provided  by  Transduction  Laboratories.  The  extent  of  the  
immunoreactivity  was quantified by  a score ranging from 0 to 3 in epithe-
lium and in lamina propria. The score was: 0 when <  10% of the cells were 
stained.  I  when  10%  to  30%  were  stained,  2  when  30%.  to  50%.  were  
stained, 3 when > 50%. of the cells  were stained. 
Determination  of iNOS  enzymatic  activity.  Activity  of  iNOS was estimated 
by measuring  the conversion  of  L-l"CJ-arginine  monohydrochloride  to L-
[uC]-citrul!ine,  as  described7.  Briefly,  duodenal  or  colonic  sample  was  
homogenized  in  HEPES  buffer  containing  protease  inhibitors.  After  
centrifugation (10,000 g, 30 min, 4°C), an aliquot of supernatant  was added 
to prewarmed  buffer containing  (final concentration) potassium  phosphate  
(50 mM,  pH  7.4).  valine  <50 mM).  MgCl.l  l  mM),  CaCl,  (200 pM).  DL-
DTT (I  mM), L-eitrulline (1 mM), NADPH  (0.3 mM),  FAD (3 pM),  FMN 
(3  pM),  BH4  (3  pM).  L-[IJC]-arginine  monohydrochloride  (I5.S  nM:  
Amersham.  Les  Ulis.  France)  and  incubated  30  min  at  37JC. The  incuba-
tion was terminated  by the binding of arginine,  by addition of a  1:1 suspen-
sion  of  Dowex  (AG  50W-8;  Sigma)  in  water.  After  centrifugation,  
supernatant  was taken for scintillation  counting. Activity  of iNOS was  that  
which  was  inhibited  by  in  vitro incubation  with the NO synthase  inhibitor  
Nc-monomethyl-L-arginine  (L-NMMA;  300  pM;  Sigma)  but  not  with  
EGTA (I  mM),  and was expressed  as pmolmin-'-mg-'  protein1*.  
Reverse  transcription-polymerase  chain  reaction  (RT-PCR).  Expression  of  
IL-2,  IL-10,  and  IFN-y  in  the  duodenal  mucosa  was estimated  by  mRNA  
detection  with  RT-PCR, and  was semiquantified  by comparison  with  actin  
mRNA  expression.  Total  RNA  was  isolated  with  the  TRI  reagent  
(Molecular  Research Center, Cincinnati, OH, USA) and reverse transcribed 
into  complementary  DNA  (cDNA)  using  AMV  reverse  transcriptase  
(Proinega,  Madison,  Wl,  USA). Amplification  was carried  out  in a  1(H) pi 
volume containing 250 ng cDNA,  125 pM  of each 2'-deoxynucleoside  5'-
triphosphate, 2 U of Taq DNA polymerase (Appligene. Illkirch, France). 50 
ng  of  each  primer,  and  10 pi  of  10  x  PCR  buffer. The  following  primer  
sequences  were used: IL-2 sense 5'-GTC ACA AAC  ACiT OCA CCT AC-
S',  antisense  5'-CCC  TCiG  GTC TTA AGT  GAA AG-3';  IL-10 sense  5'-
A A A T IT GGT TCT AGG CCG GG-3', antisense 5 '-G AG TAC TCT GGT 
TGG TCT TC-3;  IFN-y sense 5'-GCA  GAG  CCA AAT TGT CTC CT-3\  
antisense  5'-ATC> CTCTTC GAC CTC GAA AC-3'; B-actln sense 5'-GCiG 
TCA GAA GGA TTC CTA TG-3\  antisense 5 -GGT CTC AAA CAT GAT 
CTG CiG-3'. Amplification conditions consisted of 3 min at 94*C followed 
by  35 cycles  of  denaturation  at 94'C  for 30 s,  annealing  for 30 s at  57°C.  
extension at 72°C for 30 s, and by final elongation at 72°C for  10 min. Fifty 
microliters of  PCR product  were eleclrophoresed  on agarose gel.  Negative  
pictures  of  the  gels  were  taken  for  quantitation  with  a  Personal  
Densitometer  using  the  Image  Quant  3.3  software (Molecular  Dynamics,  
Sunnyvale,  CA,  USA).  Data  are  expressed  in  arbitrary  units  as  the  ratio  
between  optical  density  for the  specific cDNA and  the  one  for B-actin  on  
the same  sample.  
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Statistics.  Quantitative  variables  were  expressed  as  mean  ±  SEM.  
Contingency  analysis  was  performed  using  the  Fisher  exact  test.  Single  
comparisons were made by the Student t test or by Wilcoxon  nonparametric  
lest where appropriate. Links between the different histological scores were 
by  Kruskal-Wallis  nonparametric  or  parametric  analysis  of  variance  
(ANOVA)  test.  Multiple  comparisons  between  groups  were  performed  
using one-way ANOVA. P values  < 0.05 were considered  significant.  
RESULTS 
Clinical  results and H. pylori  status.  There  were no signifi-
cant  differences  in  the  mean  ages  (±  SEM)  of  the  groups:  
41.9  ±  2,  42.9  ±  5,  51.0  ±  3,  and  52.0  ±  2  years  For  AS 
untreated,  AS  NSA1D  users,  ulcerative  colitis  groups,  and  
controls  taking  NSA1D  or  not,  respectively.  Diarrhea,  
defined as regular episodes  of diarrhea  with stool frequency 
> 4 per day,  was observed  in  7 (17%) patients  with AS  and  
in all  patients  with  ulcerative  colitis.  
Endoscopic  examination  of  the  gastroduodenal  or  
colonic mucosa did not reveal any macroscopic lesion in AS 
or  control  patients.  Colonic  examination  of  patients  with  
ulcerative  colitis  revealed  pancolitis  in  5  patients,  left-side 
colitis  in  10 patients. No patient  showed  dysplasia  or  toxic  
megacolon. 
H. pylori  status, analyzed  in patients who had  esophago-
gastroduodenoscopy,  was  positive  in  10  of  24  (42%)  
patients  with  AS  who  were  non-NSAID  users,  in  4  of  12  
(33%) patients  with AS  who  were NSAID  users,  and  in  23  
of  35 (66%) controls.  
Histological  characteristics.  Duodenum.  The  infiltration  
scores  of  lymphocytes  in  the  lamina  propria  of  the  
duodenum  and  of  intraepithelial  lymphocytes  are  shown  in  
Tables  1 and  2, respectively.  Lymphocytic  infiltration  in the 
duodenal  lamina  propria  was  found  more  frequently  and  
was  more  intense  in  patients  with  AS,  both  treated  or  not  
treated  with  NSAID,  as  compared  to  the  corresponding  
control group (Table  1). Intraepithelial  lymphocytosis  in the 
duodenum  was  also  found  more  frequently  and  was  more  
marked  in  AS  patients  treated  or  not  with  NSAID  than  in  
controls  (Table 2). 
In  patients  with AS, the percentage  of  H. pylori  positive  
patients  that  showed  lymphocytic  infiltration  in  lamina  
propria  (79%)  or  increased  intraepithelial  lymphocytes  
(86%) was not different compared to that of //. pylori  nega-
tive AS patients  (86%  and  64%,  respectively).  
Histological  characteristics.  Colon.  In  the  colon,  the  
frequency or  the  mean  grade  of  lamina  propria  infiltration  
by  lymphocytes  was  not  different  between  AS  patients  
treated  with  NSAID  or  untreated  and  the  control  patients  
(Table  1).  
The  intraepithelial  lymphocytosis  in  colon  was  more  
frequently  observed  and  the  mean  score  was  significantly  
higher  in  AS  patients  both  treated  and  not  treated  with  
NSAID than  in control  patients  (Table 2). 
In patients  with  ulcerative  colitis,  the  frequency  and  the  
mean grade of  lymphocytic  infiltration  in lamina propria  or  
intraepithelial  lymphocytes  was  increased  compared  to  the  
control  group (Tables  1 and 2).  
Immunohistochemistry.  Duodenum.  As  shown  in  Figure  1  
and  Table  3,  iNOS  staining  in  the  duodenum  was  more  
frequently  detected  and  the  mean  grade  was  higher  in  
lamina  propria  inflammatory  cells  from  patients  with  AS,  
whatever  the  NSAID  user  status,  than  in  controls.  The  
frequency and the mean grade of iNOS staining in epithelial 
cells,  however,  was  not different  in  the  untreated  or  treated  
AS  groups  from that  in  the  control  group  (Table  4).  There  
was  a correlation  between  the  iNOS  immunostaining  score  
and  the  score  of  lymphocytic  infiltration  in  the  duodenal  
lamina propria  (p < 0.02).  
Immunohistochemistry.  Colon.  In  the  colon,  iNOS  staining  
was  observed  more  frequently  and  with  a  higher  score  in  
lamina  propria  from  AS  patients  (NSAID  treated  or  not)  
than  in  control  patients  (Table  3,  Figure  2).  In  contrast,  
iNOS  staining  in  colonic  epithelial  cells  was  found  more  
frequently  and  with  higher  score  only  in AS  patients  who  
were  not  treated  with  NSAID,  as  compared  to  control  
patients  (Table  4).  The  iNOS  staining  in  colonic  lamina  
Table  I.  Infiltration  score  of  lymphocytes  in  lamina  propria  of  the duodenum  and  colon  in  biopsies  from the 
control group, patients  with AS either treated  with NSAID or untreated, and  patients with ulcerative  colitis.  
n  Grade a  1 (%)  Mean Grade (0-3  scale)  
Duodenum 
Control 28 17 (48.6) 0.50 ±0.1 
AS  untreated  24 20* (83.3)  0.92  ±0.1**  
AS treated  with  NSAID  12 10* (83.3) 0.92  ±0.1** 
Colon 
Control 12 4(33.3) 0.38  ±0.15  
AS  untreated  12 5(41.7) 0.75  ±0.14  
AS treated  with  NSAID  11 3  (27.3)  0.63 ±0.1 
Ulcerative  colitis  10 10* (100) 2.56 ±0.16** 
* p<0.05  vs corresponding control group, Fisher exact test. ** p = 0.0l  vs corresponding control  group,  Kruskal-
Wallis nonparametric  ANOVA. 
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Table  2.  Infiltration  score  of  intraepithelial  lymphocytes  in  the  duodenum  and  colon  from  biopsies  from  the  
control  group, patients  with AS treated  with  N'SAID or untreated, and patients with  ulcerative  colitis.  
n  Grade z  1 (%)  Mean Grade (0-3  scale)  
Duodenum 
Control 28 8  (28.6)  0.42 ± 0.1 
AS  untreated  24 15* (62.5) 0.88 ± 0.2** 
AS treated  with  NSAID  12 11* (91.6) 1.11 ±0.2** 
Colon 
Control 12 1  (8.3)  0.08 ±0.1 
AS  untreated  12 6* (50.0) 0.63 ± 0.2** 
AS treated  with  NSAID  11 6* (54.5) 0.59 ±0.2** 
Ulcerative  colitis  15 4* (26.7) 0.40 ±0.1** 
*  p  <  0.05  vs  corresponding  control  group,  Fisher  exact  test.  **  p  <  0.05  vs  corresponding  control  group,  
Kruskal-Wallis  nonparainetric  ANOVA.  
propria or in epithelial  cells was found more  frequently and 
was  more marked  in the ulcerative  colitis  group than  in  the  
control  group (Tables 3 and 4, Figure 2). 
iNOS  enzyme  activity  in  duodenum  and  colon.  The  iNOS  
activity  was  significantly  increased  in  the  duodenum  front  
AS  patients,  both  treated  or  not,  compared  to  control  
patients  (Table 5). 
In the colon, the iNOS activity was significantly higher in 
patients  with AS  (treated  with NSAID or  not)  or  in  patients  
with ulcerative colitis than  in control  patients  (Table 5). 
An  association  between  the  immunostaining  and  the  
iNOS activity  (p  < 0.01)  was detectable  in  28  of  31  (90%)  
AS  patients  who  had  positive  immunostaining  in  lamina  
propria  of the duodenum.  In contrast,  iNOS activity was not 
detectable  in  4  of  the  5  patients  with  negative  immunos-
taining. 
Expression  of  IL-2,  IL-10,  and  IFN-y  in  duodenal  mucosa.  
The  expression  of  cytokines  IL-2,  IFN-y,  and  IL-10  in  the  
duodenal  mucosa  was  estimated  by  mRNA  detection  with  
RT-PCR, and  was semiquantified  by comparison  with  actin  
mRNA expression. Thus the ratios of  lL-2/IJ-actin  and IFN-
y/B-actin  in  the  duodenal  mucosa  were  increased  in  AS  
patients  treated  with  NSAID  (0.30  ±  0.1  and  1.38  ±  0.4,  
respectively)  or  not  treated  with  NSAID  (0.19  ±  0.0  and  
0.21 ± 0.1, respectively)  as compared  to the control  (0.01  ±  
0.0,  p  <  0.01;  and  0.00  ±  0.0,  p  <  0.01).  IL-10  expression  
was similar  in the 3 groups (0.30 ± 0.1, 0.49 ± 0.1, and 0.13 
± 0.2,  respectively).  
DISCUSSION 
Gut inflammation in association with AS has been described 
in  the  ileum  and  the  colon17"20.  To extend  these  findings to 
another  gut  region  using  both  histological  and  biochemical  
approaches,  we  evaluated  both  colonic  and  duodenal  
inflammation  in  patients  with  AS,  both  those  treated  with  
NSAID and those  not treated, using both  lymphocytic infil-
tration and expression  of  iNOS as markers of the inflamma-
tory  process.  
We observed  lymphocytic  infiltration in duodenal  lamina  
propria  in 83% of patients with AS. Lymphocytic infiltration 
has  been  previously  described  in  ileal  mucosa from 57% of 
AS  patients,  independently  of  G1 symptoms2.  This  higher  
frequency  of  histologically  detected  inflammation  in  the  
duodenum  in our study could be related to the site of the gut 
studied, or more likely to the population  of patients we eval-
uated,  95%  of  whom  had  axial  involvement,  known  to  be  
associated  with  inflammation  in the gut20.  
However,  lymphocytic  infiltration  in  the colonic  lamina  
propria  was  not found more  frequently  in AS  patients  than  
in  the  control  group.  In  a  previous  study  with  systematic  
biopsy  samples,  it  was  reported  that  inflammation  in  the  
colon  occurred  less  frequently  than  that  in  the  ileum  (40%  
and 60%, respectively) and that the major number of patients 
(60%) had inflammation detectable only  in the ileum117. The 
lack  of  lymphocytic  infiltration  in  lamina  propria  of  the  
colon  in the present study supports  the finding of no colonic 
macroscopic  damage,  as  assessed  by  colonoscopy  in  these  
patients,  who  were  a  relatively  homogeneous  group  with  
axial  involvement without peripheral  arthritis.  In contrast,  in  
a  previous  study,  31%  of  the  AS  patients  exhibited  endo-
scopic features of colonic inflammation1.  
The predominant  intestinal  involvement  of  inflammation  
was not  associated  with  excessive frequency of  diarrhea  as  
compared  to other studies.  We found diarrhea  in  17% of AS 
patients,  comparable  to  that  in  another  study  on  354  
patients, where diarrhea was reported  in  19% of the group20. 
Intraepithelial  lymphocytes  were  increased  in  the  
duodenum  and  colon  of  AS  patients  treated  with  NSAID,  
but  only  in  the  colon  in  patients  not  treated  with  NSAID.  
Such an increase has not been reported previously,  although 
lymphocytes  from  the  lamina  propria  located  along  the  
epithelial  basement  membrane  of  the  ileum  have  been  
described21.  Intraepithelial  lymphocytes  could  be  involved  
in AS related inflammation, as lymphocyte expression of the 
aB  heterodimer  of  the  T  cell  receptor  was  found  in  AS  
patients, similar to that in patients  with Crohn's  disease22.  
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Figure  !.  Detection  of  inducible  nitric oxide  synthase (¡NOS)  by immunohistochemistry  in  the  
duodenal  mucosa.  A.  Duodenum  from  patient  with  AS.  The  section  shows  mild  infiltration  
with  lymphocytes  in  the  lamina  propria  and  immunohistochemical  localization  of  iNOS  as  
brown  staining,  mainly  in  the  inflammatory  cells  (original  magnification  x200).  B.  Normal  
duodenum  from  a control  patient. The  section  shows  negative  iNOS immunostaining  (original  
magnification  x200).  
Duodenal  lymphocyte  infiltration  was  not  modified  by  
the  H.  pylori  status.  The  bacterium  usually  causes  inflam-
mation  in  the  duodenal  bulb,  especially  in  patients  having  
ulceration23.  In our  study,  biopsies  were  taken  distally  in  the  
second  part  of  the  duodenum,  where  no  ulcerative  damage  
was  seen  by  endoscopy  in  any  patient24.  
It could  be anticipated  that  histological  changes  in the gut  
would  be  associated  with  NSA1D  intake.  The  group  of  
untreated AS patients did  not take NS AID for at least  5 days 
before the  study, although  it has been  proposed  that  NSAID  
intestinal  damage  may  persist  for up to several  months after 
discontinuation  of  drugs25.  However,  the  degree  and  nature  
of  the  inflammation  that  we observed  in  the  duodenum  and  
colon  are  probably  not  related  to  the  NSAID.  Thus,  we  
found  no  ulcerative  damage  or  polymorphonuclear  infiltra-
tion,  as  usually  described  with  NSAID-related  damage,  in  
duodenum  from  AS  or  control  treated  patients.  Similarly,  
other  studies  involving  histological  examination  of  biopsies  
taken  from  patients  treated  with  NSAID  also  did  not  find  
duodenal  inflammation23.  
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Table 3.  Immunohisiochemical  analysis of iNOS in lainina propria of the duodenum  and colon  in biopsies from 
the control  group, patients with AS treated  with NSAID or untreated, and patients  with  ulcerative  colitis.  
n  Grade a  1 (%)  Mean Grade (0-3  scale)  
Duodenum 
Control 28 16(57.1) 0.64 ±0.1  
AS  untreated  24 22*  (91.7)  1.33 ±0.3** 
AS treated  with  NSAID  12 9* (75.0) 1.17 ±  1.0**  
Colon 
Control 12 3  (25.0)  0.54 ± 0.2 
AS  untreated  12 12* (100.0) 1.63 ±0.2** 
AS treated  with  NSAID  II 10* (91.0) 0.95 ± 0.2** 
Ulcerative  colitis  15 11* (73.3) 1.37 ±0.3** 
*  p  <  0.01  vs  corresponding  control  group,  Fisher  exact  test.  **  p  <  0.01  vs  corresponding  control  group,  
Kruskal-Wallis  nonparametric  ANOVA and  Dunn's  multiple comparison  test.  
Table 4.  Immunohisiochemical  analysis of  iNOS  in epithelial  cells  in duodenum  and colon  from control  group,  
patients  with AS treated  with  NSAID or untreated,  and patients with  ulcerative  colitis.  
n  Grade a  1 (%)  Mean Grade (0-3  scale)  
Duodenum 
Control 28 9(32.1) 0.36 ±0.1 
AS  untreated  24 11 (45.8) 0.58  ±0.2  
AS treated  with  NSAID  12 6  (50.0)  0.67 ±0.8 
Colon 
Control 12 4 (33.0)  0.92  ±0.3  
AS  untreated  12 12* (100.0) 1.81  ±0.3**  
AS treated  with  NSAID  11 6  (54.4)  1.00 ±0.3 
Ulcerative  colitis  15 15* (100.0) 2.63 ±0.1** 
* p < 0.01  vs control  group,  Fisher exact  test.  ** p < 0.05 vs control  group by ANOVA. 
Consistent with our findings of duodenal  or colonic infil-
tration  of  lymphocytes  in  AS  patients  independent  of  their  
NSAID status, mucosal lymphocyte infiltration or  increased 
intestinal  permeability  have  been  described  in AS  patients,  
either  not  treated  with  NSAID  or  independent  of  NSAID  
intake36'30.  Thus,  in  a  series  of  254  AS  patients  who  had  
undergone  ileocolonoscopy,  histological  inflammation  of  
ileum  or  colon  was  not  more  frequent  in  patients  treated  
with NSAID (23%) than  in those not treated (33%)20. In AS 
patients  having  ileal  and  colonic  biopsies,  60%  of  those  
treated  with NSAID had normal  biopsies17.  
In  our  study,  the  calcium-independent  iNOS  activity  in  
duodenum and colon was increased in AS patients compared 
to  control  patients.  These  findings  of  increased  iNOS  
expression or activity were confirmed by immunostaining  in  
both  duodenum  and colon.  Previous  studies  describe  iNOS  
activity  in ulcerative colitis not only  in the inflamed area but 
also  in  endoscopically  normal  areas4'31,32.  Such  findings  
suggest  that  iNOS  is  implicated  in  the  moderate  stage  of  
mucosal  inflammation  in  inflammatory  bowel  disease.  In  
our study, the level of  iNOS enzyme activity  in the colon of  
AS patients  was lower  than that  seen  in patients  with  ulcer-
ative colitis,  which  may reflect the  lower  grade  of  mucosal  
inflammation. 
The expression  of  iNOS  in lamina  propria  inflammatory  
cells may thus be a marker of active intestinal inflammation, 
which has been previously found in the vicinity  of  ulcerated  
lesions  in  patients  with  inflammatory  bowel  disease33"35.  
Such  an expression  of  iNOS  in AS  patients  could  reflect a 
local  inflammatory process  and not simply  the migration  of  
activated  inflammatory  cells36,37.  
The presence of iNOS, determined  by  immunochemistry  
in  colonic  epithelial  cells,  was  shown  in  tissue  from  
untreated  AS  patients.  Similarly,  iNOS  has  been  found  in  
colonic epithelial cells in patients with ulcerative colitis, and 
is  associated  with  areas  of  intense  inflammation  and  clini-
cally active colitis33,34,38"40.  However,  in this study the induc-
tion  of  iNOS  in the epithelium  or  the lamina  propria  in AS 
patients was not associated  with  any overt mucosal  damage.  
Some  reports  have  suggested  that  the  role  of  iNOS  in  the  
pathogenesis  of  inflammatory  bowel  disease  is  not  detri-
mental,  but  may  facilitate the  repair  process  and  restore  or  
maintain mucosal  integrity41,42.  Mice deficient in iNOS have 
more  severe  damage  and  delayed  healing  as  compared  to  
controls  in the experimental  colitis  provoked  by acetic acid. 
In  addition,  the  inhibition  of  NO  synthesis  by  L-N6-0-
iminoethyl)lysine given orally aggravated the severity  of the 
spontaneous colitis observed  in rats that are in the transgenic 
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Figure  2.  Detection  of  inducible  nitric  oxide  synthase  (iNOS)  by  immunohistochemistry  in  the  colonic  mucosa.  A. Colon  fron  
untreated  AS.  The  section  shows  lymphocytic  infiltration  in  the  lamina  propria  and  immunohistochemical  localization  of  iNOS  as  brown  
staining  in the inflammatory cells  of the lamina propria and  in the crypts and surface epithelium  (original magnification  x200).  B. Colon front 
patient  with AS treated  with NSAID.  Immunostaining  is present  in inflammatory cells of lamina propria. C. Colon  from patient  with  untreated  
AS. This  section  shows  at  higher  magnification  the cellular  location  of  immunostaining  in  the  lymphocytes  of  the  lamina  propria  and  in  the  
crypt  epithelial  cells  (original  magnification  xlOOO).  D.  Colon  from  patient  with  ulcerative  colitis.  The  section  shows  ulceration,  cryptic  
abscess,  and  marked  infiltration  of  inflammatory  cells.  Immunohistochemical  localization  of  iNOS  as  brown  staining,  mainly  in  the  cryptic  
and  surface  epithelium  (original  magnification  x200).  Some  inflammatory  cells  are  also  immunostained.  E.  Normal  colon  from  control  
patients. There  is  no epithelial  or  inflammatory  cell  staining  (original  magnification  x200).  F. Colon  from patient  with  untreated  AS.  Control  
experiment  showing absence  of iNOS  immunostaining  after incubating  the antibody  2  h with the iNOS peptide (original magnification  x200).  
for  HLA-B27  and  the human  B,-microglobulin  that  develop  
a  spontaneous  inflammatory  disease  that  resembles  human  
AS  in patients  who  are  positive  for  HLA-B279.  
iNOS  expression  was  found  in  both  lamina  propria  and  
epithelial cells  in the colon from AS patients not treated  with  
NSAID.  In AS patients receiving  NSAID,  the  iNOS  expres-
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Table 5.  Activity  of  iNOS in biopsies of the duodenum  and colon from the 
control  group,  patients  with  AS  treated  with  NSAID  or  untreated,  and  
patients with  ulcerative  colitis.  
n  iNos activity  (± SEM) 
pmol  min"1  mg  protein"1  
Duodenum 
Control 28 1.8 ±0.6 
AS  untreated  24 17.5 ±3.8* 
AS treated  with  NSAID  12 5.8 ± 6.8** 
Colon 
Control 12 2.12 ±  1.0  
AS  untreated  12 11.5 ±2.3* 
AS treated  with  NSAID  II 9.0 ± 2.8** 
Ulcerative  colitis  10 43.47  ±6.1*  
*  p =  0.01  vs corresponding  control  group,  VVilcoxon  nonparametric  test.  
** p = 0.05 vs corresponding  control  group,  Wilcoxon  noparametric  test.  
sion  was  only  found  in  the  lamina  propria.  The  immunos-
taining  localization  was  not  superimposed  on  the  lympho-
cytic  infiltration  that  was found only  in the epithelium  and  
not  in  the  lamina  propria.  The  lack  of  correspondence  
between  these  findings  is  not  surprising,  as  iNOS  can  be  
induced  in  inflammatory  cells,  especially  lymphocytes,  
involved  in the initiation or the regulation  of the inflamma-
tory  process. The role  of these cells  is  not fully  understood  
and  it  is possible  that  they  are  not  consistently  localized  in  
the lymphocytic infiltrate43.  
Patients  with  ulcerative colitis were selected  as a control 
group with lesions since they express iNOS consistently  and  
uniformly  in  the  colon.  However,  in  Crohn's  disease,  the  
inflammation is patchy and iNOS expression  is not uniform 
over the colon,  thus  limiting the  reproducibility  of the data 
in such  a control  group44.  
Expression  of  iNOS  and  IFN-y,  determined  by  mRNA  
detection  with  RT-PCR,  was found  in  duodenum  from AS 
patients and not from control patients. Such an association is 
consistent  with  previous findings on the  induction  of  iNOS  
that  is  dependent  on  IFN-y10.  Lymphocytes  infiltrating  the  
mucosa,  and particularly  intraepithelial  lymphocytes,  could  
be the source of IFN-y  in AS. In this study, IL-2 but not IL-
10 was also found  in duodenum from AS patients,  as deter-
mined  by  mRNA detection.  The  induction  of  iNOS  that  is  
dependent  on  IL-2  has  been  observed  in  natural  killer  
lymphocytes45.  This  finding  suggests  that  lymphocytes  in  
gut mucosa from AS patients  may express  iNOS.  
This  study  found duodenal  and  colonic  inflammation  in  
association  with  iNOS  induction  in  more  than  80%  of  
patients  with AS. These findings suggest a diffuse intestinal 
inflammatory process  in the upper and lower intestine of AS 
patients.  Such  events  may  cause  changes  in  intestinal  
permeability,  permitting  exogenous  antigen,  especially  of  
bacterial  origin,  to  pass  through  the  mucosa  and  initiate  a  
systemic inflammatory response localized  in joints  in genet-
ically predisposed  patients.  
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Successful Treatment  of  Steroid  
Resistant  Ulcerative  Colitis  Associated  
With  Severe Autoimmune  Hemolytic  
Anemia  With  Oral  Microemulsion  
Cyclosporin—A  Brief  Case  Report  
TO THE EDITOR: Since  the first publication  by  Gupta  et  
al.  in  1984 (I),  the beneficial effect of cyclosporin A (CsA)  
in the treatment of severe ulcerative colitis (UC) has bccome 
evident on the basis of placebo-controllcd, randomized trials 
(2,3).  The results of some pilot studies suggest that the  p.o.  
microemulsion cyclosporine  formulation is  at least as effec-
tive  as  i.v.  administration of  CsA (4),  CsA  has  also proved 
its efficacy in the treatment of pyoderma  gangrenosum (5).  
Autoimmune  hemolytic  anemia is  a  condition  rarely  as-
sociated with UC; the frequency of association is  about  1%  
to  2%  (6).  We  have  treated  five  patients  with  manifest  
Coombs positive hemolysis out of more than 400 UC cases 
observed  since  1986  (7).  The  step-up  treatment  option  of  
associated  autoimmune  hemolytic  anemia  depends  on  the  
severity of hemolysis; high dose corticosteroid,  either alone 
or in combination with azathioprine,  is the basis of conser-
vative treatment.  If these  therapeutic modalities  remain un-
successful,  splenectomy  is  indicated  first  and,  in  case  of  
failure,  total colectomy is  the method of choice  (8).  
There are only two case reports about the beneficial effect 
of  CsA  in  UC-associated  hematological  disorders.  In  the  
first,  a  good  therapeutic  efficacy  of  combined  CsA  and  
fluocortolone  was  reported  in  the  treatment  of  ulcerative  
proctocolitis  complicated  by severe immune hemolytic ane-
mia  (9),  whereas  in the  second, CsA  treatment  resulted the  
healing  of  cyclic  neutropenia  associated  with  ankylosing  
spondylitis  and ulcerative  colitis  (10).  In  our case,  CsA by 
induction of remission in steroid resistant UC not only saved 
the  young  woman  from  colectomy  but  also  stopped  the  
conventional  drug  and  splenectomy  resistant,  transfusion  
requiring,  autoimmune  hemolysis.  
A  35-yr-old  woman  was  admitted  to  our  department  in  
October,  2001,  because  of  a severe  flare-up of UC  associ-
ated  with  mild  jaundice  and  poor  general  well-being.  Her  
pancolitis was diagnosed  according to  standard  endoscopic  
and  histological  criteria  in  1988. An  autoimmune  Coombs  
positive hemolytic anemia with cold and warm autoantibod-
ies  developed  in  July,  I99S.  Twelve  units  of  erythrocyte  
concentration  were  transfused.  A  high  dose  steroid  (meth-
ylprcdnisone,  2  mg/kg  i.v.)  and  azathioprine  (2  mg/kg)  
therapy  was  then  introduced.  After  a  9-month  remission  
achieved  with  azathioprine,  UC  and  hemolysis  reactivated  
simultaneously.  The  patient  underwent  transfusion  again,  
steroid  use was  restarted  (mcthylprednisonc,  1 mg/kg),  and  
danasolc  was  started  (400  mg  daily)  in  combination  with  
azathioprine. After a partial response,  splenectomy was  per-
formed because  of  the  therapy  resistant  hemolysis  in  May,  
2000.  Three  months  before  the  patient's  present  admission  
to  our  department,  bloody  diarrhea  started  (number  of  
stools,  10-20/day).  She  had  a  weight  loss  of  12  kg  until  
October,  2001.  Physical  examination  showed  a  moonface  
caused by steroid therapy, as well  as anemia, mild jaundice, 
and abdominal  tenderness  at the  time of  admission.  Labo-
ratory values were  as  follows:  erythrocyte sedimention  rate  
77  mm/h,  hemoglobin  84  g/L,  hematocrit  27%;  serum  bil-
irubin total  22.37  pumoVL, lactate dehydrogenase  819  g/ml,  
and  CRP  68  mg/L.  Direct  and  indirect  Coombs  tests  were  
both highly positive (+ + + +) .  As an ultimate  preoperative  
therapeutic possibility,  CsA (Sandimmun Neoral;  Novartis)  
was given  at  a dose  of  5  mg  per  kilogram  of body  weight  
(CsA  serum  concentrations,  81-83  ng/ml,  respectively).  
The  activity  of  UC  started  to  decrease  and  the  hemolysis  
resolved  1 wk after the initiation of Neoral. Now,  10 months 
later,  the  patient  is  receiving  combined  azathioprine  (2.5  
mg/kg)  and  CsA (4  mg/kg p.o.)  therapy.  Under this  thera-
peutic regimen,  there  are still mild signs of UC activity but 
without hemolysis  (Coombs test is consequently  negative).  
CsA suppresses the immune response by inhibiting signal 
transduction pathways.  CsA  binds to  their  intracellular  re-
ceptors,  immunophilins,  creating  composite  surfaces  that  
block the  activity of the specific  target,  calcineurin.  Inhibi-
tion of the action of  calcineurin results in a complete block 
in the  translocation of  the cytosolic  component  of  the  nu-
clear factor of activated T cells (11). This effect of CsA seems 
favorable not only in the induction of remission of UC, but also 
in the cure of a particular extraintestinal  manifestation of UC, 
namely, pyoderma gangrenosum.  Our case suggests that CsA 
may have beneficial effect in the treatment of another extraint-
estinal  manifestation,  namely,  autoimmune  haemolytic  ane-
mia. The reduction of UC activity is surely a key factor of this 
mechanism,  but  CsA  may  also  influence  the  autoimmune  
hemolysis itself in a favorable manner. The  rare association 
of autoimmune hemolysis  and UC probably makes placebo-
controlled  studies  unlikely; therefore,  on the basis of  these  
few reported cases, the use of CsA  in the treatment of  these 
associated  conditions  is  worth  considering.  
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Plummer-Vinson  Syndrome  Associated  
With  Celiac  Disease  and  Complicated  
by Postcricoid  Carcinoma  and  
Carcinoma  of  the  Tongue  
TO THE  EDITOR: We read with  interest two  previous  re-
ports in the Journal  on celiac disease-associated  Plummer-
Vinson syndrome (1) complicated by upper esophageal  can-
cer  (2).  We  report  another  case  in  which,  in  addition  to  
upper  esophageal  cancer,  a  carcinoma  of  the  tongue  was  
present. 
A 61-yr-old white woman was  admitted  for evaluation of 
dysphagia  and  severe  microcytic  anemia  (Hb  4.9  g/dl)  in  
2002.  Her history was unremarkable except  for tuberculosis 
in  1947,  appcndcctomy  in  1968,  and  cholecystectomy  in  
1976.  Since  1992  she  had  experienced  dysphagia,  which  
forced  her to eat  slowly  and to take small  portions of  food,  
but  she  did  not  consult  a  physician.  During  the  5  wk  pre-
ceding  admission,  her dysphagia  had  worsened  so  that  she  
was  able  to swallow  liquid  foods only,  and she  lost  10 kg. 
At  admission  she  weighed  42  kg  and  was  160  cm  tall.  
Physical  examination  revealed pale  skin,  onychodystrophy,  
oral  fissures, and atrophic glossitis,  with  an indurated  lesion  
at the left side of  the tongue.  Laboratory investigations were 
normal  except  for severe  iron deficiency  anemia.  A  test  for 
fecal  occult  blood  was  negative.  
Gastroscopy  revealed  an  ulcerating  tumor  in  the  upper  
esophagus,  resulting  in  a  5-cm-long  stenosis  that  could  be  
passed  only  after  endoscopic  dilation.  Biopsy  specimens  
taken  from the  tumor  showed  an invasive,  moderately  dif-
ferentiated squamous  cell  carcinoma  grade 2.  Biopsy  spec-
imens from the antrum and duodenum showed  Helicobacter  
£y/or/-associated  atrophic  gastritis  and  villous  atrophy  of  
the  duodenal  mucosa,  stage  3C  according  to  the  modified  
MARSH classification (3),  corresponding  to celiac  disease.  
A  test  for  antiendomysial  antibodies  was  positive.  A  CT  
scan showed  a stenosing tumor in the  upper esophagus  that  
was  1.7 cm in diameter, as well as one enlarged lymph node 
at the  azygo-esophageal  angle  (stage  T3N1M0).  Biopsy  of  
the  indurated tongue  lesion revealed  a highly differentiated 
squamous cell carcinoma. There was no evidence for further 
lymph  node  metastases  by  endosonography  and  cervical  
ultrasound. 
Initially  the  patient  received  two  units  of  packed  red  
blood  cells.  On  a  gluten  free  diet  there  was  a  continuous  
increase in Hb  and  serum  iron. The patient  refused  surgeiy  
but  was  treated  with  three  cycles  of  chemotherapy  with  
carboplatin and 5-fluorouracil; both tumors did not respond. 
Currently the patient is  undergoing brachytherapy  and tele-
therapy for her lingual and esophageal  cancers, respectively. 
This patient had more than one possible reason for severe 
iron deficiency. The improvement of iron deficiency anemia 
on a gluten free diet suggests  that malabsorption  caused  by  
celiac  disease  (1)  was  the  prime  reason.  GI  symptoms  are  
absent  as  frequently  in the silent or oligosymptomatic  form  
of this disease.  In addition to anemia, iron deficiency may be 
directly linked to the occurrence of esophageal cancer in this 
patient The upper esophageal web in Plummer-Vinson syn-
drome  is  an  established  risk  factor  for the  development  of  
esophageal cancer (2,4).  Our patient had chronic dysphagia 
and  long-standing  iron deficiency.  Despite  a  lack of  direct  
evidence,  it  is  likely  that  an  upper  esophageal  web  was  
present in addition to anemia and atrophic glossitis, which is 
consistent  with  a  retrospective  diagnosis  of  Plummer-Vin-
son  syndrome.  Dysphagia  was  present  for  10 yr,  and  onset  
of  celiac  disease  presumably  occurred  many  years  or  de-
cades  before.  Delay  of  diagnosis  has  been  rccognizcd  as a 
major  risk  factor  for ccliac  discasc-associatcd  malignancy  
in  large  scries  (4,  5).  
To  our knowledge,  an association between atrophic  glos-
sitis  or ccliac  disease  and  carcinoma  of  the tongue  has  not  
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Open Questions  Concerning  Cyclosporine  
Therapy  in Ulcerative  Colitis  
Dear  Sir:  
We  read  with  interest  the  article  "Randomized,  double-blind  
comparison  of  4  mg/kg  versus  2  mg/kg  intravenous  cyclosporine  in  
severe  ulcerative  colitis"'  by  Gert  van  Assche  et  al.  in  the  October  
2003  issue  of  GASTROENTEROLOGY.  The  authors  compared  the  effi-
cacy  and  safety  of  2 different cyclosporine  regimens  given  by  contin-
uous  24-hour  infusion  followed  by  oral  treatment  from  the  day  8.  
Some points  in  this  instructive work  deserve  reflection. First,  the  title  
seems somewhat  misleading:  the  basis  of the  study  was  not  the  use  of  
different  doses,  but  to  attainment  of  2  different  blood  level  ranges.  
The  apparent  goal  of  the  blood  level-based  administration  (full  area  
under  curve [AUC] monitoring)  was  to achieve  the  best safety  profile  
during  the  7-day  infusion  therapy.  Both  ranges  (150-250  and  2 5 0 -
350  ng/mL)  had  been  considered  therapeutic  at  the  authors'  institu-
tion  before the  start  of the  study.  In  fact, no  significant differences in  
efficacy  or  safety  were  found  between  the  2  groups,  which  is  not  
surprising. 
A comparison  of the frequency of adverse events observed  in  the  "4  
mg/kg  group"  with  that  in  the group  examined  by  Lichtiger  et  al.  in  
the  first  famous cyclosporine  study'-  reveals  appreciable  differences  in  
the frequencies of hypertension  (9 of 38  vs.  4  of  11) and  of  paresthesia  
(3  of  38  vs.  4  of  11,  respectively).  Lichtiger  et  al. administered  really  
4  mg/kg  cyclosporine  by  continuous  infusion  and  attained  a  higher  
blood  level  (mean, 482;  range, 3 3 9 - 6 5 3  ng/mL).  These  data  suggest  
that  the  most  important  consideration  during  cyclosporine  therapy  is  
to  keep  the  blood  level  within  the  narrow  therapeutic  range.*  The  
results  of  van  Assche et  al. suggest  that  a reduced  dose could  improve  
the  safety  of  cyclosporine  treatment,  but  the  lower  and  upper  ranges  
within  the  therapeutic  blood  levels  (237  ±  33  ng/mL  vs.  332  ±  43  
ng/mL)  differed  only  statistically,  and  not  biologically.  
However,  why  should  we compare  different  blood  levels  measured  
during  infusion  for  a  certain  number  of  days  of  therapy?  We  are  not  
sure  that  patients  displaying  fecal  urgency  on,  say  5 - 1 0  occasions  
daily  should  be  treated  in  this  way.  The  authors  write  that  "most  
patients  with  severe  colitis  feel  sick  and  may  not  be  able  to  comply  
with  taking  Neoral  (Novartis)  capsules."  It  is  rather  difficult  to  
believe that  patients who  can  tolerate  2 endoscopic examinations  (and  
preparations) within  8  days,  are  not  able  to  take  2 capsules daily.  The  
cyclosporine  microemulsion  has  favorable  pharmacokintetic  parame-
ters"  with  few  associated  side  effects.'  It  proved  effective as  first-line  
therapy  at  a  daily  dose  of  7 -7 .5  mg/kg  in  patients  with  severe  
steroid-refractory  ulcerative colitis.6  Our  own  results  presented  at  the  
UEG W  in Madrid,  a lower oral dose of 4 mg/kg  cyclosporine  may  also  
be  effective,  with  a  good  safety  profile.7  Complete  remission  was  
achieved  in  12  of  14  patients  after  1 month,  and  only  1 patient  was  
operated  on  during  the  6-month  follow-up period,  van  Assche  et  al.  
used  a higher  oral  dose  (8  mg/kg)  for  3  months  monitoring  only  the  
fasting  blood  level.  They  did  not  publish  any  data  on  the  oral  
treatment  phase,  and  therefore  we do  not  know  whether  the  therapy  
was  safe  enough  with  this  monitoring  and  what  the  late  colectomy  
rate  was.  
The  best  safety  and  efficacy profile  during  oral  cyclosporine  (Ne-
oral)  therapy  can  be  achieved  by  using  2 sampling  times.  The  0  and  
2-hour  (post-dosing)  values provide  a close  correlation  with  the  AUC  
with  an  t 2  value  of 0.97,  while  monitoring  of  the 0-hour  blood  level  
alone  is  of  very  low  predictive  value."  
By  using  a markedly  lower  dose of Sandimmune  Neoral  (Novartis)  
as  described  earlier,  we  could  achieve  a  therapeutic  blood  concentra-
tion  of  cyclosporine  (between  800  and  1200  ng/mL)  2  hours  post-
dosing.  The  0-hour  level  was  the  same  (150-300  ng/mL)  as  that  
measured  in  the  "2  mg/kg  intravenous  group,"  or  in  the  patients  
treated  orally  with  8  mg/kg  in  the  study  by  van  Assche  et  al.  
A  high  peak  level  may  guarantee  therapeutic  efficacy, but  a  lower  
basic  level  may  ensure  safety.  A  beneficial  acute  therapeutic  effect  of  
oral  cyclosporine  was  also  observed  by  van  Assche  et  al.  during  the  
treatment  of  their  patients  after  an  anaphylactic  reaction  due  to  the  
infusion. The  data  mentioned  above  lead  to  the  conclusion  that  there  
is  no  theoretical  advantage  of continuous  intravenous  infusion  versus  
oral  therapy.  
Finally,  another  very  interesting  and  important  part  of  their  pub-
lication  was  the  examination  of  parameters  which  may  have  influ-
enced  the  effect  of  cyclosporine.  The  results  of  the  multivariate  
analysis  are  somewhat  unexpected.  The  study  by  van  Assche  et  al.  
suggested  that  smoking  has  unfavorable  effects  in  the  severe  ulcer-
ative  colitis  group.  However,  other  reports,9  have  indicated  that  
smoking  influences  the  course  of  ulcerative  colitis  in  a  favorable  
manner,  while  the cessation  of smoking  can  aggravate  the  symptoms.  
To  return  to  the  mode  of  therapy,  continuous  intravenous  adminis-
tration  probably  prevents  the  continuation  of  smoking,  and  the  
abrupt  withdrawal  of  nicotine  may  therefore  be  responsible  for  the  
poorer  outcome  in  patients  who  smoke.  
TAMÁS  MOLNAR  
ZOLTÁN  SZEPES  
FERENC  NAGY  
PÁL  SZENOHRADSZKI  
JÁNOS  LONOVICS  
First  Department  of  Medicine  
and 
Department  of  Transplantation  
Faculty  of  Medicine  
University  of Szeged 
Szeged.  Hungary  
1.  Van Assche  G, D'Haens  G,  Noman  M, Vermeire  S,  Hiele  M, Asnong 
K,  Arts  J,  D'Hoore  A,  Penninckx  F,  Rutgeerts  P.  Randomized,  
double-blind  comparison  of  4  mg/kg versus  2  mg/kg  intravenous  
1496  CORRESPONDENCE  GASTROENTEROLOGY  Vol.  126,  No.  5  
cyclosporine  in  severe  ulcerative  colitis.  Gastroenterology  2003;  
125:1018-1024. 
2.  Lichtiger  S,  Present  DH,  Kornbluth  A,  Gelernt  I,  Bauer J,  Galler  G,  
Michelassi  F,  Hanauer  S.  Cyclosporine  in severe  ulcerative  colitis  
refractory to steroid therapy.  N Engl J Med  1994;330:1841-1845.  
3.  Keown  P,  Kahan  BD,  Johnston  A,  Levy  G,  Dunn  SP,  Cittero  F,  Grino  
JM,  Hoyer  PF,  Wolf  P,  Halloran  PF.  Optimization  of cyclosporine  ther-
apy with  new therapeutic  drug  monitoring  strategies:  report from the 
International  Neoral  TDM  Advisory  Consensus  Meeting  (Vancouver,  
November  1997).  Transplant  Proc  1998;30:1645-1649.  
4.  Humbert  H.  Variability  of the  bioavailability  of cyclosporine:  benefit  
of the  Neoral  formulation.  Therapie  1997;52:353-357.  
5.  Corbett  J,  Ross  K.  Neoral:  the  new  cyclosporine.  ANNA  J  1998;  
25:71-72. 
6.  Navazo  L, Salata  H, Morales S,  Dorta MC, Pgrez  F, de las Casas  D,  
Avilas  J.  Oral  microemulsion  cyclosporine  in the  treatment  of  ste-
roid-refractory  attacks  of  ulcerative  and  indeterminate  colitis.  
Scand  J  Gastroenterol  2001;36:610-614.  
7.  Molnär  T,  Szepes  Z,  Nagy  F,  Lonovics  J.  Oral  cyclosporine  rescue  
therapy  in  severe,  steroid  refractory  ulcerative  colitis.  Gut  2003;  
52(Suppl  IV):A210.  
8.  Keown  P.  Experience  with  use  of  sparse-sample-derived  AUCs  for  
management  of  Neoral.  Focus  on  Medicine  1998;13:11-14.  
9.  Boyko  EJ,  Perera  DR,  Koepseli  TD,  Keane  EM,  Inui TS.  Coffee  and  
alcohol  use  and  the  risk  of  ulcerative  colitis.  Am  J  Gastroenterol  
1989;84:530-534. 
doi:10.1053/j.gastro.2004.03.040 
Reply.  W r  thank  the  authors  of  this  lt-ttct  for  their  tcilections  on  
our  recent  article  in  GASTROENTEROLOGY1  and  for  sharing  their  
open-label  experience  with  oral  cyclosporine  in  the  treatment  of  
severe  ulcerative  colitis.  W e  would  like  to  reply  to  some  of  the  
concerns  raised  in  this  letter.  
First,  controlled  evidence  on  the  use  of  IV  cyclosporine  for  severe  
colitis  is  scarce2,1  and  no  controlled  trials  have  been  published  de-
scribing  the  use  of  oral  cyclosporine  in  this  indication.  Therefore,  it  
was  and  still  is  logical  to  investigate  the  optimal  dosing  regimen  of  
cyclosporine  IV  in  severe  ulcerative  colitis  (UC).  Second,  previous  
studies  have demonstrated  that  taken  as  a  whole  patients  with  severe  
or  fulminant  colitis  require  in-hospital  care,  not  only  because  of  the  
risk  for emergency  surgery,  but  also  because  they  often  need  intrave-
nous  treatment.4  All  the  patients  in  our  study  were  already  admitted  
and  on  IV  therapy,  most  often  steroids,  before  they  were  included  in  
the  trial.  The  use  of  cyclosporine  IV,  therefore,  was  not  an  extra  
burden  in  their  treatment.  The  use of Neoral  in  non-controlled  trials  
may  introduce  a  selection  bias  toward  patients  with  less  severe  
symptoms. Third,  we agree rhat  in our study cyclosporine  blood  levels  
in  both  study  arms  remained  within  the  cherapeutic  range.  These  
therapeutic  margins  however,  have  been  developed  for  preventing  
organ  rejection  and  optimal  therapeutic  blood  levels  for  ulcerative  
colitis  are unknown  again  due to  the  paucity  of controlled  crials.  Our  
study  indicates  char  UC patients  whose  blood  levels  have  been  in  the  
upper  end  of  the  margin  for  transplant  patients,  have  no  improved  
outcome.  Fourth,  the  bioavailablitiy  of  oral  cyclosporine,  even  in  an  
improved  formula  such  as  Neoral,  is  notoriously  unpredictable.  The  
more  reliable  assays  for  monitoring  oral  cyclosporine  therapy  men-
tioned  by Molnar et al.5  have only  been  introduced  in  clinical  practice  
after  our  study  was  initiated  and  there  is  no  controlled  evidence  
describing  their  use  in  UC.  
In  conclusion, we agree that  Neoral  can  be investigated  as an  initial  
treatment  for severe colitis.  However,  given  the  load  of potential  bias  
and  ethical  considerations,  a  study  investigating  the  role  of  oral  
cyclosporine  in  this  indication  can  only  be  designed  as  a  randomized  
controlled  trial with  cyclosporine I V  as  the active comparator.  Such a 
trial  needs to be a multicenter  effort,  since fortunately  for  the  patients  
acute  fulminant  colitis  has  a  lifetime  incidence  of only  20%.  
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A Randomized  Controlled  Trial  of  
Biofeedback  That  Does  Not  Have  the  
Power to  Conclude  
Dear  Sir:  
In  the  article  recently  published  by  Norton  et  al.,1  several  meth-
odological  issues  need  to  be  stressed  to  avoid  misleading  interpreta-
tion  of  the  results.  
The  sample  size  calculations  were  based  on  the  hypothesis  that  
67%  of individuals  would  be improved  in  the group with  biofeedback  
versus  only  30%  in  the  standard  care  group.  The  expected  improve-
ment  of  the  group  with  biofeedback  compared  with  the  standard  
group  may  be  expressed  either  as  the  absolute  difference,  i.e.,  37%  
(67%—30%) or more regularly,  as the  relative difference that  is  123%  
(67%  representing  a  123%  increase  of  30%).  Such  large  relative  
differences are not  observed  for most  interventions  used  in  healthcare.  
As  a  result,  the  minimal  sample  size  theoretically  required,  i.e.,  40  
subjects  in  each  group  is  underestimated.  Additionally,  3  out  of  4  
groups do not  even  reach the minimum  size calculated  by the  authors.  
The  group  used  as  a  reference  for  the  statistics  included  only  29  
patients  which  leads  to  a  power  of 75%,  i.e.,  a  risk  of 25%  to  fail  to  
show  the  relative  improvement  of  123%  expected  by  the  authors.  
Fifty-four  percent  of  the  patients  were  improved  in  the  standard  
group.  This  percentage  is  simply  an  average,  and  the  confidence  
intervals,  not  provided,  are  probably  very  large,  meaning  rhat  this  
percentage  may  well  be  very different  in  reality  than  that  observed  in  
this  study.  If  the  standard  care  really  improved  40%  of  the  patients  
instead  of 30%, with  29 patients  in this group,  the power of the  study  
was  less  than  50%  with  a  50%  chance  to  conclude  no  statistical  
difference whereas  there  really  is  a  difference.  
The  reference group  is  not  only  too  small  but  is  probably  biased  
since  30%  of  subjects  were  lost  to  follow  up.  If  those  subjects  
